Pleiotropic Effects of 3-Hydroxy-3-Methylglutaryl Coen

Arteriosclerosis, Thrombosis, and Vascular Biology
21, 1712-1719
DOI: 10.1161/hq1101.098486

Citation Report

#	Article	IF	Citations
1	Disappearance of highâ€incidence amyotrophic lateral sclerosis and parkinsonismâ€dementia on Guam. Neurology, 1985, 35, 193-193.	1.5	229
2	Management of Neurological Disorders. Journal of Neurology, Neurosurgery and Psychiatry, 1996, 61, 658-658.	0.9	0
3	Pharmacology of 3-Hydroxy-3-Methylglutaryl-Coenzyme A Reductase Inhibitors (Statins), Including Rosuvastatin and Pitavastatin. Journal of Clinical Pharmacology, 2002, 42, 835-845.	1.0	81
4	HIV Therapies and Atherosclerosis. Arteriosclerosis, Thrombosis, and Vascular Biology, 2002, 22, 1758-1760.	1.1	4
5	Simvastatin Reduces Expression of Cytokines Interleukin-6, Interleukin-8, and Monocyte Chemoattractant Protein-1 in Circulating Monocytes From Hypercholesterolemic Patients. Arteriosclerosis, Thrombosis, and Vascular Biology, 2002, 22, 1194-1199.	1.1	340
6	Preprocedural Statin Medication Reduces the Extent of Periprocedural Nonâ€“Q-Wave Myocardial Infarction. Circulation, 2002, 106, 2180-2183.	1.6	158
7	Statin-Induced Expression of Decay-Accelerating Factor Protects Vascular Endothelium Against Complement-Mediated Injury. Circulation Research, 2002, 91, 696-703.	2.0	85
8	How best to counteract the enemies? By controlling inflammation in the coronary circulation. European Heart Journal Supplements, 2002, 4, G53-G65.	0.0	2
10	Ist Cholesterin ein Risikofaktor fÃ¼r den Schlaganfall?. Aktuelle Neurologie, 2002, 29, 247-253.	0.1	0
11	Re-endothelialization Via Bone Marrow-Derived Progenitor Cells. Arteriosclerosis, Thrombosis, and Vascular Biology, 2002, 22, 1509-1511.	1.1	11
12	Simvastatin Promotes Atherosclerotic Plaque Stability in ApoE-Deficient Mice Independently of Lipid Lowering. Arteriosclerosis, Thrombosis, and Vascular Biology, 2002, 22, 1832-1837.	1.1	135
13	TLR4-mediated inflammatory activation of human coronary artery endothelial cells by LPS. Cardiovascular Research, 2002, 56, 126-134.	1.8	191
14	Therapeutic Controversies; Lack of Therapeutic Interchangeability of HMG-CoA Reductase Inhibitors. Annals of Pharmacotherapy, 2002, 36, 1907-1917.	0.9	30
15	Cholesterol Depletion from the Plasma Membrane Triggers Ligand-independent Activation of the Epidermal Growth Factor Receptor. Journal of Biological Chemistry, 2002, 277, 49631-49637.	1.6	167
16	Pravastatin promotes coronary collateral circulation in patients with coronary artery disease. Coronary Artery Disease, 2002, 13, 377-381.	0.3	21
17	Early initiation of statin therapy after a coronary event. Current Opinion in Lipidology, 2002, 13, 631-635.	1.2	3
18	Interactions between hypercholesterolemia and hypertension: implications for therapy. Current Opinion in Nephrology and Hypertension, 2002, 11, 489-496.	1.0	52
19	Genes potentially involved in plaque rupture. Current Opinion in Lipidology, 2002, 13, 545-552.	1.2	17

#	Article	IF	Citations
20	Beyond LDL-C â€“ The Importance of Raising HDL-C. Current Medical Research and Opinion, 2002, 18, 36-44.	0.9	42
21	Clinical Importance of Endothelial Function in Arteriosclerosis and Ischemic Heart Disease. Circulation Journal, 2002, 66, 529-533.	0.7	97
22	3-Hydroxy-3-methylglutaryl coenzyme A reductase inhibitors and rhabdomyolysis: considerations in the renal failure patient. Current Opinion in Nephrology and Hypertension, 2002, 11, 123-133.	1.0	27
23	Simvastatin normalizes QTc dispersion and reduces ventricular electrical instability in isolated hypercholesterolemia. Journal of Endocrinological Investigation, 2002, 25, RC16-RC18.	1.8	11
24	Fundamentals of Endothelial Function for the Clinical Cardiologist. Circulation, 2002, 105, 546-549.	1.6	496
25	Lipoprotein metabolism and molecular pathogenesis of atherosclerosis. Advances in Cell Aging and Gerontology, 2002, 11, 23-77.	0.1	0
26	A dietary portfolio approach to cholesterol reduction: Combined effects of plant sterols, vegetable proteins, and viscous fibers in hypercholesterolemia. Metabolism: Clinical and Experimental, 2002, 51, 1596-1604.	1.5	159
27	Regulated accumulation of 3-hydroxy-3-methylglutaryl CoA reductase protein in potato cell cultures: effects of calcium and enzyme inhibitors. Journal of Plant Physiology, 2002, 159, 1301-1307.	1.6	5
28	Insulin Resistance, ADMA Levels, and Cardiovascular Disease. JAMA - Journal of the American Medical Association, 2002, 287, 1451.	3.8	27
29	Statin Lipid-Lowering Therapy for Acute Myocardial Infarction and Unstable Angina: Efficacy and Mechanism of Benefit. Mayo Clinic Proceedings, 2002, 77, 1085-1092.	1.4	43
31	Reduction of bFGF-induced smooth muscle cell proliferation and endothelin receptor mRNA expression by mevastatin and atorvastatin. Biochemical Pharmacology, 2002, 64, 497-505.	2.0	31
32	Hypercholesterolemia promotes inflammation and microvascular dysfunction: role of nitric oxide and superoxide1. Free Radical Biology and Medicine, 2002, 33, 1026-1036.	1.3	228
33	Role of statin drugs in acute coronary syndromes. Current Atherosclerosis Reports, 2002, 4, 161-163.	2.0	0
34	Statins: the new aspirin?. Cellular and Molecular Life Sciences, 2002, 59, 1771-1786.	2.4	86
35	Atherogenesis in perspective: Hypercholesterolemia and inflammation as partners in crime. Nature Medicine, 2002, 8, 1211-1217.	15.2	623
36	Caveolin: a key target for modulating nitric oxide availability in health and disease. Molecular and Cellular Biochemistry, 2003, 247, 101-109.	1.4	9
37	Statins and the role of nitric oxide in chronic heart failure. Heart Failure Reviews, 2003, 8, 99-106.	1.7	64
38	Comparing HMG-CoA reductase inhibitors. Clinical Cardiology, 2003, 26, 15-20.	0.7	18

#	Article	IF	Citations
39	Isoprenoid metabolism and the pleiotropic effects of statins. Current Atherosclerosis Reports, 2003, 5, 372-378.	2.0	84
42	Therapeutic potential of lovastatin in multiple sclerosis. Journal of Neurology, 2003, 250, 754-755.	1.8	92
43	Molecular mechanism of the anti-cancer activity of cerivastatin, an inhibitor of HMG-CoA reductase, on aggressive human breast cancer cells. Cellular Signalling, 2003, 15, 327-338.	1.7	112
44	Usefulness of elevated levels of soluble vascular cell adhesion molecule-1 in predicting in-hospital prognosis in patients with unstable angina pectoris. American Journal of Cardiology, 2003, 92, 1195-1197.	0.7	28
45	Effect of atorvastatin on exercise-induced myocardial ischemia in patients with stable angina pectoris. American Journal of Cardiology, 2003, 92, 1192-1195.	0.7	8
46	Statin effects on cholesterol micro-domains in brain plasma membranes. Biochemical Pharmacology, 2003, 65, 843-856.	2.0	162
47	Effects of statins on the vasculature. American Journal of Cardiology, 2003, 91, 14-22.	0.7	69
48	Atorvastatin inhibits expression of minichromosome maintenance proteins in vascular smooth muscle cells. European Journal of Pharmacology, 2003, 462, 15-23.	1.7	14
49	The lipid and non-lipid effects of statins. , 2003, 99, 95-112.		217
50	Pitavastatin alters the expression of thrombotic and fibrinolytic proteins in human vascular cells. Journal of Cellular Biochemistry, 2003, 90, 23-32.	1.2	47
51	The appearance of aggregated erythrocytes in the peripheral blood of individuals with insulin resistance. Diabetes/Metabolism Research and Reviews, 2003, 19, 386-391.	1.7	10
52	Inhibition of the thrombogenic and inflammatory properties of antiphospholipid antibodies by fluvastatin in an in vivo animal model. Arthritis and Rheumatism, 2003, 48, 3272-3279.	6.7	138
53	Anti-inflammatory and immunomodulatory effects of statins. Kidney International, 2003, 63, 12-23.	2.6	279
54	Low-density Lipoprotein Apheresis in the Prevention of Recurrent Coronary Heart Disease: A Review. Therapeutic Apheresis and Dialysis, 2003, 7, 408-412.	0.4	15
55	Effects of statins on adhesion molecule expression in endothelial cells. Journal of Thrombosis and Haemostasis, 2003, 1, 2290-2299.	1.9	30
56	No acute impact of lipid apheresis treatment on free radical scavenging enzyme gene expression in white blood cells. European Journal of Clinical Investigation, 2003, 33, 134-140.	1.7	3
57	Mechanisms, challenges and opportunities in stroke. Nature Reviews Neuroscience, 2003, 4, 399-414.	4.9	1,584
58	TratamientoÂ farmacolÃ³gico del riesgo cardiovascular metabÃ³lico. Medicine, 2003, 8, 6382-6395.	0.0	0

#	Article	IF	Citations
60	Interactions between inflammation, oxidative stress, and endothelial dysfunction in end-stage renal disease. , 2003, 13, 144-148.		68
61	Influence of 3-hydroxy-3-methylglutaryl-CoA (HMG-CoA) reductase inhibitors on endothelial nitric oxide synthase and the formation of oxidants in the vasculature. Atherosclerosis, 2003, 169, 19-29.	0.4	53
62	Atorvastatin markedly improves type III hyperlipoproteinemia in association with reduction of both exogenous and endogenous apolipoprotein B-containing lipoproteins. Atherosclerosis, 2003, 168, 359-366.	0.4	19
63	Atorvastatin, administered at the onset of reperfusion, and independent oflipid lowering, protects the myocardiumby up-regulating a pro-survival pathway. Journal of the American College of Cardiology, 2003, 41, 508-515.	1.2	226
64	Benefits and Risks of Simvastatin in Patients with Familial Hypercholesterolaemia. Drug Safety, 2003, 26, 769-786.	1.4	5
65	The Pleiotropic Effects of HMG-CoA Reductase Inhibitors. Drugs, 2003, 63, 139-152.	4.9	47
66	Mevastatin suppresses lipopolysaccharide-induced Rac activation in the human monocyte cell line THP-1. Surgery, 2003, 134, 306-311.	1.0	17
67	Inflammation in atherosclerosis: causal or casual? The need for randomized trials. American Heart Journal, 2003, 146, 199-202.	1.2	2
68	Plasma thioredoxin levels and platelet aggregability in patients with acute myocardial infarction. American Heart Journal, 2003, 146, 465-471.	1.2	44
69	Statin use is associated with enhanced collateralization of severely diseased coronary arteries. American Heart Journal, 2003, 146, 876-881.	1.2	52
70	New Insights on Oxidative Stress and Diabetic Complications May Lead to a "Causal" Antioxidant Therapy. Diabetes Care, 2003, 26, 1589-1596.	4.3	644
71	Old and new cardiovascular risk factors: from unresolved issues to new opportunities. Atherosclerosis Supplements, 2003, 4, 5-17.	1.2	31
72	3-Hydroxy-3-methylglutaryl coenzyme A reductase inhibitors prevent the development of cardiac hypertrophy and heart failure in rats. Journal of Molecular and Cellular Cardiology, 2003, 35, 953-960.	0.9	83
73	Mechanism of simvastatin on induction of heat shock protein in osteoblasts. Archives of Biochemistry and Biophysics, 2003, 415, 6-13.	1.4	38
74	Simvastatin stimulates VEGF release via p44/p42 MAP kinase in vascular smooth muscle cells. Biochemical and Biophysical Research Communications, 2003, 301, 198-203.	1.0	34
75	PKC is required for activation of ROCK by RhoA in human endothelial cells. Biochemical and Biophysical Research Communications, 2003, 304, 714-719.	1.0	43
76	The effect of combining plant sterols, soy protein, viscous fibers, and almonds in treating hypercholesterolemia. Metabolism: Clinical and Experimental, 2003, 52, 1478-1483.	1.5	127
77	Atorvastatin reduces interleukin-6 plasma concentration and adipocyte secretion of hypercholesterolemic rabbits. Clinica Chimica Acta, 2003, 336, 103-108.	0.5	41

#	Article	IF	Citations
78	Results of the Heart Protection Study: can we still assume a class effect?. International Congress Series, 2003, 1253, 253-259.	0.2	0
79	Coronary atherosclerosis and somatic mutations: an overview of the contributive factors for oxidative DNA damage. Mutation Research - Reviews in Mutation Research, 2003, 543, 67-86.	2.4	126
80	Atherosclerosis: anti-inflammatory and immunomodulatory activities of statins. Autoimmunity Reviews, 2003, 2, 332-338.	2.5	94
81	Editorial: Rho-Kinase Inhibitors: Potential Therapeutics for Benign Prostate Hyperplasia. Journal of Urology, 2003, 170, 2523-2524.	0.2	4
82	Age-Related Endothelial Dysfunction. Drugs and Aging, 2003, 20, 527-550.	1.3	73
83	Oxidative Stress and Endothelial Nitric Oxide Bioactivity. Antioxidants and Redox Signaling, 2003, 5, 181-194.	2.5	80
84	New drugs for the treatment of hypercholesterolaemia. Expert Opinion on Investigational Drugs, 2003, 12, 1777-1789.	1.9	29
85	Reduced Connexin43 Expression Inhibits Atherosclerotic Lesion Formation in Low-Density Lipoprotein Receptorâ€“Deficient Mice. Circulation, 2003, 107, 1033-1039.	1.6	155
86	Flow, NO, and atherogenesis. Proceedings of the National Academy of Sciences of the United States of America, 2003, 100, 768-770.	3.3	125
87	Noncholesterol-Lowering Effects of Statins. Vascular and Endovascular Surgery, 2003, 37, 301-313.	0.3	22
88	Asymmetric dimethylarginine (ADMA) modulates endothelial function - therapeutic implications. Vascular Medicine, 2003, 8, 149-151.	0.8	52
89	Statins in multiple sclerosis: a new therapeutic option?. Multiple Sclerosis Journal, 2003, 9, 429-430.	1.4	10
90	Statin-exposed vascular smooth muscle cells secrete proteoglycans with decreased binding affinity for LDL. Journal of Lipid Research, 2003, 44, 2152-2160.	2.0	22
91	The association between statin use and age related maculopathy. British Journal of Ophthalmology, 2003, 87, 1121-1125.	2.1	118
92	Early Embryonic Lethality Caused by Targeted Disruption of the 3-Hydroxy-3-methylglutaryl-CoA Reductase Gene. Journal of Biological Chemistry, 2003, 278, 42936-42941.	1.6	94
93	Review: Lipid lowering drugs, inflammation and cardiovascular disease. British Journal of Diabetes and Vascular Disease, 2003, 3, 178-182.	0.6	2
94	Pitavastatin-Induced Thrombomodulin Expression by Endothelial Cells Acts Via Inhibition of Small G Proteins of the Rho Family. Arteriosclerosis, Thrombosis, and Vascular Biology, 2003, 23, 512-517.	1.1	114
95	Variants of Toll-Like Receptor 4 Modify the Efficacy of Statin Therapy and the Risk of Cardiovascular Events. Circulation, 2003, 107, 2416-2421.	1.6	211

#	Article	IF	Citations
96	Rho-Associated Protein Kinase Contributes to Early Atherosclerotic Lesion Formation in Mice. Circulation Research, 2003, 93, 884-888.	2.0	155
98	Simvastatin Reduces the Expression of Adhesion Molecules in Circulating Monocytes From Hypercholesterolemic Patients. Arteriosclerosis, Thrombosis, and Vascular Biology, 2003, 23, 397-403.	1.1	138
99	Reduced Expression of Endothelial Connexin37 and Connexin40 in Hyperlipidemic Mice. Arteriosclerosis, Thrombosis, and Vascular Biology, 2003, 23, 1391-1397.	1.1	62
100	Simvastatin attenuates leucocyte-endothelial interactions after coronary revascularisation with cardiopulmonary bypass. British Heart Journal, 2003, 89, 538-543.	2.2	59
101	Statins Promote Potent Systemic Antioxidant Effects Through Specific Inflammatory Pathways. Circulation, 2003, 108, 426-431.	1.6	380
102	Inhibition of Hydroxymethylglutaryl-Coenzyme A Reductase Reduces Th1 Development and Promotes Th2 Development. Circulation Research, 2003, 93, 948-956.	2.0	176
103	Statins and Autoimmunity. Handbook of Systemic Autoimmune Diseases, 2003, 1, 97-106.	0.1	0
104	HMG-CoA Reductase Inhibitors Regulate Inflammatory Transcription Factors in Human Endothelial and Vascular Smooth Muscle Cells. Arteriosclerosis, Thrombosis, and Vascular Biology, 2003, 23, 58-63.	1.1	320
105	Statins Inhibit Secretion of Metalloproteinases-1, -2, -3, and -9 From Vascular Smooth Muscle Cells and Macrophages. Arteriosclerosis, Thrombosis, and Vascular Biology, 2003, 23, 769-775.	1.1	318
106	Mechanisms of oxidative stress and vascular dysfunction. Postgraduate Medical Journal, 2003, 79, 195-200.	0.9	151
107	Rapid Effect of 3-Hydroxy-3-Methylglutaryl Coenzyme A Reductase Inhibition on Coronary Endothelial Function. Circulation Research, 2003, 93, e98-103.	2.0	153
108	Statins (HMG-CoA reductase inhibitors) reduce CD40 expression in human vascular cells. Cardiovascular Research, 2003, 59, 755-766.	1.8	115
109	Role of Mechanical Stress in Monocytes / Macrophages: Implications for Atherosclerosis. Current Vascular Pharmacology, 2003, 1, 315-319.	0.8	30
110	Effect of Atorvastatin on Adhesive Phenotype of Human Endothelial Cells Activated By Tumor Necrosis Factor Alpha. Journal of Cardiovascular Pharmacology, 2003, 41, 316-324.	0.8	39
111	Prophylactic but Not Delayed Administration of Simvastatin Protects Against Long-Lasting Cognitive and Morphological Consequences of Neonatal Hypoxic-Ischemic Brain Injury, Reduces Interleukin-1Î² and Tumor Necrosis Factor-Î± mRNA Induction, and Does Not Affect Endothelial Nitric Oxide Synthase Expression. Stroke, 2003, 34, 2007-2012.	1.0	83
112	Statins Regulate Î±2Î²1-Integrin Expression and Collagen Iâ€“Dependent Functions in Human Vascular Smooth Muscle Cells. Journal of Cardiovascular Pharmacology, 2003, 41, 89-96.	0.8	16
113	Brain Cholesterol, Statins and Alzheimerâ€™s Disease. Pharmacopsychiatry, 2003, 36, 113-119.	1.7	41
114	Endothelial Therapy of Atherosclerosis and its Risk Factors. Current Vascular Pharmacology, 2003, 1, 111-121.	0.8	26

#	Article	IF	Citations
115	Statins Can Inhibit Proliferation of Human Breast Cancer Cells in Vitro. Experimental and Clinical Endocrinology and Diabetes, 2003, 111, 47-48.	0.6	92
116	Statins increase thrombomodulin expression and function in human endothelial cells by a nitric oxide-dependent mechanism and counteract tumor necrosis factor alpha-induced thrombomodulin downregulation. Blood Coagulation and Fibrinolysis, 2003, 14, 575-585.	0.5	109
117	Effects of Cerivastatin on Human Arterial Smooth Muscle Cell Growth and Extracellular Matrix Expression at Varying Glucose and Low-density Lipoprotein Levels. Journal of Cardiovascular Pharmacology, 2003, 41, 422-433.	0.8	14
118	The HMG-CoA Reductase Inhibitor Cerivastatin Enhances the Nitric Oxide Bioavailability of the Endothelium. Journal of Cardiovascular Pharmacology, 2003, 42, 356-363.	0.8	8
119	Emerging role of myeloperoxidase and oxidant stress markers in cardiovascular risk assessment. Current Opinion in Lipidology, 2003, 14, 353-359.	1.2	130
120	Acute Vasodilator Effects of HMG-CoA Reductase Inhibitors: Involvement of P13-kinase/Akt Pathway and Kv Channels. Journal of Cardiovascular Pharmacology, 2003, 42, 118-123.	0.8	31
121	C-reactive protein and interleukin-6 in vascular disease. Journal of Hypertension, 2003, 21, 1787-1803.	0.3	152
122	Interrelationship of Free Oxygen Radicals and Endothelial Dysfunction–Modulation by Statins. Endothelium: Journal of Endothelial Cell Research, 2003, 10, 23-33.	1.7	58
125	Innate Immunity, Inflammation, and Atherogenesis. Handbook of Systemic Autoimmune Diseases, 2003, , 75-88.	0.1	1
126	Effects of Statins on Nonlipid Serum Markers Associated with Cardiovascular Disease. Annals of Internal Medicine, 2003, 139, 670.	2.0	167
127	Statins and their role in vascular protection. Clinical Science, 2003, 105, 251-266.	1.8	100
128	Pravastatin Prevents Arrhythmias Induced by Coronary Artery Ischemia/Reperfusion in Anesthetized Normocholesterolemic Rats. Journal of Pharmacological Sciences, 2003, 93, 87-94.	1.1	45
129	Rac regulates cardiovascular superoxide through diverse molecular interactions: more than a binary GTP switch. American Journal of Physiology - Cell Physiology, 2003, 285, C723-C734.	2.1	114
130	3â€Hydroxyâ€3â€methylglutaryl Coenzyme A Reductase Inhibitors Improve Myocardial Highâ€Energy Phosphate Metabolism in Men. Journal of Cardiovascular Magnetic Resonance, 2003, 5, 595-602.	1.6	12
131	Risk Factors for the Progression of Early Carotid Atherosclerosis in a Male Working Population.. Hypertension Research, 2003, 26, 465-471.	1.5	29
132	Small G Proteins as Novel Therapeutic Targets in Cardiovascular Medicine. Physiology, 2003, 18, 18-22.	1.6	10
133	Attenuation of chronic hypoxic pulmonary hypertension by simvastatin. American Journal of Physiology - Heart and Circulatory Physiology, 2003, 285, H938-H945.	1.5	145
134	Statins in the Primary Prevention of Atherosclerosis-Related Events. , 2004, , 53-92.		1

#	Article	IF	Citations
135	Anticoagulant Effects of Statins. , 2004, , 233-256.		0
136	Chronic mevastatin modulates receptor-dependent vascular contraction in eNOS-deficient mice. American Journal of Physiology - Regulatory Integrative and Comparative Physiology, 2004, 287, R342-R348.	0.9	21
137	Atorvastatin completely inhibits VEGF-induced ACE upregulation in human endothelial cells. American Journal of Physiology - Heart and Circulatory Physiology, 2004, 286, H2096-H2102.	1.5	24
138	Global Analysis of RNA Expression Profile in Human Vascular Cells Treated with Statins. Journal of Atherosclerosis and Thrombosis, 2004, 11, 62-72.	0.9	64
139	Endothelial Secretory Function and Atherothrombosis. , 0, , 267-276.		5
140	Long-Term Treatment with Probucol Improves Endothelial Function in Patients with Coronary Artery Disease. Hypertension Research, 2004, 27, 311-318.	1.5	20
141	New nonlipid effects of statins and their clinical relevance in cardiovascular disease. Thrombosis and Haemostasis, 2004, 91, 1065-1077.	1.8	60
143	Antioxidant Effects of Statins via S -Nitrosylation and Activation of Thioredoxin in Endothelial Cells. Circulation, 2004, 110, 856-861.	1.6	201
144	Statins and the Role of Nitric Oxide in Chronic Heart Failure. , 2004, , 187-194.		1
145	Pulse Pressure Is an Independent Predictor for the Progression of Aortic Wall Calcification in Patients With Controlled Hyperlipidemia. Hypertension, 2004, 43, 536-540.	1.3	57
146	Endothelial Function and Oxidative Stress. Endothelium: Journal of Endothelial Cell Research, 2004, 11, 123-132.	1.7	145
147	Reconstituted High-Density Lipoprotein Inhibits Thrombin-Induced Endothelial Tissue Factor Expression Through Inhibition of RhoA and Stimulation of Phosphatidylinositol 3-Kinase but not Akt/Endothelial Nitric Oxide Synthase. Circulation Research, 2004, 94, 918-925.	2.0	99
148	Statins Inhibit Î²-Adrenergic Receptorâ€“Stimulated Apoptosis in Adult Rat Ventricular Myocytes via a Rac1-Dependent Mechanism. Circulation, 2004, 110, 412-418.	1.6	65
149	Atorvastatin Restores Endothelial Function in Normocholesterolemic Smokers Independent of Changes in Low-Density Lipoprotein. Circulation Research, 2004, 95, 217-223.	2.0	124
150	The â€œCholesteRORâ€•Protective Pathway in the Vascular System. Arteriosclerosis, Thrombosis, and Vascular Biology, 2004, 24, 637-643.	1.1	65
151	Pitavastatin Downregulates Expression of the Macrophage Type B Scavenger Receptor, CD36. Circulation, 2004, 109, 790-796.	1.6	78
152	Beyond the Laboratory: Clinical Implications for Statin Pleiotropy. Circulation, 2004, 109, II-42-II-48.	1.6	161
153	Statins for Stroke Prevention: Disappointment and Hope. Circulation, 2004, 109, III-44-III-49.	1.6	58

#	Article	IF	Citations
154	High-Dose Atorvastatin Reduces Total Plasma Levels of Oxidized Phospholipids and Immune Complexes Present on Apolipoprotein B-100 in Patients With Acute Coronary Syndromes in the MIRACL Trial. Circulation, 2004, 110, 1406-1412.	1.6	209
155	Statin Induction of Liver Fatty Acid-Binding Protein (L-FABP) Gene Expression Is Peroxisome Proliferator-activated Receptor-Î±-dependent. Journal of Biological Chemistry, 2004, 279, 45512-45518.	1.6	84
156	Statins' Coat of Many Colors Receives Yet Another Hue. Journal of the American Society of Nephrology: JASN, 2004, 15, 1098-1100.	3.0	3
157	Absence of Interaction Between Atorvastatin or Other Statins and Clopidogrel. Archives of Internal Medicine, 2004, 164, 2051.	4.3	142
158	Statins and Stroke Prevention. Cerebrovascular Diseases, 2004, 17, 81-88.	0.8	28
159	Effect of Withdrawal of Statin on C-Reactive Protein. Cardiology, 2004, 102, 166-170.	0.6	35
160	Impaired myocardial vasodilatation during hyperaemic stress is improved by simvastatin but not by pravastatin in patients with hypercholesterolaemia. European Heart Journal, 2004, 25, 671-679.	1.0	21
161	Statins to prevent cardiovascular events in hypertensive patients. The ASCOT-LLA study. Nephrology Dialysis Transplantation, 2004, 19, 528-531.	0.4	19
162	Monitoring the Cellular Effects of HMG-CoA Reductase Inhibitors In Vitro and Ex Vivo. Arteriosclerosis, Thrombosis, and Vascular Biology, 2004, 24, 2046-2050.	1.1	38
163	Statins and Other Cholesterol-Lowering Medications and the Presenceof Glaucoma. JAMA Ophthalmology, 2004, 122, 822.	2.6	122
164	Effect of 3-hydroxy-3-methylglutarylcoenzyme A Reductase Inhibitors (Statins) on Tissue Paraoxonase 1 and Plasma Platelet Activating Factor Acetylhydrolase Activities. Journal of Cardiovascular Pharmacology, 2004, 43, 121-127.	0.8	31
165	Modulatory effects of HMGâ€CoA reductase inhibitors in diabetic microangiopathy. FASEB Journal, 2004, 18, 805-815.	0.2	73
166	Simvastatin Induces Heme Oxygenase-1. Circulation, 2004, 110, 1296-1302.	1.6	260
167	Actions of Statins on Ox-LDL-Mediated Signaling and Inflammation. , 2004, , 203-218.		0
168	HMG-CoA reductase inhibitor attenuates experimental autoimmune myocarditis through inhibition of T cell activation. Cardiovascular Research, 2004, 64, 412-420.	1.8	51
169	New Insights from Trials of Statins in Animal Models of Atherosclerosis. , 2004, , 13-35.		0
170	Simvastatin Modulates Angiotensin II Signaling Pathway by Preventing Rac1-Mediated Upregulation of p27. Journal of the American Society of Nephrology: JASN, 2004, 15, 1711-1720.	3.0	28
171	Acute activation and phosphorylation of endothelial nitric oxide synthase by HMG-CoA reductase inhibitors. American Journal of Physiology - Heart and Circulatory Physiology, 2004, 287, H560-H566.	1.5	101

#	Article	IF	Citations
172	The use of statins in optimising reduction of cardiovascular risk: focus on fluvastatin. International Journal of Clinical Practice, 2004, 58, 494-503.	0.8	8
173	Fluvastatin inhibits up-regulation of tissue factor expression by antiphospholipid antibodies on endothelial cells. Journal of Thrombosis and Haemostasis, 2004, 2, 1558-1563.	1.9	121
174	Circulating Monocytes and Plasma Inflammatory Biomarkers in Active CrohnÊ¼s Disease. Inflammatory Bowel Diseases, 2004, 10, 193-200.	0.9	30
175	Are statins a treatment option for multiple sclerosis?. Lancet Neurology, The, 2004, 3, 369-371.	4.9	77
176	Down-regulating effect of nicotine on connexin43 gap junctions in human umbilical vein endothelial cells is attenuated by statins. European Journal of Cell Biology, 2004, 82, 589-595.	1.6	38
177	The Role of Statins in Vascular Disease. European Journal of Vascular and Endovascular Surgery, 2004, 27, 6-16.	0.8	48
178	A Combination of Statins and Beta-blockers is Independently Associated with a Reduction in the Incidence of Perioperative Mortality and Nonfatal Myocardial infarction in Patients Undergoing Abdominal Aortic Aneurysm Surgery. European Journal of Vascular and Endovascular Surgery, 2004, 28, 343-352.	0.8	204
179	Effect of fluvastatin on long-term outcome after coronary revascularization with stent implantation. American Journal of Cardiology, 2004, 93, 92-95.	0.7	12
180	Effect of atorvastatin 80 mg on endothelial cell function (forearm blood flow) in patients with pretreatment serum low-density lipoprotein cholesterol levels <130 mg/dl. American Journal of Cardiology, 2004, 93, 84-88.	0.7	49
181	The antioxidant defense protein heme oxygenase 1 is a novel target for statins in endothelial cells. Free Radical Biology and Medicine, 2004, 37, 2064-2071.	1.3	156
182	Statins upregulate CD36 expression in human monocytes, an effect strengthened when combined with PPAR-Î³ ligands Putative contribution of Rho GTPases in statin-induced CD36 expression. Biochemical Pharmacology, 2004, 67, 303-313.	2.0	61
183	Rho Proteins and Cancer. Breast Cancer Research and Treatment, 2004, 84, 13-19.	1.1	174
184	Lipid-Lowering Effects of Ethyl 2-Phenacyl-3-aryl-1H-pyrrole- 4-carboxylates in Rodents. Molecules, 2004, 9, 134-157.	1.7	25
185	Vitamin E for the Treatment of Cardiovascular Disease: Is There a Future?. Annals of the New York Academy of Sciences, 2004, 1031, 292-304.	1.8	25
186	The effect of simvastatin on serum cytokine levels and bone metabolism in postmenopausal subjects: negative correlation between TNF-Î± and anabolic bone parameters. Journal of Bone and Mineral Metabolism, 2004, 22, 365-371.	1.3	13
188	Pulmonary arterial hypertension in children. Pediatric Pulmonology, 2004, 38, 2-22.	1.0	134
189	Mechanistic and epidemiologic considerations in the evaluation of adverse birth outcomes following gestational exposure to statins. American Journal of Medical Genetics Part A, 2004, 131A, 287-298.	2.4	171
190	Statins inhibit in vitro calcification of human vascular smooth muscle cells induced by inflammatory mediators. Journal of Cellular Biochemistry, 2004, 93, 1011-1019.	1.2	44

#	Article	IF	Citations
191	Use of statins prior to percutaneous coronary intervention reduces myonecrosis and improves clinical outcome. Catheterization and Cardiovascular Interventions, 2004, 62, 193-197.	0.7	45
192	Simple, sensitive and rapid LCâ€“MS/MS method for the quantitation of cerivastatin in human plasma â€" application to pharmacokinetic studies. Journal of Pharmaceutical and Biomedical Analysis, 2004, 36, 505-515.	1.4	25
193	A Novel Anti-Inflammatory Role of Simvastatin in a Murine Model of Allergic Asthma. Journal of Immunology, 2004, 172, 2903-2908.	0.4	288
194	Statins in Stroke Prevention and Carotid Atherosclerosis. Stroke, 2004, 35, 2902-2909.	1.0	686
195	Estatinas y enfermedad cardiovascular: Â¿el descenso de colesterol es un efecto secundario de estos fÃ¡rmacos?. ClÃnica E InvestigaciÃ³n En Arteriosclerosis, 2004, 16, 204-206.	0.4	0
196	ATORVASTATIN AMELIORATES RENAL TISSUE DAMAGE IN UNILATERAL URETERAL OBSTRUCTION. Journal of Urology, 2004, 172, 2456-2459.	0.2	48
197	Perfil de la expresiÃ³n gÃ©nica de los macrÃ³fagos humanos en cultivo en respuesta a atorvastatina. ClÃnica E InvestigaciÃ³n En Arteriosclerosis, 2004, 16, 175-184.	0.4	1
198	Nitric oxide, angiotensin II, and hypertension. Seminars in Nephrology, 2004, 24, 366-378.	0.6	103
200	Simvastatin enhances hepatic nitric oxide production and decreases the hepatic vascular tone in patients with cirrhosis. Gastroenterology, 2004, 126, 749-755.	0.6	258
201	Direct inhibition by a statin of TNFÎ±-induced leukocyte recruitment in rat pial venules â€" in vivo confocal microscopic study. Pathophysiology, 2004, 11, 121-128.	1.0	10
202	Can statins treat the strokes they fail to prevent?. Journal of the Neurological Sciences, 2004, 221, 1-2.	0.3	6
204	Fluvastatin. Drugs, 2004, 64, 1305-1323.	4.9	23
205	Are Cardiovascular Disease and Osteoporosis Directly Linked?. Sports Medicine, 2004, 34, 779-807.	3.1	32
206	Strategies to Increase HMG-CoA Reductase Inhibitor Use After Acute Myocardial Infarction. Drugs and Aging, 2004, 21, 583-595.	1.3	1
207	Statins in Hypertensive Patients. Drugs, 2004, 64, 61-67.	4.9	5
208	Abrogation of Insulin-like Growth Factor-I (IGF-I) and Insulin Action by Mevalonic Acid Depletion. Journal of Biological Chemistry, 2004, 279, 38353-38359.	1.6	65
209	New directions for protecting the heart against ischaemiaâ€“reperfusion injury: targeting the Reperfusion Injury Salvage Kinase (RISK)-pathway. Cardiovascular Research, 2004, 61, 448-460.	1.8	873
210	Is Oxidative Stress the Pathogenic Mechanism Underlying Insulin Resistance, Diabetes, and Cardiovascular Disease? The Common Soil Hypothesis Revisited. Arteriosclerosis, Thrombosis, and Vascular Biology, 2004, 24, 816-823.	1.1	1,151

#	Article	IF	Citations
211	Vascular Smooth Muscle Cell Migration: Current Research and Clinical Implications. Vascular and Endovascular Surgery, 2004, 38, 11-23.	0.3	95
212	Antioxidants Inhibit Nuclear Export of Telomerase Reverse Transcriptase and Delay Replicative Senescence of Endothelial Cells. Circulation Research, 2004, 94, 768-775.	2.0	350
213	Fluvastatin and fluvastatin extended release: a clinical and safety profile. Expert Review of Cardiovascular Therapy, 2004, 2, 641-652.	0.6	15
214	Atorvastatin enhances cellular uptake of oxidized LDL in adipocytes from hypercholesterolemic rabbits. Clinica Chimica Acta, 2004, 339, 189-194.	0.5	21
215	Simvastatin reduces interleukin-1Î² secretion by peripheral blood mononuclear cells in patients with essential hypertension. Clinica Chimica Acta, 2004, 344, 195-200.	0.5	34
216	Pravastatin up-regulates transforming growth factor-Î²1 in THP-1 human macrophages: effect on scavenger receptor class A expression. Biochemical and Biophysical Research Communications, 2004, 314, 704-710.	1.0	20
217	Statins downregulate ATP-binding-cassette transporter A1 gene expression in macrophages. Biochemical and Biophysical Research Communications, 2004, 316, 790-794.	1.0	57
218	Statin decreases endothelial microparticle release from human coronary artery endothelial cells: implication for the Rho-kinase pathway. Biochemical and Biophysical Research Communications, 2004, 320, 34-38.	1.0	126
219	Immunologic manipulation for the threatened fetus. Thrombosis Research, 2004, 114, 427-434.	0.8	3
220	Optimal management of hyperlipidemia in primary prevention of cardiovascular disease. International Journal of Cardiology, 2004, 97, 355-366.	0.8	28
221	Simvastatin suppresses LPS-induced Akt phosphorylation in the human monocyte cell line THP-1. Journal of Surgical Research, 2004, 116, 116-120.	0.8	29
222	Novel cardioprotective effects of pravastatin in human ventricular cardiomyocytes subjected to hypoxia and reoxygenation: beneficial effects of statins independent of endothelial cells1. Journal of Surgical Research, 2004, 119, 66-71.	0.8	35
223	Fluvastatin and bisoprolol for the reduction of perioperative cardiac mortality and morbidity in high-risk patients undergoing non-cardiac surgery: Rationale and design of the DECREASE-IV study. American Heart Journal, 2004, 148, 1047-1052.	1.2	77
224	Effect of amlodipine?atorvastatin combination on fibrinolysis in hypertensive hypercholesterolemic patients with insulin resistance. American Journal of Hypertension, 2004, 17, 823-827.	1.0	41
225	Atorvastatin reduces arterial stiffness in patients with rheumatoid arthritis. Annals of the Rheumatic Diseases, 2004, 63, 1571-1575.	0.5	116
226	Stroke prevention, blood cholesterol, and statins. Lancet Neurology, The, 2004, 3, 271-278.	4.9	115
227	Integrins and Coagulation: A Role for ROS/Redox Signaling?. Antioxidants and Redox Signaling, 2004, 6, 757-764.	2.5	54
228	HMG-CoA reductase inhibitors suppress maturation of human dendritic cells: new implications for atherosclerosis. Atherosclerosis, 2004, 172, 85-93.	0.4	132

#	Article	IF	Citations
229	Fluvastatin inhibits raft dependent FcÎ³ receptor signalling in human monocytes. Atherosclerosis, 2004, 172, 219-228.	0.4	65
230	Inhibitory efficacy of pitavastatin on the early inflammatory response and neointimal thickening in a porcine coronary after stenting. Atherosclerosis, 2004, 174, 253-259.	0.4	36
231	Simvastatin inhibits lymphocyte function in normal subjects and patients with cardiovascular disease. Atherosclerosis, 2004, 175, 305-313.	0.4	64
232	Convergence of atherosclerosis and Alzheimer's disease: inflammation, cholesterol, and misfolded proteins. Lancet, The, 2004, 363, 1139-1146.	6.3	510
233	Emphasis on pleiotropic effects, a new paradigm shift?. Coronary Artery Disease, 2004, 15, 223-225.	0.3	13
234	Overexpression of Neural Cell Adhesion Molecule in Regenerative Muscle Fibers in 3-Hydroxy-3-Methylglutaryl Coenzyme: A Reductase Inhibitor-induced Rhabdomyolysis. Applied Immunohistochemistry and Molecular Morphology, 2004, 12, 234-239.	0.6	3
235	Pitavastatin, a 3-Hydroxy-3-methylglutaryl-coenzyme A Reductase Inhibitor, Blocks Vascular Smooth Muscle Cell Populated-Collagen Lattice Contraction. Journal of Cardiovascular Pharmacology, 2004, 43, 808-814.	0.8	17
236	Nutrition and metabolism. Current Opinion in Lipidology, 2004, 15, 77-79.	1.2	0
237	Nitric oxide signaling: systems integration of oxygen balance in defense of cell integrity. Current Opinion in Hematology, 2004, 11, 7-14.	1.2	31
238	Residual coronary risk in men aged 50â€“59 years treated for hypertension and hyperlipidaemia in the population. Journal of Hypertension, 2004, 22, 415-423.	0.3	25
239	Vitamin E and other antioxidants in the prevention of cardiovascular disease. , 2004, , 77-98.		0
240	Evidence for anti-inflammatory activity of statins and PPARÎ± activators in human C-reactive protein transgenic mice in vivo and in cultured human hepatocytes in vitro. Blood, 2004, 103, 4188-4194.	0.6	166
241	Endothelial cell expression of tissue factor in sickle mice is augmented by hypoxia/reoxygenation and inhibited by lovastatin. Blood, 2004, 104, 840-846.	0.6	180
242	Statins Induce the Regression of Left Ventricular Mass in Patients With Angina. Circulation Journal, 2004, 68, 121-125.	0.7	30
243	Simvastatin, an HMG-CoA Reductase Inhibitor, Reduced the Expression of Matrix Metalloproteinase-9 (Gelatinase B) in Osteoblastic Cells and HT1080 Fibrosarcoma Cells. Journal of Pharmacological Sciences, 2004, 94, 403-409.	1.1	45
244	Effect of Prior Statin Use on Functional Outcome and Delayed Vasospasm after Acute Aneurysmal Subarachnoid Hemorrhage: A Matched Controlled Cohort Study. Neurosurgery, 2005, 56, 476-484.	0.6	107
245	CD40-ligand-dependent induction of COX-2 gene expression in endothelial cells by activated platelets: inhibitory effects of atorvastatin. Blood Coagulation and Fibrinolysis, 2005, 16, 105-110.	0.5	23
246	Effect of statins in stroke prevention. Current Opinion in Lipidology, 2005, 16, 614-618.	1.2	20

#	Article	IF	Citations
247	Atorvastatin and Myocardial Reperfusion Injury. Journal of Cardiovascular Pharmacology, 2005, 45, 247-252.	0.8	70
248	The statins - therapeutic diversity in renal disease?. Current Opinion in Nephrology and Hypertension, 2005, 14, 17-24.	1.0	22
249	Statins in the prevention of perioperative cardiovascular complications. Current Opinion in Anaesthesiology, 2005, 18, 51-55.	0.9	11
250	Novel and simple high-performance liquid chromatographic method for determination of 3-hydroxy-3-methylglutaryl-coenzyme A reductase activity. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 2005, 819, 307-313.	1.2	7
252	Inflammation, Atherosclerosis, and Coronary Artery Disease. New England Journal of Medicine, 2005, 352, 1685-1695.	13.9	7,433
253	Negative impact of depression on outcomes in patients with coronary artery disease: mechanisms, treatment considerations, and future directions. Journal of Thrombosis and Haemostasis, 2005, 3, 897-908.	1.9	53
254	Pharmacologic adjuvants to epoetin in the treatment of anemia in patients on hemodialysis. Hemodialysis International, 2005, 9, 7-22.	0.4	16
255	Protective Effects of Statins Involving Both eNOS and tPA in Focal Cerebral Ischemia. Journal of Cerebral Blood Flow and Metabolism, 2005, 25, 722-729.	2.4	137
256	The bisphosphonate acute phase response: rapid and copious production of proinflammatory cytokines by peripheral blood gd T cells in response to aminobisphosphonates is inhibited by statins. Clinical and Experimental Immunology, 2005, 139, 101-111.	1.1	215
257	The imidazoline-like drug S23515 affects lipid metabolism in hepatocyte by inhibiting the oxidosqualene:lanosterol cyclase activity. Biochemical Pharmacology, 2005, 69, 1041-1048.	2.0	8
258	Effect of statins on the proteasomal activity in mammalian endothelial and vascular smooth muscle cells. Biochemical Pharmacology, 2005, 70, 520-526.	2.0	25
259	Effects of Statins on 3-Hydroxy-3-Methylglutaryl Coenzyme A Reductase Inhibition Beyond Low-Density Lipoprotein Cholesterol. American Journal of Cardiology, 2005, 96, 24-33.	0.7	243
260	Statin attenuates high glucose-induced and diabetes-induced oxidative stress in vitro and in vivo evaluated by electron spin resonance measurement. Free Radical Biology and Medicine, 2005, 39, 444-452.	1.3	62
261	Predicting Perioperative Cardiac Risk. Progress in Cardiovascular Diseases, 2005, 47, 240-257.	1.6	39
262	Clinical impact of vasomotor function assessment and the role of ACE-inhibitors and statins. Vascular Pharmacology, 2005, 42, 125-140.	1.0	37
263	Effects of atorvastatin on inflammation and oxidative stress. Heart and Vessels, 2005, 20, 133-136.	0.5	75
265	Effects of simvastatin on bone mineral density and remodeling parameters in postmenopausal osteopenic subjects: 1-year follow-up study. Clinical Rheumatology, 2005, 24, 447-452.	1.0	33
266	Statin use in the metabolic syndrome. Current Atherosclerosis Reports, 2005, 7, 17-21.	2.0	11

#	Article	IF	Citations
267	Pleiotropic effects of statins: Moving beyond cholesterol control. Current Atherosclerosis Reports, 2005, 7, 34-39.	2.0	19
268	Counteracting Effects of High Density Lipoprotein-Cholesterol Subfractions on Statin-Induced Growth Arrest. Cardiovascular Drugs and Therapy, 2005, 19, 113-118.	1.3	3
269	Immediate Effects of Fluvastain on Circulating Soluble Endothelial Protein C and Free Tissue Factor Pathway Inhibitor in Acute Coronary Syndromes. Cardiovascular Drugs and Therapy, 2005, 19, 177-181.	1.3	8
272	Diverse effects of statins on endothelial cells?. Thrombosis and Haemostasis, 2005, 93, 186-188.	1.8	8
273	Fluvastatin increases the expression of adhesion molecules, monocyte chemoattractant protein-1 and tissue factor in HUVEC stimulated by patient IgG fractions containing antiphospholipid antibodies. Thrombosis and Haemostasis, 2005, 93, 339-345.	1.8	25
274	Effect of Statin on Restenosis after Radius Stent Implantation in Patients with Acute Coronary Syndrome. Journal of Atherosclerosis and Thrombosis, 2005, 12, 302-306.	0.9	2
275	HMG-CoA Reductase Inhibitors: Effects on Chronic Subacute Inflammation and Onset of Atherosclerosis Induced by Dietary Cholesterol. Current Drug Targets Cardiovascular & Haematological Disorders, 2005, 5, 441-453.	2.0	40
276	Commentary. Journals of Gerontology - Series A Biological Sciences and Medical Sciences, 2005, 60, 598-598.	1.7	0
277	Dual Role of Matrix Metalloproteinases (Matrixins) in Intimal Thickening and Atherosclerotic Plaque Rupture. Physiological Reviews, 2005, 85, 1-31.	13.1	730
278	Endothelial Function in the Forearm Circulation of Patients with the Metabolic Syndrome â€“ Effect of Different Lipid-Lowering Regimens. Cardiology, 2005, 104, 176-180.	0.6	37
279	Simvastatin Blunts Endotoxin-Induced Tissue Factor In Vivo. Circulation, 2005, 111, 1841-1846.	1.6	136
280	Prostaglandins mediate the cardioprotective effects of atorvastatin against ischemia?reperfusion injury. Cardiovascular Research, 2005, 65, 345-355.	1.8	122
281	Association of active Î³-secretase complex with lipid rafts. Journal of Lipid Research, 2005, 46, 904-912.	2.0	127
282	Statins Suppress Oxidized Low Density Lipoprotein-induced Macrophage Proliferation by Inactivation of the Small G Protein-p38 MAPK Pathway. Journal of Biological Chemistry, 2005, 280, 6627-6633.	1.6	77
283	The effect of intensive lipid lowering on coronary atheroma and clinical outcome. Heart, 2005, 93, 149-151.	1.2	4
284	Polymorphonuclear Leukocytes May Impair Endothelial Function. Arteriosclerosis, Thrombosis, and Vascular Biology, 2005, 25, 1262-1267.	1.1	33
285	Tumour necrosis factor antagonists improve disease activity but not arterial stiffness in rheumatoid arthritis. Rheumatology, 2005, 44, 1428-1432.	0.9	85
286	HMG-CoA Reductase Inhibitors Inhibit Endothelial Exocytosis and Decrease Myocardial Infarct Size. Circulation Research, 2005, 96, 1185-1192.	2.0	75

#	Article	IF	Citations
287	Treatment With Simvastatin Suppresses the Development of Experimental Abdominal Aortic Aneurysms in Normal and Hypercholesterolemic Mice. Annals of Surgery, 2005, 241, 92-101.	2.1	152
288	Rad GTPase Attenuates Vascular Lesion Formation by Inhibition of Vascular Smooth Muscle Cell Migration. Circulation, 2005, 111, 1071-1077.	1.6	69
289	The sterol response element binding protein regulates cyclooxygenase-2 gene expression in endothelial cells. Journal of Lipid Research, 2005, 46, 862-871.	2.0	18
290	Prevention of perioperative cardiovascular complications in non-cardiac surgery: the future role of statins. Future Cardiology, 2005, 1, 701-704.	0.5	0
291	Implications of statin adverse effects in the elderly. Expert Opinion on Drug Safety, 2005, 4, 389-397.	1.0	34
292	Effects of Acute Treatment With Pravastatin on Cerebral Vasospasm, Autoregulation, and Delayed Ischemic Deficits After Aneurysmal Subarachnoid Hemorrhage. Stroke, 2005, 36, 1627-1632.	1.0	422
293	High-density lipoprotein, but not low-density lipoprotein cholesterol levels influence short-term prognosis after acute coronary syndrome: results from the MIRACL trial. European Heart Journal, 2005, 26, 890-896.	1.0	187
294	Atorvastatin: An Update of Recent Clinical Trial Experience. Journal of Pharmacy Technology, 2005, 21, 197-202.	0.5	0
295	Regulation of Macrophage Cholesterol Efflux through Hydroxymethylglutaryl-CoA Reductase Inhibition. Journal of Biological Chemistry, 2005, 280, 22212-22221.	1.6	112
296	Rosuvastatin Reduces Platelet Activation in Heart Failure. Arteriosclerosis, Thrombosis, and Vascular Biology, 2005, 25, 1071-1077.	1.1	64
297	3-Hydroxy-3-Methylglutaryl-Coenzyme A Reductase Inhibitors Attenuate Â-Amyloid-Induced Microglial Inflammatory Responses. Journal of Neuroscience, 2005, 25, 299-307.	1.7	164
298	Simvastatin Attenuates Expression of Cytokine-inducible Nitric-oxide Synthase in Embryonic Cardiac Myoblasts. Journal of Biological Chemistry, 2005, 280, 13503-13511.	1.6	80
299	HMG-CoA Reductase Inhibitors Reduce Matrix Metalloproteinase-9 Activity in Human Varicose Veins. European Surgical Research, 2005, 37, 370-378.	0.6	26
300	Statins and Blood Coagulation. Arteriosclerosis, Thrombosis, and Vascular Biology, 2005, 25, 287-294.	1.1	235
301	Effects of Diet and Simvastatin on Fatty Acid Composition in Hypercholesterolemic Men. Arteriosclerosis, Thrombosis, and Vascular Biology, 2005, 25, 1952-1959.	1.1	71
302	Statins Decrease Toll-Like Receptor 4 Expression and Downstream Signaling in Human CD14 + Monocytes. Arteriosclerosis, Thrombosis, and Vascular Biology, 2005, 25, 1439-1445.	1.1	160
303	Treatment with statins in the acute phase of ischemic stroke. Expert Review of Neurotherapeutics, 2005, 5, 211-221.	1.4	21
304	Mechanisms for Antiplatelet Action of Statins. Current Drug Targets Cardiovascular & Haematological Disorders, 2005, 5, 121-126.	2.0	19

#	Article	IF	Citations
305	Cholesterol-independent Effects of Statins in Inflammation, Immunomodulation and Atherosclerosis. Current Drug Targets Cardiovascular & Haematological Disorders, 2005, 5, 127-134.	2.0	40
306	Editorial Statins: [Hot Topic: Statins: Effects Beyond Cholesterol Lowering (Guest Editor: Garry X.) Tj ETQq1 1 0.784314 rgBT /Overlock	2.0	1
307	Oxidative-Nitrosative Stress as a Contributing Factor to Cardiovascular Disease in Subjects with Diabetes. Current Vascular Pharmacology, 2005, 3, 253-266.	0.8	20
308	Commentary. Journals of Gerontology - Series A Biological Sciences and Medical Sciences, 2005, 60, 597-598.	1.7	0
309	Benefits and risks assessment of simvastatin in familial hypercholesterolaemia. Expert Opinion on Drug Safety, 2005, 4, 171-181.	1.0	8
310	Regulation of Vascular Tone from Spontaneously Hypertensive Rats by the HMG-CoA Reductase Inhibitor, Simvastatin. Pharmacology, 2005, 74, 209-215.	0.9	15
311	Effect of Low Dose Atorvastatin Versus Diet-Induced Cholesterol Lowering on Atherosclerotic Lesion Progression and Inflammation in Apolipoprotein E*3â€“Leiden Transgenic Mice. Arteriosclerosis, Thrombosis, and Vascular Biology, 2005, 25, 161-167.	1.1	77
312	Do statins influence the prognostic impact of non-sustained ventricular tachycardia after ST-elevation myocardial infarction?. European Heart Journal, 2005, 26, 1078-1085.	1.0	21
313	HMG-CoA Reductase Inhibitors Reduce IÎºB Kinase Activity Induced by Oxidative Stress in Monocytes and Vascular Smooth Muscle Cells. Journal of Cardiovascular Pharmacology, 2005, 45, 468-475.	0.8	30
315	JTT-705 blocks cell proliferation and angiogenesis through p38 kinase/p27kip1 and Ras/p21waf1 pathways. Atherosclerosis, 2005, 182, 267-275.	0.4	21
316	Rho-Kinase Is an Important Therapeutic Target in Cardiovascular Medicine. Arteriosclerosis, Thrombosis, and Vascular Biology, 2005, 25, 1767-1775.	1.1	447
317	Hydrophilic statin suppresses vein graft intimal hyperplasia via endothelial cell-tropic Rho-kinase inhibition. Journal of Vascular Surgery, 2005, 42, 757-764.	0.6	52
318	Statins Ameliorate Endothelial Barrier Permeability Changes in the Cerebral Tissue of Streptozotocin-Induced Diabetic Rats. Diabetes, 2005, 54, 2977-2982.	0.3	80
319	Effects of rosuvastatin on endothelial function in patients with familial combined hyperlipidaemia (FCH). Current Medical Research and Opinion, 2005, 21, 1469-1476.	0.9	21
320	The link between cholesterol and Alzheimer's disease. World Journal of Biological Psychiatry, 2005, 6, 85-97.	1.3	54
321	Evaluation of HMG-CoA Reductase Inhibitors for Multiple Sclerosis. CNS Drugs, 2005, 19, 833-841.	2.7	17
322	Therapeutic Potential of Rho-Kinase Inhibitors in Cardiovascular Diseases. American Journal of Cardiovascular Drugs, 2005, 5, 31-39.	1.0	70
323	Mechanisms, Pathophysiology, and Therapy of Arterial Stiffness. Arteriosclerosis, Thrombosis, and Vascular Biology, 2005, 25, 932-943.	1.1	1,451

#	Article	IF	Citations
324	Neuroprotective Effect of Simvastatin in Stroke: A Comparison Between Adult and Neonatal Rat Models of Cerebral Ischemia. NeuroToxicology, 2005, 26, 929-933.	1.4	51
325	Influence of withdrawal of statin treatment on proinflammatory response and fibrinolytic activity in humans: an effect independent on cholesterol elevation. International Journal of Cardiology, 2005, 98, 459-464.	0.8	38
326	Rapid effect of pravastatin on endothelial function and lipid peroxidation in unstable angina. International Journal of Cardiology, 2005, 101, 65-70.	0.8	36
327	The effect of preoperative statin therapy on cardiovascular outcomes in patients undergoing infrainguinal vascular surgery. International Journal of Cardiology, 2005, 104, 264-268.	0.8	91
328	Relaxant effects of pravastatin, atorvastatin and cerivastatin on isolated rat aortic rings. Life Sciences, 2005, 76, 1771-1786.	2.0	23
329	Blockade of geranylgeranylation by rosuvastatin upregulates eNOS expression in human venous endothelial cells. Biochemical and Biophysical Research Communications, 2005, 336, 1005-1009.	1.0	13
330	A randomized, open-label study to evaluate the efficacy and safety of pitavastatin compared with simvastatin in korean patients with hypercholesterolemia. Clinical Therapeutics, 2005, 27, 1074-1082.	1.1	49
331	Impact of simvastatin on hemostatic and fibrinolytic regulators in Type 2 diabetes mellitus. Diabetes Research and Clinical Practice, 2005, 70, 110-118.	1.1	34
332	Statin-inhibited endothelial permeability could be associated with its effect on PECAM-1 in endothelial cells. FEBS Letters, 2005, 579, 1272-1278.	1.3	21
333	Statins as coronary vasodilators in isolated bovine coronary arteriesâ€"involvement of PGI2 and NO. Prostaglandins Leukotrienes and Essential Fatty Acids, 2005, 72, 133-138.	1.0	7
334	HMG CoA Reductase Inhibitors (Statins): Do They Have a Role in Age-related Macular Degeneration?. Survey of Ophthalmology, 2005, 50, 194-206.	1.7	52
337	Mechanisms, Significance and Treatment of Vascular Dysfunction in Type 2 Diabetes Mellitus. Drugs, 2005, 65, 31-74.	4.9	66
338	Effect of Maximum Dose of Atorvastatin on Inflammation, Thrombogenesis, and Fibrinolysis in High-Risk Patients With Ischemic Heart Disease. Revista Espanola De Cardiologia (English Ed), 2005, 58, 934-940.	0.4	4
339	Rho/Rho Kinase Signal Transduction Pathway in Cardiovascular Disease and Cardiovascular Remodeling. Revista Espanola De Cardiologia (English Ed), 2005, 58, 951-961.	0.4	10
340	Effects of Aggressive Versus Conventional Lipid-Lowering Therapy by Simvastatin on Human Atherosclerotic Lesions. Journal of the American College of Cardiology, 2005, 46, 106-112.	1.2	257
341	Putative mechanisms of action of statins in multiple sclerosis â€“ comparison to interferon-Î² and glatiramer acetate. Journal of the Neurological Sciences, 2005, 233, 173-177.	0.3	29
342	Anti-RhoA and Anti-RhoC siRNAs Inhibit the Proliferation and Invasiveness of MDA-MB-231 Breast Cancer Cells in Vitro and in Vivo. Molecular Therapy, 2005, 11, 267-274.	3.7	229
343	3-Hydroxy-3-methylglutaryl coenzyme A reductase inhibitors reduce the risk of perioperative stroke and mortality after carotid endarterectomy. Journal of Vascular Surgery, 2005, 42, 829-836.	0.6	176

#	Article	IF	Citations
345	Statins and Prostate Cancer Risk: A Case-Control Study. American Journal of Epidemiology, 2005, 162, 318-325.	1.6	217
346	Targets for Pharmacological Modulation of Cardiac Fibrosis. , 2005, , 275-310.		1
348	Papel de la atorvastatina en la prevenciÃ³n del ictus. Â¿Puede estar relacionado con su acciÃ³n sobre la activaciÃ³n plaquetaria? Consideraciones basadas en nuestra propia experiencia. Hipertension Y Riesgo Vascular, 2006, 23, 260-265.	0.3	1
349	Oxidatively Modified Low-Density Lipoproteins and Thrombosis. , 2006, , 150-167.		0
350	Autologous bone-marrow mononuclear cell implantation for patients with Rutherford grade II-III thromboangiitis obliterans. Journal of Vascular Surgery, 2006, 44, 732-739.	0.6	128
351	Treatment of High-Risk Hypertensive Patients. High Blood Pressure and Cardiovascular Prevention, 2006, 13, 13-19.	1.0	0
352	A review of drug options in age-related macular degeneration therapy and potential new agents. Expert Opinion on Pharmacotherapy, 2006, 7, 2355-2368.	0.9	8
353	Simvastatin Decreases IL-6 and IL-8 Production in Epithelial Cells. Journal of Dental Research, 2006, 85, 520-523.	2.5	138
354	Papel de la atorvastatina en la prevenciÃ³n del ictus. Â¿Puede estar relacionado con su acciÃ³n sobre la activaciÃ³n plaquetaria? Consideraciones basadas en nuestra propia experiencia. Hipertension, 2006, 23, 260-265.	0.0	2
355	Endothelial nitric oxide synthase gene variant modulates the relationship between serum cholesterol levels and blood pressure in the general population: New evidence for a direct effect of lipids in arterial blood pressure. Atherosclerosis, 2006, 184, 193-200.	0.4	62
356	Simvastatin suppresses endotoxin-induced upregulation of toll-like receptors 4 and 2 in vivo. Atherosclerosis, 2006, 189, 408-413.	0.4	137
358	Statin Use and Functional Decline in Patients With and Without Peripheral Arterial Disease. Journal of the American College of Cardiology, 2006, 47, 998-1004.	1.2	89
359	The Dynamics of Statins. Stroke, 2006, 37, 294-296.	1.0	40
360	Endothelial Urocortin Has Potent Antioxidative Properties and Is Upregulated by Inflammatory Cytokines and Pitavastatin. Journal of Vascular Research, 2006, 43, 131-138.	0.6	45
361	Peripheral Arterial Disease: A Review of Disease Awareness and Management. American Journal of Geriatric Pharmacotherapy, 2006, 4, 365-379.	3.0	28
362	Preoperative Statin Therapy and Troponin T Predict Early Complications of Coronary Artery Surgery. Annals of Thoracic Surgery, 2006, 81, 78-83.	0.7	46
363	SREBP inhibits VEGF expression in human smooth muscle cells. Biochemical and Biophysical Research Communications, 2006, 342, 354-360.	1.0	16
364	Tissue-specific effects of statins on the expression of heme oxygenase-1 in vivo. Biochemical and Biophysical Research Communications, 2006, 343, 738-744.	1.0	98

#	Article	IF	Citations
365	Pitavastatin attenuates the PDGF-induced LR11/uPA receptor-mediated migration of smooth muscle cells. Biochemical and Biophysical Research Communications, 2006, 348, 1367-1377.	1.0	34
366	Differential roles of MAP kinases in atorvastatin-induced VEGF release in cardiac myocytes. Life Sciences, 2006, 79, 1214-1220.	2.0	6
367	Reduced risks of death and CHF are associated with statin therapy administered acutely within the first 24 h of AMI. International Journal of Cardiology, 2006, 108, 314-319.	0.8	19
368	HMG-CoA reductase inhibitors may affect thrombin generation by reducing factor VII activity in hyperlipidemic patients. Thrombosis Research, 2006, 118, 665-666.	0.8	1
369	The Anti-Atherosclerotic Effects of Lipid Lowering with Atorvastatin in Patients with Hypercholesterolemia. Journal of Atherosclerosis and Thrombosis, 2006, 13, 216-219.	0.9	48
370	Statins Inhibited the ADP-Stimulated Activation of Integrins Î±_vÎ²₅and Î±_vÎ²₃of Vascular Smooth Muscle Cells. Korean Circulation Journal, 2006, 36, 809.	0.7	1
371	Effect of Cardiac Rehabilitation and Statin Treatment on Anti-HSP Antibody Titers in Patients With Coronary Artery Disease After Percutaneous Coronary Intervention. International Heart Journal, 2006, 47, 671-682.	0.5	24
372	Medical treatment for carotid stenosis. , 0, , 59-71.		0
373	Oxidative Stress, Insulin Resistance and Cardiovascular Disease. , 2006, , 189-205.		1
374	The Immune System in Atherosclerosis and in Acute Myocardial Infarction. Heart International, 2006, 2, 182618680600200.	0.4	0
375	Lower Level of Low-density Lipoprotein Cholesterol by Statin Prevents Progression of Coronary Restenosis after Successful Stenting in Acute Myocardial Infarction. Internal Medicine, 2006, 45, 885-890.	0.3	20
376	Cross-Over Trial of Intensive Monotherapy With Atorvastatin and Combined Therapy With Atorvastatin and Colestimide for Japanese Familial Hypercholesterolemia. Circulation Journal, 2006, 70, 14-20.	0.7	8
377	Anti-inflammatory Effect of Pitavastatin on NF-.KAPPA.B Activated by TNF-.ALPHA. in Hepatocellular Carcinoma Cells. Biological and Pharmaceutical Bulletin, 2006, 29, 634-639.	0.6	33
378	Oxidative Stress, Insulin Resistance, and Cardiovascular Disease. , 2006, , 537-556.		1
379	Statins: A Valuable Tool for the Prevention/Regression of Abdominal Aortic Aneurysms. Vascular Disease Prevention, 2006, 3, 41-44.	0.2	0
380	Potential benefit of statins for vascular disease in systemic sclerosis. Current Opinion in Rheumatology, 2006, 18, 594-600.	2.0	24
381	Statin-Associated Pleiotropy: Possible Beneficial Effects Beyond Cholesterol Reduction. Pharmacotherapy, 2006, 26, 85S-97S.	1.2	47
382	Association between the dosage and duration of statin treatment with coronary collateral development. Coronary Artery Disease, 2006, 17, 561-565.	0.3	16

#	Article	IF	Citations
383	Controlling oxidative stress as a novel molecular approach to protecting the vascular wall in diabetes. Current Opinion in Lipidology, 2006, 17, 510-518.	1.2	60
384	Vascular surgery critical care: Perioperative cardiac optimization to improve survival. Critical Care Medicine, 2006, 34, S200-S207.	0.4	22
385	Anesthesia drugs, immunity, and long-term outcome. Current Opinion in Anaesthesiology, 2006, 19, 423-428.	0.9	75
386	3-HMG-Coenzyme A Reductase Inhibition and Extracellular Matrix Gene Expression in the Pressure-Overloaded Rat Heart. Journal of Cardiovascular Pharmacology, 2006, 47, 521-530.	0.8	10
388	STATINS REDUCE MACROPHAGE INFLAMMATORY PROTEIN-1? EXPRESSION IN HUMAN ACTIVATED MONOCYTES. Clinical and Experimental Pharmacology and Physiology, 2006, 33, 1144-1149.	0.9	22
389	The effects of lipid-lowering drug therapy on cardiovascular responsiveness in type 2 diabetic patients. Diabetes, Obesity and Metabolism, 2006, 8, 8-14.	2.2	9
390	Pulmonary arterial hypertension: New insights and new hope. Respirology, 2006, 11, 6-17.	1.3	56
391	The 4G/5G PAI-1 polymorphism influences the endothelial response to IL-1 and the modulatory effect of pravastatin. Journal of Thrombosis and Haemostasis, 2006, 4, 1798-1803.	1.9	15
392	The Cellular Biochemistry of Cholesterol and Statins: Insights into the Pathophysiology and Therapy of Alzheimer's Disease. CNS Neuroscience & Therapeutics, 2004, 10, 127-146.	4.0	48
393	Oxidative Stress and Cardiovascular Disease: Antioxidants and Unresolved Issues. Cardiovascular Drug Reviews, 2006, 23, 115-132.	4.4	75
394	Re-assessing the relationship between cholesterol, statins and Alzheimer's disease. Acta Neurologica Scandinavica, 2006, 114, 63-70.	1.0	91
395	The Role of Statins in Reversing Atherosclerosis: What the Latest Regression Studies Show. Journal of Interventional Cardiology, 2006, 19, 3-9.	0.5	22
396	The immune response in atherosclerosis: a double-edged sword. Nature Reviews Immunology, 2006, 6, 508-519.	10.6	1,890
397	Effect of atorvastatin withdrawal on circulating coenzyme Q₁₀ concentration in patients with hypercholesterolemia. BioFactors, 2006, 28, 177-184.	2.6	22
398	Statin therapy for coronary heart disease and its effect on stroke. Current Atherosclerosis Reports, 2006, 8, 337-342.	2.0	3
399	Effects of macronutrient excess and composition on oxidative stress: Relevance to diabetes and cardiovascular disease. Current Atherosclerosis Reports, 2006, 8, 472-476.	2.0	18
400	Simvastatin inhibits the migration and adhesion of monocytic cells and disorganizes the cytoskeleton of activated endothelial cells. European Journal of Pharmacology, 2006, 548, 53-63.	1.7	29
401	Managing Risk Factors for Atherosclerosis in Critical Limb Ischaemia. European Journal of Vascular and Endovascular Surgery, 2006, 32, 478-483.	0.8	27

#	Article	IF	Citations
402	Can Statins Reduce Perioperative Morbidity and Mortality in Patients Undergoing Non-Cardiac Vascular Surgery?. European Journal of Vascular and Endovascular Surgery, 2006, 32, 286-293.	0.8	125
403	Effects of Obesity on Lipid-Lowering, Anti-Inflammatory, and Antiatherosclerotic Benefits of Atorvastatin or Pravastatin in Patients With Coronary Artery Disease (from the REVERSAL Study). American Journal of Cardiology, 2006, 97, 1553-1557.	0.7	64
404	Molecular Basis of Differences Among Statins and a Comparison with Antioxidant Vitamins. American Journal of Cardiology, 2006, 98, S34-S41.	0.7	51
405	Pharmacologic Modulation of Operative Risk in Patients Who Have Cardiac Disease. Anesthesiology Clinics, 2006, 24, 365-379.	1.4	1
406	Effects of rosiglitazone and atorvastatin on the expression of genes that control cholesterol homeostasis in differentiating monocytes. Biochemical Pharmacology, 2006, 71, 605-614.	2.0	33
407	Cholesterol and Alzheimer's diseaseâ€"is there a relation?. Mechanisms of Ageing and Development, 2006, 127, 138-147.	2.2	86
408	Immunomodulatory effects of 3-hydroxy-3-methylglutaryl coenzyme-A reductase inhibitors, potential therapy for relapsing remitting multiple sclerosis. Journal of Neuroimmunology, 2006, 178, 130-139.	1.1	40
409	Simvastatin reduces caspase-3 activation and inflammatory markers induced by hypoxiaâ€"ischemia in the newborn rat. Neurobiology of Disease, 2006, 21, 119-126.	2.1	42
410	Simvastatin promotes heat shock protein 27 expression and Akt activation in the rat retina and protects axotomized retinal ganglion cells in vivo. Neurobiology of Disease, 2006, 21, 421-430.	2.1	80
411	Activation of NF-kB and ERK1/2 after permanent focal ischemia is abolished by simvastatin treatment. Neurobiology of Disease, 2006, 22, 445-451.	2.1	66
412	Pharmacological regulation of low density lipoprotein receptor expression: Current status and future developments. , 2006, 111, 424-433.		14
413	Modulatory Effects of Atorvastatin on Endothelial Cellâ€"Derived Chemokines, Cytokines, and Angiogenic Factors. Pharmacotherapy, 2006, 26, 395-402.	1.2	26
414	Statins as antiinflammatory and immunomodulatory agents: A future in rheumatologic therapy?. Arthritis and Rheumatism, 2006, 54, 393-407.	6.7	127
415	Apoptosis of rheumatoid synovial cells by statins through the blocking of protein geranylgeranylation: A potential therapeutic approach to rheumatoid arthritis. Arthritis and Rheumatism, 2006, 54, 579-586.	6.7	84
416	Simvastatin affects cell motility and actin cytoskeleton distribution of microglia. Glia, 2006, 53, 115-123.	2.5	36
417	Simvastatin enhances learning and memory independent of amyloid load in mice. Annals of Neurology, 2006, 60, 729-739.	2.8	138
418	Antioxidants Suppress Plasma Levels of Lectinlike Oxidized Low-Density Lipoprotein Receptor-Ligands and Reduce Atherosclerosis in Watanabe Heritable Hyperlipidemic Rabbits. Journal of Cardiovascular Pharmacology, 2006, 48, 177-183.	0.8	52
419	Atorvastatin Reduces the Expression of Prostaglandin E2 Receptors in Human Carotid Atherosclerotic Plaques and Monocytic Cells. Journal of Cardiovascular Pharmacology, 2006, 47, 60-69.	0.8	70

#	Article	IF	Citations
420	Statin therapy of calcific aortic stenosis: hype or hope?. European Heart Journal, 2006, 27, 773-778.	1.0	38
421	Simvastatin causes endothelial cell apoptosis and attenuates severe pulmonary hypertension. American Journal of Physiology - Lung Cellular and Molecular Physiology, 2006, 291, L668-L676.	1.3	156
422	Fluvastatin Ameliorates Podocyte Injury in Proteinuric Rats via Modulation of Excessive Rho Signaling. Journal of the American Society of Nephrology: JASN, 2006, 17, 754-764.	3.0	108
423	Activation of sterol regulatory element-binding proteins (SREBPs) is critical in IL-8-induced angiogenesis. Journal of Leukocyte Biology, 2006, 80, 608-620.	1.5	20
424	Effect of Atorvastatin on in vitro Expression of Resistin in Adipocytes and Monocytes/Macrophages and Effect of Atorvastatin Treatment on Serum Resistin Levels in Patients with Type 2 Diabetes. Pharmacology, 2006, 76, 34-39.	0.9	27
425	Inflammatory Markers in Coronary Artery Disease: Pathophysiological Mechanisms, Prognostic and Therapeutic Implications. Current Cardiology Reviews, 2006, 2, 173-184.	0.6	1
426	HMG-CoA reductase inhibitor simvastatin mitigates VEGF-induced â€œinside-outâ€•signaling to extracellular matrix by preventing RhoA activation. American Journal of Physiology - Renal Physiology, 2006, 291, F995-F1004.	1.3	32
427	Stroke Prevention and Statin Treatment. Clinical and Experimental Hypertension, 2006, 28, 335-344.	0.5	7
428	Statins and Renal Diseases: From Primary Prevention to Renal Replacement Therapy. Journal of the American Society of Nephrology: JASN, 2006, 17, S148-S152.	3.0	27
429	Statins for Diabetic Cardiovascular Complications. Current Vascular Pharmacology, 2006, 4, 245-251.	0.8	34
430	Modulation of Smooth Muscle Cell Migration by Members of the Low-Density Lipoprotein Receptor Family. Arteriosclerosis, Thrombosis, and Vascular Biology, 2006, 26, 1246-1252.	1.1	35
431	Innate Immune Molecular Connections Between Atherosclerosis and Statins. American Journal of Clinical Pathology, 2006, 125, 8-15.	0.4	1
432	Chronic Kidney Disease as a Situation of High Added Risk in Hypertensive Patients. Journal of the American Society of Nephrology: JASN, 2006, 17, S136-S140.	3.0	17
433	Recent Insights into the Cell Biology of Bladder Smooth Muscle. Nephron Experimental Nephrology, 2006, 102, e1-e7.	2.4	13
434	Effect of Atorvastatin on Plasma Osteopontin Levels in Patients With Hypercholesterolemia. Arteriosclerosis, Thrombosis, and Vascular Biology, 2006, 26, e129-30.	1.1	17
435	Rho Kinases in Cardiovascular Physiology and Pathophysiology. Circulation Research, 2006, 98, 322-334.	2.0	484
436	Putative Immune Regulatory Role of Statins. Current Immunology Reviews, 2006, 2, 55-64.	1.2	0
437	Acute Antiinflammatory Properties of Statins Involve Peroxisome Proliferatorâ€“Activated Receptor-Î± via Inhibition of the Protein Kinase C Signaling Pathway. Circulation Research, 2006, 98, 361-369.	2.0	157

#	Article	IF	Citations
438	Statin Use and Cancer Risk: An Epidemiologic Review. Cancer Investigation, 2006, 24, 413-424.	0.6	24
439	Methods of detecting atherosclerosis in non-cardiac surgical patients; the role of biochemical markers. British Journal of Anaesthesia, 2006, 97, 758-769.	1.5	50
440	Statins Prevent Dextrose-Induced Endothelial Barrier Dysfunction, Possibly Through Inhibition of Superoxide Formation. Diabetes, 2006, 55, 474-479.	0.3	24
441	Statin Therapy at Carotid Angioplasty and Stent Placement: Effect on Procedure-related Stroke, Myocardial Infarction, and Death. Radiology, 2006, 240, 145-151.	3.6	81
442	Simvastatin promotes Th2-type responses through the induction of the chitinase family member Ym1 in dendritic cells. Proceedings of the National Academy of Sciences of the United States of America, 2006, 103, 7777-7782.	3.3	109
443	Retinal Degenerations. , 2007, , .		7
444	Farnesyltransferase Inhibitor, Manumycin A, Prevents Atherosclerosis Development and Reduces Oxidative Stress in Apolipoprotein E-Deficient Mice. Arteriosclerosis, Thrombosis, and Vascular Biology, 2007, 27, 1390-1395.	1.1	33
445	Effect of pravastatin on sympathetic reinnervation in postinfarcted rats. American Journal of Physiology - Heart and Circulatory Physiology, 2007, 293, H3617-H3626.	1.5	23
446	Influence of Statin Use on Endothelial Function: From Bench to Clinics. Current Pharmaceutical Design, 2007, 13, 1771-1786.	0.9	53
447	Intensive statin therapy in acute coronary syndromes and stable coronary heart disease: a comparative meta-analysis of randomised controlled trials. Heart, 2007, 93, 914-921.	1.2	108
449	Pitavastatin ameliorates albuminuria and renal mesangial expansion by downregulating NOX4 in db/db mice. Kidney International, 2007, 72, 473-480.	2.6	84
450	Effects of Intense Low-Density Lipoprotein Cholesterol Reduction in Patients With Stroke or Transient Ischemic Attack. Stroke, 2007, 38, 3198-3204.	1.0	302
451	MDR3 (ABCB4) Defects: A Paradigm for the Genetics of Adult Cholestatic Syndromes. Seminars in Liver Disease, 2007, 27, 077-098.	1.8	188
452	Dose-dependency in pleiotropic effects of atorvastatin. International Journal of Angiology, 2007, 16, 89-91.	0.2	14
453	Coenzyme Q10 Reduction with Statins: Another Pleiotropic Effect. Current Drug Therapy, 2007, 2, 39-51.	0.2	3
454	Endothelial function, arterial stiffness and lipid lowering drugs. Expert Opinion on Therapeutic Targets, 2007, 11, 1143-1160.	1.5	39
455	Evaluation of atorvastatin and simvastatin for treatment of multiple sclerosis. Expert Review of Neurotherapeutics, 2007, 7, 547-556.	1.4	24
456	Do Statins Lower Blood Pressure?. Journal of Cardiovascular Pharmacology and Therapeutics, 2007, 12, 112-123.	1.0	17

#	Article	IF	Citations
457	Critical Role for FoxO3a-Dependent Regulation of p21 CIP1/WAF1 in Response to Statin Signaling in Cardiac Myocytes. Circulation Research, 2007, 100, 50-60.	2.0	68
458	State of the Art Reviews: The Anti-Inflammatory Actions of Exercise Training. American Journal of Lifestyle Medicine, 2007, 1, 220-235.	0.8	98
459	Statin Treatment Upregulates Vascular Neuronal Nitric Oxide Synthase Through Akt/NF-Î¹B Pathway. Arteriosclerosis, Thrombosis, and Vascular Biology, 2007, 27, 92-98.	1.1	80
460	Protective effect of atorvastatin on acute systemic inflammation-induced endothelial dysfunction in hypercholesterolaemic subjects. European Heart Journal, 2007, 28, 2102-2109.	1.0	45
461	Statins Activate Peroxisome Proliferator-Activated Receptor Î³ Through Extracellular Signal-Regulated Kinase 1/2 and p38 Mitogen-Activated Protein Kinaseâ€“Dependent Cyclooxygenase-2 Expression in Macrophages. Circulation Research, 2007, 100, 1442-1451.	2.0	214
462	Oxidative Stress in the Pathogenesis/Treatment of Diabetes and its Complications. Current Nutrition and Food Science, 2007, 3, 194-199.	0.3	4
463	Preoperative C-reactive protein levels predict 9-month mortality after coronary artery bypass grafting surgery for the treatment of left main coronary artery stenosis. European Journal of Cardio-thoracic Surgery, 2007, 31, 685-690.	0.6	23
464	Effects of lipoprotein lipase and statins on cholesterol uptake into heart and skeletal muscle. Journal of Lipid Research, 2007, 48, 646-655.	2.0	44
465	Action on Vascular Risk Factors: Importance of Blood Pressure and Lipid Lowering in Stroke Secondary Prevention. Cerebrovascular Diseases, 2007, 24, 96-106.	0.8	8
466	Recent Progress in the Treatment of Pulmonary Arterial Hypertension: Expectation for Rho-Kinase Inhibitors. Tohoku Journal of Experimental Medicine, 2007, 211, 309-320.	0.5	61
467	Pravastatin Reduces Myocardial Infarct Size Via Increasing Protein Kinase C-Dependent Nitric Oxide, Decreasing Oxyradicals and Opening the Mitochondrial Adenosine Triphosphate-Sensitive Potassium Channels in Rabbits. Circulation Journal, 2007, 71, 1622-1628.	0.7	33
468	Pitavastatin Restores Vascular Dysfunction in Insulin-Resistant State by Inhibiting NAD(P)H Oxidase Activity and Uncoupled Endothelial Nitric Oxide Synthase-Dependent Superoxide Production. Journal of Cardiovascular Pharmacology, 2007, 49, 122-130.	0.8	34
469	Effects of Atorvastatin on C-reactive Protein Secretions by Adipocytes in Hypercholesterolemic Rabbits. Journal of Cardiovascular Pharmacology, 2007, 50, 281-285.	0.8	16
470	Prophylactic Neuroprotection. Current Drug Targets, 2007, 8, 846-849.	1.0	13
471	Statins Ameliorate Glomerular Permeability Changes in Streptozotocin-Induced Diabetic Rats. American Journal of Therapeutics, 2007, 14, 41-45.	0.5	10
472	l-Arginine plus atorvastatin for prevention of atheroma formation in genetically hypercholesterolaemic rabbits. British Journal of Nutrition, 2007, 97, 1083-1089.	1.2	10
473	Statins and foam cell formation: Impact on LDL oxidation and uptake of oxidized lipoproteins via scavenger receptors. Biochimica Et Biophysica Acta - Molecular and Cell Biology of Lipids, 2007, 1771, 1117-1124.	1.2	35
474	Effect of pitavastatin on experimental choroidal neovascularization in rats. Experimental Eye Research, 2007, 84, 1074-1080.	1.2	24

#	Article	IF	Citations
475	Immunomodulation by statins: Inhibition of cholesterol vs. isoprenoid biosynthesis. Biomedicine and Pharmacotherapy, 2007, 61, 400-407.	2.5	42
476	Simvastatin inhibits NF-Î¹B signaling in intestinal epithelial cells and ameliorates acute murine colitis. International Immunopharmacology, 2007, 7, 241-248.	1.7	79
477	The effect of statin on the aortic gene expression profiling. International Journal of Cardiology, 2007, 114, 71-77.	0.8	16
478	Cerivastatin reduces cytokine-induced surface expression of ICAM-1 via increased shedding in human endothelial cells. Atherosclerosis, 2007, 190, 43-52.	0.4	48
479	Newly developed reconstituted high-density lipoprotein containing sphingosine-1-phosphate induces endothelial tube formation. Atherosclerosis, 2007, 194, 159-168.	0.4	35
481	Statins and sepsis: multiple modifications at multiple levels. Lancet Infectious Diseases, The, 2007, 7, 358-368.	4.6	268
482	Effects of Atorvastatin on Ventricular Late Potentials and Repolarization Dispersion in Patients with Hypercholesterolemia. Kaohsiung Journal of Medical Sciences, 2007, 23, 217-224.	0.8	11
483	Statins Reduce Amyloid-Î² Production through Inhibition of Protein Isoprenylation. Journal of Biological Chemistry, 2007, 282, 26832-26844.	1.6	156
484	Statin treatment increases formation of carbon monoxide and bilirubin in mice:Âa novel mechanism of in vivo antioxidant protection. Canadian Journal of Physiology and Pharmacology, 2007, 85, 800-810.	0.7	61
485	Atorvastatin and statins in the treatment of heart failure. Expert Opinion on Pharmacotherapy, 2007, 8, 3061-3068.	0.9	17
486	Pitavastatin: Protection against Neuronal Retinal Damage Induced by Ischemia-Reperfusion Injury in Rats. Current Eye Research, 2007, 32, 991-997.	0.7	19
487	Oxidative stress in childhood type 1 diabetes: Results from a study covering the first 20 years of evolution. Free Radical Research, 2007, 41, 919-928.	1.5	24
488	CD36 and macrophages in atherosclerosis. Cardiovascular Research, 2007, 75, 468-477.	1.8	304
489	Statins: An essential component in the management of carotid artery disease. Journal of Vascular Surgery, 2007, 46, 373-386.e9.	0.6	79
491	Role of HMG-CoA Reductase Inhibitors in Neurological Disorders. Drugs, 2007, 67, 2111-2120.	4.9	34
492	Asymmetric Dimethylarginine Determines the Improvement of Endothelium-Dependent Vasodilation by Simvastatin. Journal of the American College of Cardiology, 2007, 49, 2274-2282.	1.2	84
494	Sickle cell disease: old discoveries, new concepts, and future promise. Journal of Clinical Investigation, 2007, 117, 850-858.	3.9	279
495	Simvastatin Elicits Dilation of Isolated Porcine Retinal Arterioles: Role of Nitric Oxide and Mevalonate-Rho Kinase Pathways. , 2007, 48, 825.		52

#	Article	IF	Citations
496	Anti-inflammatory Effects of Simvastatin on Human Oral Cells. Inflammation and Regeneration, 2007, 27, 107-111.	1.5	6
497	Atorvastatin inhibits angiotensin-converting enzyme induction in differentiating human macrophages. American Journal of Physiology - Heart and Circulatory Physiology, 2007, 292, H1917-H1921.	1.5	19
498	Potential link between HMGâ€CoA reductase inhibitor (statin) use and interstitial lung disease. Medical Journal of Australia, 2007, 186, 91-94.	0.8	23
499	Discovery of pyrrole-based hepatoselective ligands as potent inhibitors of HMG-CoA reductase. Bioorganic and Medicinal Chemistry, 2007, 15, 5576-5589.	1.4	33
500	Rosuvastatin restores superoxide dismutase expression and inhibits accumulation of oxidized LDL in the aortic arch of obese dyslipidemic mice. British Journal of Pharmacology, 2007, 151, 347-355.	2.7	40
501	Anti-adipogenic action of pitavastatin occurs through the coordinate regulation of PPARÎ³ and Pref-1 expression. British Journal of Pharmacology, 2007, 151, 807-815.	2.7	43
502	Hyperglycaemia and cardiovascular disease. Journal of Internal Medicine, 2007, 262, 145-156.	2.7	52
503	Treatment with atorvastatin reduces serum adipocyteâ€fatty acid binding protein value in patients with hyperlipidaemia. European Journal of Clinical Investigation, 2007, 37, 637-642.	1.7	65
504	Improved endothelial function and reduced platelet activation by chronic HMG-CoA-reductase inhibition with rosuvastatin in rats with streptozotocin-induced diabetes mellitus. Biochemical Pharmacology, 2007, 73, 1367-1375.	2.0	22
505	Postischemic administration of HMG CoA reductase inhibitor inhibits infarct expansion after transient middle cerebral artery occlusion. Brain Research, 2007, 1181, 125-129.	1.1	16
506	Anti-inflammatory mechanism of simvastatin in mouse allergic asthma model. European Journal of Pharmacology, 2007, 557, 76-86.	1.7	113
507	Attenuation of contractile dysfunction by atorvastatin after intestinal ischemia reperfusion injury in rats. European Journal of Pharmacology, 2007, 562, 138-147.	1.7	25
508	Low-dose treatment with atorvastatin leads to anti-oxidative and anti-inflammatory effects in diabetes mellitus. European Journal of Pharmacology, 2007, 569, 204-211.	1.7	48
509	NCX 6560, a nitric oxide-releasing derivative of atorvastatin, inhibits cholesterol biosynthesis and shows anti-inflammatory and anti-thrombotic properties. European Journal of Pharmacology, 2007, 570, 115-124.	1.7	43
510	Comparison of Cardiovascular Events in Patients With Angiographically Documented Coronary Narrowing With Combined Renin-Angiotensin System Inhibitor Plus Statin Versus Renin-Angiotensin System Inhibitor Alone Versus Statin Alone (from the Japanese Coronary Artery Disease Study). American Journal of Cardiology, 2007, 100, 1750-1753.	0.7	14
511	Alzheimer's Disease: cholesterol, membrane rafts, isoprenoids and statins. Journal of Cellular and Molecular Medicine, 2007, 11, 383-392.	1.6	119
512	Changes in oxidantâ€antioxidant status in young diabetic patients from clinical onset onwards. Journal of Cellular and Molecular Medicine, 2007, 11, 1352-1366.	1.6	15
513	From pathophysiology to targeted therapy for atherothrombosis: A role for the combination of statin and aspirin in secondary prevention. , 2007, 113, 184-196.		49

#	Article	IF	Citations
514	Can Intensive Statin Therapy Halt the Progression of Atherosclerosis? Recent Evidence and Potential Implications for Patient Management. Progress in Cardiovascular Nursing, 2007, 22, 207-213.	0.5	4
515	Effects of Atorvastatin on Coronary Flow Reserve in Patients with Slow Coronary Flow. Clinical Cardiology, 2007, 30, 475-479.	0.7	77
516	Does the prevalence of nasal polyps increase in patients using statins?. Advances in Therapy, 2007, 24, 1330-1339.	1.3	5
517	Anti-inflammatory effects of atorvastatin improve left ventricular function in experimental diabetic cardiomyopathy. Diabetologia, 2007, 50, 1977-1986.	2.9	118
518	Involvement of the Rho/Rho Kinase Signaling Pathway in Platelet-Derived Growth Factor BB-induced Vascular Endothelial Growth Factor Expression in Diabetic Rat Retina. Japanese Journal of Ophthalmology, 2007, 51, 424-430.	0.9	36
519	Effect of pravastatin on phenotypical transformation of fibroblasts and hypertrophy of cardiomyocytes in culture. Bulletin of Experimental Biology and Medicine, 2007, 143, 54-57.	0.3	9
520	Pathology, natural history and treatment of abdominal aortic aneurysms. Clinical Research in Cardiology, 2007, 96, 140-151.	1.5	40
521	Endotoxin-induced effects on platelets and monocytes in an in vivo model of inflammation. Basic Research in Cardiology, 2007, 102, 460-466.	2.5	46
522	Atherosclerosis regression: Is low-density lipoprotein or high-density lipoprotein the answer?. Current Atherosclerosis Reports, 2007, 9, 266-273.	2.0	11
523	SPARCL: The glimmer of statins for stroke risk reduction. Current Atherosclerosis Reports, 2007, 9, 347-351.	2.0	4
524	Intensive lipid lowering in the cardiovascular patient: Who, how low, and for how long?. Current Cardiovascular Risk Reports, 2007, 1, 290-295.	0.8	0
525	Modulation of calcification of vascular smooth muscle cells in culture by calcium antagonists, statins, and their combination. Molecular and Cellular Biochemistry, 2008, 308, 25-33.	1.4	40
526	Atorvastatin accelerates extracellular nucleotide degradation in human endothelial cells. Molecular and Cellular Biochemistry, 2008, 308, 209-217.	1.4	5
527	Beneficial Effects of Fluvastatin on Liver Microcirculation and Regeneration After Massive Hepatectomy in Rats. Digestive Diseases and Sciences, 2008, 53, 2989-2994.	1.1	16
528	Atorvastatin induces associated reductions in platelet P-selectin, oxidized low-density lipoprotein, and interleukin-6 in patients with coronary artery diseases. Heart and Vessels, 2008, 23, 249-256.	0.5	43
529	Cholestin (Monascus purpureus rice) inhibits homocysteine-induced reactive oxygen species generation, nuclear factor-ÎºB activation, and vascular cell adhesion molecule-1 expression in human aortic endothelial cells. Journal of Biomedical Science, 2008, 15, 183-196.	2.6	27
530	Do statins reduce events in patients with metabolic syndrome?. Current Atherosclerosis Reports, 2008, 10, 39-44.	2.0	9
531	Pitavastatin may Reduce Risk of Steroid-induced Osteonecrosis in Rabbits: A Preliminary Histological Study. Clinical Orthopaedics and Related Research, 2008, 466, 1054-1058.	0.7	44

#	Article	IF	Citations
532	Statinsâ€™ immunomodulatory potential against Th17 cell-mediated autoimmune response. Immunologic Research, 2008, 41, 165-174.	1.3	34
533	Abdominal aortic aneurysm repair in cardiac high risk patients â€“ medication, surgery or stent?. Clinical Research in Cardiology, 2008, 97, 215-221.	1.5	2
534	Statin Therapy Increases Carotid Plaque Echogenicity in Hypercholesterolemic Patients. Ultrasound in Medicine and Biology, 2008, 34, 1353-1359.	0.7	40
535	Simvastatin prevents the inflammatory process and the dopaminergic degeneration induced by the intranigral injection of lipopolysaccharide. Journal of Neurochemistry, 2008, 105, 445-459.	2.1	81
536	Cardiovascular drugs as antidiabetic agents: evidence for the prevention of type 2 diabetes. Diabetes, Obesity and Metabolism, 2008, 10, 533-544.	2.2	8
537	Direct effect of statins on homocysteineâ€induced endothelial adhesiveness: potential impact to human atherosclerosis. European Journal of Clinical Investigation, 2008, 38, 106-116.	1.7	15
538	Effects of Câ€reactive Protein and Homocysteine on Cytokine Production: Modulation by Pravastatin. Archives of Drug Information, 2008, 1, 14-22.	1.6	11
539	Cross-talk Between Statins and PPARÎ± in Cardiovascular Diseases: Clinical Evidence and Basic Mechanisms. Trends in Cardiovascular Medicine, 2008, 18, 73-78.	2.3	51
540	Markers of instability in high-risk carotid plaques are reduced by statins. Journal of Vascular Surgery, 2008, 47, 513-522.	0.6	45
542	Effect of Simvastatin in Apolipoprotein E Deficient Mice With Surgically Induced Chronic Renal Failure. Journal of Urology, 2008, 179, 1631-1636.	0.2	27
543	Targeting Reactive Oxygen Species in Hypertension. Antioxidants and Redox Signaling, 2008, 10, 1061-1078.	2.5	49
544	A critique of paradoxes in current advice on dietary lipids. Progress in Lipid Research, 2008, 47, 77-106.	5.3	108
545	Atorvastatin Attenuates Cardiomyocyte Loss in Adult Rats From Protein-Restricted Dams. Journal of Cardiac Failure, 2008, 14, 151-160.	0.7	18
546	Atorvastatin Inhibits Renal Crystal Retention in a Rat Stone Forming Model. Journal of Urology, 2008, 180, 2212-2217.	0.2	46
547	Effect of pravastatin on the development of diabetes and adiponectin production. Atherosclerosis, 2008, 196, 114-121.	0.4	82
548	The effect of HMG-CoA reductase inhibitors on naturally occurring CD4+CD25+ T cells. Atherosclerosis, 2008, 197, 829-839.	0.4	238
549	Myeloperoxidase levels are not associated with carotid atherosclerosis progression in patients with familial hypercholesterolemia. Atherosclerosis, 2008, 197, 916-921.	0.4	18
551	CaracterÃsticas clÃnicas, bases celulares y moleculares de la hipertensiÃ³n arterial del anciano. Medicina ClÃnica, 2008, 131, 387-395.	0.3	3

#	Article	IF	Citations
552	Antiarrhythmic Effects of Statins in Heart Failure. Heart Failure Clinics, 2008, 4, 187-200.	1.0	2
553	Observational Studies of Statins in Systolic Heart Failure. Heart Failure Clinics, 2008, 4, 201-208.	1.0	14
554	Redox Control of Endothelial Function and Dysfunction: Molecular Mechanisms and Therapeutic Opportunities. Antioxidants and Redox Signaling, 2008, 10, 1713-1766.	2.5	339
555	Atorvastatin does not affect insulin sensitivity and the adiponectin or leptin levels in hyperlipidemic Type 2 diabetes. Journal of Endocrinological Investigation, 2008, 31, 42-47.	1.8	35
556	Effect of statins on soluble CD40 ligand in hypercholesterolemic Type 2 diabetic patients. Journal of Endocrinological Investigation, 2008, 31, 660-665.	1.8	18
557	Lipidomics-Based Safety Biomarkers for Lipid-Lowering Treatments. Angiology, 2008, 59, 65S-68S.	0.8	23
558	Chlamydophila pneumoniaeand Endothelial Activation. Circulation Research, 2008, 102, 861-863.	2.0	2
559	Pravastatin Attenuates Left Ventricular Remodeling and Diastolic Dysfunction in Angiotensin II-Induced Hypertensive Mice. Journal of Cardiovascular Pharmacology, 2008, 51, 62-70.	0.8	55
560	Simvastatin ReducesChlamydophila pneumoniaeâ€“Mediated Histone Modifications and Gene Expression in Cultured Human Endothelial Cells. Circulation Research, 2008, 102, 888-895.	2.0	41
561	Effects of Statins on Adipose Tissue Inflammation. Arteriosclerosis, Thrombosis, and Vascular Biology, 2008, 28, 871-877.	1.1	94
562	Simvastatin Inhibits Central Sympathetic Outflow in Heart Failure by a Nitric-Oxide Synthase Mechanism. Journal of Pharmacology and Experimental Therapeutics, 2008, 326, 278-285.	1.3	57
563	Specific signals involved in the long-term maintenance of radiation-induced fibrogenic differentiation: a role for CCN2 and low concentration of TGF-Î²1. American Journal of Physiology - Cell Physiology, 2008, 294, C1332-C1341.	2.1	43
564	Rosuvastatin provides pleiotropic protection against pulmonary hypertension, right ventricular hypertrophy, and coronary endothelial dysfunction in rats. American Journal of Physiology - Heart and Circulatory Physiology, 2008, 294, H801-H809.	1.5	47
565	HMG-CoA Reductase Inhibitor Simvastatin Inhibits Cell Cycle Progression at the G₁/S Checkpoint in Immortalized Lymphocytes from Alzheimer's Disease Patients Independently of Cholesterol-Lowering Effects. Journal of Pharmacology and Experimental Therapeutics, 2008, 324, 352-359.	1.3	30
566	Simvastatin suppresses LPS-induced MMP-1 expression in U937 mononuclear cells by inhibiting protein isoprenylation-mediated ERK activation. Journal of Leukocyte Biology, 2008, 84, 1120-1129.	1.5	32
567	Lipid-Lowering Therapy is Related to Inflammatory Markers and 3-Year Mortality in Patients With Critical Limb Ischemia. Angiology, 2008, 59, 542-548.	0.8	17
568	Are Statins an Option in the Management of Abdominal Aortic Aneurysms?. Vascular and Endovascular Surgery, 2008, 42, 128-134.	0.3	27
569	Involvement of Heat Shock Factor 1 in Statin-Induced Transcriptional Upregulation of Endothelial Thrombomodulin. Circulation Research, 2008, 103, 369-377.	2.0	35

#	Article	IF	Citations
570	Metabolomic strategies to identify tissue-specific effects of cardiovascular drugs. Expert Opinion on Drug Metabolism and Toxicology, 2008, 4, 665-680.	1.5	13
571	Potential therapeutic role of statins in neurological disorders. Expert Review of Neurotherapeutics, 2008, 8, 827-837.	1.4	21
572	Therapeutic potential of statins in multiple sclerosis: immune modulation, neuroprotection and neurorepair. Future Neurology, 2008, 3, 153-167.	0.9	25
573	Targeting of RhoA/ROCK Signaling Ameliorates Progression of Diabetic Nephropathy Independent of Glucose Control. Diabetes, 2008, 57, 714-723.	0.3	182
574	Do Statins Need to be Prescribed for All Patients with Left Ventricular Dysfunction?. Internal Medicine, 2008, 47, 335-336.	0.3	0
575	Importance of Lipid Levels in Elderly Diabetic Individuals Baseline Characteristics and 1-Year Survey of Cardiovascular Events. Circulation Journal, 2008, 72, 218-225.	0.7	12
576	Preprocedural Statin Administration can Reduce Thrombotic Reaction After Stent Implantation. Circulation Journal, 2008, 72, 232-237.	0.7	20
577	Pharmacogenomics of Cardiovascular Pharmacology: Molecular Network Analysis in Pleiotropic Effects of Statin â€" an Experimental Elucidation of the Pharmacologic Action From Protein-Protein Interaction Analysis. Journal of Pharmacological Sciences, 2008, 107, 15-19.	1.1	16
578	Molecular Mechanisms of Pulmonary Arterial Hypertension. Chest, 2008, 134, 1271-1277.	0.4	70
579	In-vivo effects of simvastatin and rosuvastatin on global gene expression in peripheral blood leucocytes in a human inflammation model. Pharmacogenetics and Genomics, 2008, 18, 109-120.	0.7	24
580	Temporal Gene Expression Analysis of Human Coronary Artery Endothelial Cells Treated With Simvastatin. Gene Expression, 2008, 14, 229-239.	0.5	5
581	Cholesterol lowering and beyond: role of statins in Alzheimerâ€™s disease. Aging Health, 2008, 4, 171-180.	0.3	3
582	Pharmacological Preconditioning With Simvastatin Protects Liver From Ischemia-Reperfusion Injury by Heme Oxygenase-1 Induction. Transplantation, 2008, 85, 732-738.	0.5	73
583	Inhibition of Macrophage Phagocytotic Activity by a Receptor-targeted Polymer Vesicle-based Drug Delivery Formulation of Pravastatin. Journal of Cardiovascular Pharmacology, 2008, 51, 246-252.	0.8	75
584	Thiazide diuretics, endothelial function, and vascular oxidative stress. Journal of Hypertension, 2008, 26, 494-500.	0.3	62
585	Effectiveness of statins in the reduction of the risk of myocardial infarction is modified by the GNB3 C825T variant. Pharmacogenetics and Genomics, 2008, 18, 631-636.	0.7	11
586	Can HMG Co-A reductase inhibitors (“statins”) slow the progression of age-related macular degeneration? The Age-Related Maculopathy Statin Study (ARMSS). Clinical Interventions in Aging, 2008, Volume 3, 581-593.	1.3	22
587	Perioperative use of statins in noncardiac surgery. Vascular Health and Risk Management, 2008, Volume 4, 75-81.	1.0	8

#	Article	IF	Citations
588	High-dose atorvastatin in peripheral arterial disease (PAD): Effect on endothelial function, intima-media-thickness and local progression of PAD. Thrombosis and Haemostasis, 2008, 99, 182-189.	1.8	27
589	Regulation of plasminogen activator inhibitor type 1 gene expression by inflammatory mediators and statins. Thrombosis and Haemostasis, 2008, 100, 969-975.	1.8	87
590	Efectos pleiotrÃ³picos de las estatinas. Revista Medica De Chile, 2008, 136, .	0.1	20
591	The Protective Effect of Simvastatin on Monocrotaline-Induced Pulmonary Hypertension in Rats. Korean Circulation Journal, 2008, 38, 313.	0.7	4
592	Critical appraisal of the role of pitavastatin in treating dyslipidemias and achieving lipid goals. Vascular Health and Risk Management, 2009, 5, 921.	1.0	43
593	Changes inPPARgene expression and myocardial tolerance to ischaemia: relevance to pleiotropic effects of statinsThis article is one of a selection of papers published in a special issue on Advances in Cardiovascular Research.. Canadian Journal of Physiology and Pharmacology, 2009, 87, 1028-1036.	0.7	28
594	Lipid-Lowering Drugs in Ischemic Stroke Prevention and Their Influence on Acute Stroke Outcome. Cerebrovascular Diseases, 2009, 27, 126-133.	0.8	50
595	Oxidized LDL Receptor LOX-1 Binds to C-Reactive Protein and Mediates Its Vascular Effects. Clinical Chemistry, 2009, 55, 285-294.	1.5	81
596	New Idol for Cholesterol Reduction?. Clinical Chemistry, 2009, 55, 2082-2084.	1.5	13
597	Associations Between Statin Treatment and Markers of Inflammation, Vasoconstriction, and Coagulation in Patients With Abdominal Aortic Aneurysm. Vascular and Endovascular Surgery, 2009, 42, 567-573.	0.3	9
598	Lifestyle and age-related macular degeneration. Expert Review of Ophthalmology, 2009, 4, 79-102.	0.3	2
599	Statins. , 2009, , 253-280.		5
600	Human Platelets Express Organic Anion-Transporting Peptide 2B1, an Uptake Transporter for Atorvastatin. Drug Metabolism and Disposition, 2009, 37, 1129-1137.	1.7	59
601	Antimicrobial and Immunomodulatory Attributes of Statins: Relevance in Solidâ€Organ Transplant Recipients. Clinical Infectious Diseases, 2009, 48, 745-755.	2.9	56
602	Prior Statin Use, Intracranial Hemorrhage, and Outcome After Intra-Arterial Thrombolysis for Acute Ischemic Stroke. Stroke, 2009, 40, 1729-1737.	1.0	82
603	The Intermediate Enzymes of Isoprenoid Metabolism as Anticancer Targets. Anti-Cancer Agents in Medicinal Chemistry, 2009, 9, 526-542.	0.9	60
604	Placebo-Controlled Trial of High-Dose Atorvastatin in Patients With Severe Cerebral Small Vessel Disease. Stroke, 2009, 40, 1721-1728.	1.0	34
605	PLTP activity is a risk factor for subsequent cardiovascular events in CAD patients under statin therapy: the AtheroGene Study. Journal of Lipid Research, 2009, 50, 723-729.	2.0	35

#	Article	IF	Citations
606	Endothelial Dysfunction in Diabetes: From Mechanisms to Therapeutic Targets. Current Medicinal Chemistry, 2009, 16, 94-112.	1.2	237
607	Impact of Simvastatin on Adipose Tissue: Pleiotropic Effects in Vivo. Endocrinology, 2009, 150, 5262-5272.	1.4	52
608	Simvastatin Reduces Expression and Activity of Lipoprotein-Associated Phospholipase A₂ in the Aorta of Hypercholesterolaemic Atherosclerotic Rabbits. Journal of International Medical Research, 2009, 37, 1029-1037.	0.4	10
609	Rosuvastatin ameliorates the development of pulmonary arterial hypertension in the transgenic (mRen2)27 rat. American Journal of Physiology - Heart and Circulatory Physiology, 2009, 297, H1128-H1139.	1.5	26
610	Beneficial effect of rosuvastatin on cardiac dysfunction is associated with alterations in calciumâ€regulatory proteins. European Journal of Heart Failure, 2009, 11, 6-13.	2.9	19
611	Inflammatory myocardial injury: the role of lymphocytes in atherosclerosis and other heart diseases. Journal of Organ Dysfunction, 2009, 5, 224-232.	0.3	0
612	Atorvastatin Restores Endothelial Function in Offspring of Protein-Restricted Rats in a Cholesterol-Independent Manner. Hypertension, 2009, 53, 661-667.	1.3	37
613	Efficacy of Simvastatin Treatment of Valvular Interstitial Cells Varies With the Extracellular Environment. Arteriosclerosis, Thrombosis, and Vascular Biology, 2009, 29, 246-253.	1.1	49
614	Mevastatin reduces cartilage degradation in rabbit experimental osteoarthritis through inhibition of synovial inflammation. Osteoarthritis and Cartilage, 2009, 17, 235-243.	0.6	68
615	Pravastatin prevents miscarriages in antiphospholipid antibody-treated mice. Journal of Reproductive Immunology, 2009, 82, 126-131.	0.8	31
616	Simvastatin reduces myocardial infarct size via increased nitric oxide production in normocholesterolemic rabbits. Journal of Cardiology, 2009, 53, 102-107.	0.8	16
617	Counter-regulation by atorvastatin of gene modulations induced by L-NAME hypertension is associated with vascular protection. Vascular Pharmacology, 2009, 51, 253-261.	1.0	9
618	Statinâ€induced calcification in human mesenchymal stem cells is cell death related. Journal of Cellular and Molecular Medicine, 2009, 13, 4465-4473.	1.6	43
619	Photochemical properties of simvastatin and lovastatin induced by radiation. Journal of Thermal Analysis and Calorimetry, 2009, 96, 301-305.	2.0	8
620	Molecular Analysis of Endoplasmic Reticulum Stress Response After Global Forebrain Ischemia/Reperfusion in Rats: Effect of Neuroprotectant Simvastatin. Cellular and Molecular Neurobiology, 2009, 29, 181-192.	1.7	48
621	Review of the SPARCL trial and its subanalyses. Current Atherosclerosis Reports, 2009, 11, 315-321.	2.0	8
622	Low-density lipoprotein in the setting of congestive heart failure: Is lower really better?. Current Atherosclerosis Reports, 2009, 11, 343-349.	2.0	9
623	The role of statins in the treatment of the metabolic syndrome. Current Hypertension Reports, 2009, 11, 143-149.	1.5	17

#	Article	IF	Citations
624	The effects of statin therapy on inflammatory cytokines in patients with bacterial infections: a randomized double-blind placebo controlled clinical trial. Intensive Care Medicine, 2009, 35, 1255-1260.	3.9	132
625	eNOS T-786C polymorphism affects atorvastatin-induced changes in erythrocyte membrane fluidity. European Journal of Clinical Pharmacology, 2009, 65, 385-392.	0.8	25
626	Effects of statins on the secretion of human serum albumin in cultured HepG2 cells. Journal of Biomedical Science, 2009, 16, 32.	2.6	23
627	Iron behaving badly: inappropriate iron chelation as a major contributor to the aetiology of vascular and other progressive inflammatory and degenerative diseases. BMC Medical Genomics, 2009, 2, 2.	0.7	421
628	Cardiovascular risk factors and collateral artery formation. European Journal of Clinical Investigation, 2009, 39, 1036-1047.	1.7	28
629	Lovastatin restores the function of endothelial progenitor cells damaged by oxLDL. Acta Pharmacologica Sinica, 2009, 30, 545-552.	2.8	21
630	Chronic treatment with pravastatin prevents early cardiovascular changes in spontaneously hypertensive rats. British Journal of Pharmacology, 2009, 158, 541-547.	2.7	27
631	The beneficial effect of statins treatment by stroke subtype. European Journal of Neurology, 2009, 16, 127-133.	1.7	45
632	Therapeutic Neovascularization by Nanotechnology-Mediated Cell-Selective Delivery of Pitavastatin Into the Vascular Endothelium. Arteriosclerosis, Thrombosis, and Vascular Biology, 2009, 29, 796-801.	1.1	59
633	Management of the antiphospholipid syndrome: new approaches. International Journal of Clinical Rheumatology, 2009, 4, 533-549.	0.3	2
634	Statin prophylaxis and inflammatory mediators following cardiopulmonary bypass: a systematic review. Critical Care, 2009, 13, R165.	2.5	31
635	Effect of rosuvastatin on concentrations of plasma lipids, urine and plasma oxidative stress markers, and plasma high-sensitivity C-reactive protein in hypercholesterolemic patients with and without type 2 diabetes mellitus: A 12-week, open-label, pilot study. Current Therapeutic Research, 2009, 70, 439-448.	0.5	5
636	Effect of Low Doses of Atorvastatin on the Urinary Peptide Profile of Kidney Transplant Patients. Transplantation Proceedings, 2009, 41, 2111-2114.	0.3	11
637	Has the association between saturated fatty acids, serum cholesterol and coronary heart disease been over emphasized?. International Dairy Journal, 2009, 19, 345-361.	1.5	70
638	The beneficial effect of high loading dose of rosuvastatin before percutaneous coronary intervention in patients with acute coronary syndrome. International Journal of Cardiology, 2009, 137, 246-251.	0.8	104
639	Statins for post resuscitation syndrome. Medical Hypotheses, 2009, 73, 97-99.	0.8	5
640	Effect of Statin Adherence on Cerebrovascular Disease in Primary Prevention. American Journal of Medicine, 2009, 122, 647-655.	0.6	56
641	Statins Are Associated With a Reduced Risk of Hepatocellular Carcinoma in a Large Cohort of Patients With Diabetes. Gastroenterology, 2009, 136, 1601-1608.	0.6	247

#	Article	IF	Citations
642	Statins for the Treatment of Antiphospholipid Syndrome?. Annals of the New York Academy of Sciences, 2009, 1173, 736-745.	1.8	49
643	Potential role of HMG CoA reductase inhibitor on oxidative stress induced by advanced glycation endproducts in vascular smooth muscle cells of diabetic vasculopathy. Experimental and Molecular Medicine, 2009, 41, 802.	3.2	31
644	Neuroprotective Effects of Statins in an In Vitro Model of Alzheimer's Disease. Journal of Alzheimer's Disease, 2009, 17, 503-517.	1.2	21
645	Atorvastatin attenuates angiotensin II-induced inflammatory actions in the liver. American Journal of Physiology - Renal Physiology, 2009, 296, G147-G156.	1.6	79
646	Anti-atherogenic effects of montelukast associated with reduced MCP-1 expression in a rabbit carotid balloon injury model. Atherosclerosis, 2009, 205, 74-79.	0.4	30
647	Statins inhibit Rho kinase activity in patients with atherosclerosis. Atherosclerosis, 2009, 205, 517-521.	0.4	119
648	Simvastatin acutely reduces ischemic brain damage in the immature rat via Akt and CREB activation. Experimental Neurology, 2009, 220, 82-89.	2.0	43
649	Prognostic implications of C-reactive protein and troponin following percutaneous coronary intervention. Canadian Journal of Cardiology, 2009, 25, e42-e47.	0.8	19
650	Atorvastatin Ameliorates Tubulointerstitial Fibrosis and Protects Renal Function in Chronic Partial Ureteral Obstruction Cases. Journal of Urology, 2009, 182, 1860-1868.	0.2	11
651	Recurrent first trimester pregnancy loss: revised definitions and novel causes. Current Opinion in Endocrinology, Diabetes and Obesity, 2009, 16, 446-450.	1.2	68
652	SIMVASTATIN REDUCES ENDOTOXIN-INDUCED NUCLEAR FACTOR Î¹B ACTIVATION AND MORTALITY IN GUINEA PIGS DESPITE LOWERING CIRCULATING LOW-DENSITY LIPOPROTEIN CHOLESTEROL. Shock, 2009, 32, 159-163.	1.0	19
653	Salvaging the Zone of Stasis By Simvastatin: An Experimental Study in Rats. Journal of Burn Care and Research, 2009, 30, 872-879.	0.2	20
655	NADPH Oxidase Isoforms and Anti-hypertensive Effects of Atorvastatin Demonstrated in Two Animal Models. Journal of Pharmacological Sciences, 2009, 111, 260-268.	1.1	26
656	Pravastatin prevents miscarriages in mice: role of tissue factor in placental and fetal injury. Blood, 2009, 113, 4101-4109.	0.6	106
657	Importance of Rac1 Signaling Pathway Inhibition in the Pleiotropic Effects of HMG-CoA Reductase Inhibitors. Circulation Journal, 2009, 73, 361-370.	0.7	74
658	Effects of Pitavastatin on Fasting and Postprandial Endothelial Function and Blood Rheology in Patients With Stable Coronary Artery Disease. Circulation Journal, 2009, 73, 1523-1530.	0.7	30
659	Visceral Adipose Tissue and Atherosclerosis. Current Vascular Pharmacology, 2009, 7, 169-179.	0.8	60
660	Targeting MCP-1 to Reduce Vascular Complications of Obesity. Recent Patents on Cardiovascular Drug Discovery, 2009, 4, 164-176.	1.5	14

#	Article	IF	Citations
661	Diabetes and Antioxidants: Myth or Reality?. Current Vascular Pharmacology, 2010, 8, 661-672.	0.8	22
662	Effect of Statins on the Viability of Macrophages and Smooth Muscle Cells. Journal of Cardiovascular Pharmacology, 2010, 55, 269-275.	0.8	17
663	The Antiplatelet and Antithrombotic Actions of Statins. Current Pharmaceutical Design, 2010, 16, 3808-3814.	0.9	29
664	Pravastatin Counteracts Angiotensin II-Induced Upregulation and Activation of NADPH Oxidase at Plasma Membrane of Human Endothelial Cells. Journal of Cardiovascular Pharmacology, 2010, 55, 203-212.	0.8	39
665	Long-Term Statin Therapy is Associated with Better Episodic Memory in Aged Familial Hypercholesterolemia Patients in Comparison with Population Controls. Journal of Alzheimer's Disease, 2010, 21, 611-617.	1.2	16
666	Rosuvastatin reduces neointima formation in a rat model of balloon injury. European Journal of Medical Research, 2010, 15, 461.	0.9	14
667	The effects of atorvastatin on pulmonary arterial hypertension and expression of p38, p27, and Jab1 in rats. International Journal of Molecular Medicine, 2010, 26, 541-7.	1.8	10
668	Evaluation of the synergistic adverse effects of concomitant therapy with statins and fibrates on rhabdomyolysis. Journal of Pharmacy and Pharmacology, 2010, 55, 795-802.	1.2	25
669	Statin-induced apoptosis linked with membrane farnesylated Ras small G protein depletion, rather than geranylated Rho protein. Journal of Pharmacy and Pharmacology, 2010, 57, 1475-1484.	1.2	50
670	Systematic review on evidence of the effectiveness of cholesterol-lowering drugs. Advances in Therapy, 2010, 27, 348-364.	1.3	20
671	Role of Tissue Factor in the Maternal Immunological Attack of the Embryo in the Antiphospholipid Syndrome. Clinical Reviews in Allergy and Immunology, 2010, 39, 160-165.	2.9	28
672	Therapeutic Options to Further Lower C-Reactive Protein for Patients on Statin Treatment. Current Atherosclerosis Reports, 2010, 12, 34-42.	2.0	16
673	Lipid and C-Reactive Protein Levels, Cardiovascular Disease Risk Factors and Simvastatin Treatment in Brazilian Individuals. Inflammation, 2010, 33, 244-250.	1.7	11
674	Regulation of vascular smooth muscle cell proliferation by nuclear orphan receptor Nur77. Molecular and Cellular Biochemistry, 2010, 341, 159-166.	1.4	16
675	Exploring new indications for statins beyond atherosclerosis: Successes and setbacks. Journal of Cardiology, 2010, 55, 155-162.	0.8	29
676	Effects of statin and lipoprotein metabolism in heart failure. Journal of Cardiology, 2010, 55, 287-290.	0.8	14
677	Pravastatin attenuates cardiac dysfunction induced by lysophosphatidylcholine in isolated rat hearts. European Journal of Pharmacology, 2010, 640, 139-142.	1.7	3
678	Comparison of Effects of Statin Use on Mortality in Patients With Peripheral Arterial Disease With Versus Without Elevated C-Reactive Protein and D-Dimer Levels. American Journal of Cardiology, 2010, 105, 1348-1352.	0.7	24

#	Article	IF	Citations
679	Shortâ€Term Treatment with Highâ€Dose Atorvastatin Reduces LDL Cholesterol but Shows no Antiâ€Inflammatory Effects in Normolipidemic Subjects with Normal CRP Levels. Clinical and Translational Science, 2010, 3, 140-146.	1.5	14
680	Incidence of perioperative myocardial infarction and of 2-year mortality in 577 elderly patients undergoing noncardiac vascular surgery treated with and without statins. Archives of Gerontology and Geriatrics, 2010, 51, 149-151.	1.4	58
681	Hypercholesterolemia and microvascular dysfunction: interventional strategies. Journal of Inflammation, 2010, 7, 54.	1.5	123
682	Statins suppress interleukinâ€6â€induced monocyte chemoâ€attractant proteinâ€1 by inhibiting Janus kinase/signal transducers and activators of transcription pathways in human vascular endothelial cells. British Journal of Pharmacology, 2010, 159, 1294-1303.	2.7	81
683	Atorvastatin Reduces Calcification in Rat Arteries and Vascular Smooth Muscle Cells. Basic and Clinical Pharmacology and Toxicology, 2010, 107, 798-802.	1.2	27
684	Atorvastatin increases expression of lowâ€density lipoprotein receptor mRNA in human circulating mononuclear cells. Clinical and Experimental Pharmacology and Physiology, 2010, 37, 471-476.	0.9	25
685	A New Mouse Model to Explore Therapies for Preeclampsia. PLoS ONE, 2010, 5, e13663.	1.1	132
686	Simvastatin, Sildenafil and Their Combination in Monocrotaline Induced Pulmonary Arterial Hypertension. Korean Circulation Journal, 2010, 40, 659.	0.7	11
687	Prognostic Effects of Combined Treatment With Calcium Channel Blockers and Statins in Patients With Coronary Narrowing From the Japanese Coronary Artery Disease Study. International Heart Journal, 2010, 51, 299-302.	0.5	4
688	Effects of simvastatin on markers of inflammation, oxidative stress and endothelial cell apoptosis in patients on chronic hemodialysis. Journal of Atherosclerosis and Thrombosis, 2010, 17, 1256-1265.	0.9	32
689	Atorvastatin attenuates inflammatory infiltration and vascular remodeling in lung of hypercholesterolemia rabbits. Experimental Lung Research, 2010, 36, 573-592.	0.5	9
690	Oxysterols in biological systems: The gastrointestinal tract, liver, vascular wall and central nervous system. Free Radical Research, 2010, 44, 47-73.	1.5	38
691	Statins Promote the Degradation of Extracellular Amyloid Î²-Peptide by Microglia via Stimulation of Exosome-associated Insulin-degrading Enzyme (IDE) Secretion. Journal of Biological Chemistry, 2010, 285, 37405-37414.	1.6	176
692	Basic Science Review Section: Statin Therapyâ€"Part II: Clinical Considerations for Cardiovascular Disease. Vascular and Endovascular Surgery, 2010, 44, 421-433.	0.3	19
693	The role of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors (statins) in modern rheumatology. Therapeutic Advances in Musculoskeletal Disease, 2010, 2, 257-269.	1.2	22
694	A Broad Variety of Antigens Contribute to the Pathogenesis of Atherosclerosis: How to Neutralize Noxious Reactions in the Host. Endocrine, Metabolic and Immune Disorders - Drug Targets, 2010, 10, 149-160.	0.6	2
695	HYPERGLYCEMIA INDUCED CELL GROWTH AND GENE EXPRESSION VIA THE SERUM RESPONSE ELEMENT THROUGH RhoA AND Rho-KINASE IN VASCULAR SMOOTH MUSCLE CELLS. Preparative Biochemistry and Biotechnology, 2010, 40, 139-151.	1.0	14
697	Spielen Statine eine Rolle als adjuvante Therapie bei EntzÃ¼ndung? / Do statins play a role as an adjuvant therapy in inflammation?. Laboratoriums Medizin, 2010, 34, 325-335.	0.1	0

#	Article	IF	Citations
698	Lovastatin Inhibits the Thrombin-Induced Loss of Barrier Integrity in Bovine Corneal Endothelium. Journal of Ocular Pharmacology and Therapeutics, 2010, 26, 1-10.	0.6	13
699	Pravastatin Attenuates Carboplatin-Induced Nephrotoxicity in Rodents via Peroxisome Proliferator-Activated Receptor Î±-Regulated Heme Oxygenase-1. Molecular Pharmacology, 2010, 78, 36-45.	1.0	31
700	Residual cardiovascular risk in treated hypertension and hyperlipidaemia: the PRIME Study. Journal of Human Hypertension, 2010, 24, 19-26.	1.0	81
701	Stents and statins: history, clinical outcomes and mechanisms. Expert Review of Cardiovascular Therapy, 2010, 8, 1283-1295.	0.6	9
702	Cost-effectiveness of statin therapy for vascular event prevention in adults with elevated C-reactive protein: implications of JUPITER. Current Medical Research and Opinion, 2010, 26, 2485-2497.	0.9	15
704	Rosuvastatin Treatment is Associated with a Decrease of Serum Oxidised Low-Density Lipoprotein/Beta2-Glycoprotein I Complex Concentration in Type 2 Diabetes. British Journal of Diabetes and Vascular Disease, 2010, 10, 292-299.	0.6	10
705	The effect of simvastatin on the survival of ischaemic skin flap: An experimental study in rats. Journal of Plastic, Reconstructive and Aesthetic Surgery, 2010, 63, 1723-1732.	0.5	11
706	Multifarious molecular signaling cascades of cardiac hypertrophy: Can the muddy waters be cleared?â˜†. Pharmacological Research, 2010, 62, 365-383.	3.1	86
707	Nanoparticle-mediated endothelial cell-selective delivery of pitavastatin induces functional collateral arteries (therapeutic arteriogenesis) in a rabbit model of chronic hind limb ischemia. Journal of Vascular Surgery, 2010, 52, 412-420.	0.6	39
708	Synergistic action of statins and nitrogen-containing bisphosphonates in the development of rhabdomyolysis in L6 rat skeletal myoblasts. Journal of Pharmacy and Pharmacology, 2010, 61, 781-788.	1.2	9
709	Atorvastatin pretreatment diminishes the levels of myocardial ischemia markers early after CABG operation: an observational study. Journal of Cardiothoracic Surgery, 2010, 5, 60.	0.4	18
710	Atorvastatin inhibits inflammatory angiogenesis in mice through down regulation of VEGF, TNF-Î± and TGF-Î²1. Biomedicine and Pharmacotherapy, 2010, 64, 29-34.	2.5	98
711	Modulation of impact of high fat diet in pathological and physiological left ventricular cardiac hypertrophy by fluvastatin. Biomedicine and Pharmacotherapy, 2010, 64, 147-153.	2.5	7
712	Farnesyltransferase inhibitor improved survival following endotoxin challenge in mice. Biochemical and Biophysical Research Communications, 2010, 391, 1459-1464.	1.0	32
713	Down-regulation of RhoA is involved in the cytotoxic action of lipophilic statins in HepG2 cells. Atherosclerosis, 2010, 208, 112-118.	0.4	24
714	Statins improve visual field alterations related to hypercholesterolemia. Atherosclerosis, 2010, 209, 510-514.	0.4	4
715	Effect of HMG-CoA reductase inhibitors on vascular cell apoptosis: Beneficial or detrimental?. Atherosclerosis, 2010, 211, 9-14.	0.4	45
716	Fluvastatin protects vascular smooth muscle cells against oxidative stress through the Nrf2-dependent antioxidant pathway. Atherosclerosis, 2010, 213, 377-384.	0.4	46

#	Article	IF	Citations
717	Basic Science Review: Statin Therapy-Part I: The Pleiotropic Effects of Statins in Cardiovascular Disease. Vascular and Endovascular Surgery, 2010, 44, 241-251.	0.3	121
718	The role of apoptosis in LDL transport through endothelial cell monolayers. , 2010, , .		0
719	Impact of Xuezhikang on coronary events in hypertensive patients with previous myocardial infarction from the China Coronary Secondary Prevention Study (CCSPS). Annals of Medicine, 2010, 42, 231-240.	1.5	41
720	Pentoxifylline Enhances the Radioprotective Properties of Î³-Tocotrienol: Differential Effects on the Hematopoietic, Gastrointestinal and Vascular Systems. Radiation Research, 2011, 175, 297-306.	0.7	45
721	Low-Density Lipoprotein Lowering Does Not Improve Calf Muscle Perfusion, Energetics, or Exercise Performance in Peripheral Arterial Disease. Journal of the American College of Cardiology, 2011, 58, 1068-1076.	1.2	27
722	Simvastatin stimulates apoptosis in cholangiocarcinoma by inhibition of Rac1 activity. Digestive and Liver Disease, 2011, 43, 395-403.	0.4	39
723	PPARs and Myocardial Response to Ischemia in Normal and Diseased Heart. , 2011, , 135-148.		1
725	Dose-related Effect of Statins in Venous Thrombosis Risk Reduction. American Journal of Medicine, 2011, 124, 852-859.	0.6	38
726	Effects of selective H.E.L.P. LDL-apheresis on plasma inflammatory markers concentration in severe dyslipidemia: Implication for anti-inflammatory response. Cytokine, 2011, 56, 850-854.	1.4	19
727	Pleiotropic role of atorvastatin in regulation of human retinal pigment epithelial cell behaviors inÂvitro. Experimental Eye Research, 2011, 93, 842-851.	1.2	15
728	The effects of atorvastatin and rosuvastatin on oxidative stress in diabetic patients. European Journal of Internal Medicine, 2011, 22, 249-253.	1.0	23
729	Atorvastatin exerts its anti-atherosclerotic effects by targeting the receptor for advanced glycation end products. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 2011, 1812, 1130-1137.	1.8	28
730	Abrogation of neutral cholesterol ester hydrolytic activity causes adrenal enlargement. Biochemical and Biophysical Research Communications, 2011, 404, 254-260.	1.0	12
731	12-month follow-up results of high dose rosuvastatin loading before percutaneous coronary intervention in patients with acute coronary syndrome. International Journal of Cardiology, 2011, 146, 68-72.	0.8	50
732	Lovastatin Inhibits Thrombospondin-1-Induced Smooth Muscle Cell Chemotaxis. Journal of Surgical Research, 2011, 168, 149-154.	0.8	10
733	Statins Are Associated With a Reduced Risk of Gastric Cancer: A Population-Based Caseâ€“Control Study. American Journal of Gastroenterology, 2011, 106, 2098-2103.	0.2	74
734	Pitavastatin: An overview. Atherosclerosis Supplements, 2011, 12, 271-276.	1.2	48
735	Simvastatin preserves diastolic function in experimental hypercholesterolemia independently of its lipid lowering effect. Atherosclerosis, 2011, 216, 283-291.	0.4	19

#	Article	IF	Citations
736	The effect of ezetimibe on peripheral arterial atherosclerosis depends upon statin use at baseline. Atherosclerosis, 2011, 218, 156-162.	0.4	74
737	Effect of Previous Statin Therapy in Patients With Acute Coronary Syndrome and Percutaneous Coronary Intervention. Korean Circulation Journal, 2011, 41, 458.	0.7	15
738	Regulation of the endothelial plasminogen activator system by fluvastatin. Thrombosis and Haemostasis, 2011, 105, 461-472.	1.8	16
739	Endothelial Dysfunction and Therapeutic Intervention in Type 2 Diabetes. , 0, , .		0
740	Statin Drugs, Metabolic Pathways, and Asthma: A Therapeutic Opportunity Needing Further Research. Drug Metabolism Letters, 2011, 5, 40-44.	0.5	27
741	Atorvastatin reduces thrombin generation and expression of tissue factor, P-selectin and GPIIIa on platelet-derived microparticles in patients with peripheral arterial occlusive disease. Thrombosis and Haemostasis, 2011, 106, 344-352.	1.8	83
742	Vascular Biology and Atherosclerosis of Cerebral Arteries. , 2011, , 3-15.		0
743	Inflammation and thrombosis in diabetes. Thrombosis and Haemostasis, 2011, 105, S43-S54.	1.8	105
744	Immediate and short-term consequences of secondhand smoke exposure on the respiratory system. Current Opinion in Pulmonary Medicine, 2011, 17, 110-115.	1.2	29
745	Statin Use and the Risk of Pancreatic Cancer. Pancreas, 2011, 40, 669-672.	0.5	29
746	Simvastatin Reduces Lipoprotein-associated Phospholipase A2 in Lipopolysaccharide-stimulated Human Monocyteâ€“derived Macrophages Through Inhibition of the Mevalonateâ€“Geranylgeranyl Pyrophosphateâ€“RhoA-p38 Mitogen-activated Protein Kinase Pathway. Journal of Cardiovascular Pharmacology, 2011, 57, 213-222.	0.8	20
747	Pulmonary arterial hypertension and statins: an update. Current Opinion in Cardiology, 2011, 26, 322-326.	0.8	18
748	Medical Therapy of Aortic Aneurysms: A Pathophysiology-Based Approach. Current Vascular Pharmacology, 2011, 9, 572-584.	0.8	4
749	Mevalonate Pathway Is a Novel Target for Hypertension. Circulation Journal, 2011, 75, 1318-1319.	0.7	3
750	Rho Kinase Inhibition by Fasudil Has Anti-inflammatory Effects in Hypercholesterolemic Rats. Biological and Pharmaceutical Bulletin, 2011, 34, 1684-1689.	0.6	29
751	Rho kinase inhibition by fasudil exerts antioxidant effects in hypercholesterolemic rats. Clinical and Experimental Pharmacology and Physiology, 2011, 38, 688-694.	0.9	30
752	Statins potently reduce the cytokine-mediated IL-6 release in SMC/MNC cocultures. Journal of Cellular and Molecular Medicine, 2011, 15, 994-1004.	1.6	68
753	Simvastatin induces apoptosis by a Rho-dependent mechanism in cultured cardiac fibroblasts and myofibroblasts. Toxicology and Applied Pharmacology, 2011, 255, 57-64.	1.3	34

#	Article	IF	Citations
754	Immunomodulatory agents in the treatment of community-acquired pneumonia: A systematic review. Journal of Infection, 2011, 63, 187-199.	1.7	54
755	Statins: A potential role in the management of osteoarthritis?. Joint Bone Spine, 2011, 78, 31-34.	0.8	32
756	Intravenous administration of pravastatin immediately after middle cerebral artery occlusion reduces cerebral oedema in spontaneously hypertensive rats. European Journal of Pharmacology, 2011, 660, 381-386.	1.7	12
757	Arginine or citrulline associated with a statin stimulates nitric oxide production in bovine aortic endothelial cells. European Journal of Pharmacology, 2011, 670, 566-570.	1.7	8
758	A Randomised Placebo-controlled Double-blind Trial to Evaluate Lipid-lowering Pharmacotherapy on Proteolysis and Inflammation in Abdominal Aortic Aneurysms. European Journal of Vascular and Endovascular Surgery, 2011, 41, 28-35.	0.8	34
759	Reprinted Article â€œA Combination of Statins and Beta-blockers is Independently Associated with a Reduction in the Incidence of Perioperative Mortality and Nonfatal Myocardial Infarction in Patients Undergoing Abdominal Aortic Aneurysm Surgeryâ€. European Journal of Vascular and Endovascular Surgery, 2011, 42, S96-S104.	0.8	49
760	Lung Transplantation and Coronary Artery Disease. Annals of Thoracic Surgery, 2011, 92, 303-308.	0.7	37
761	Atorvastatin improved scopolamine-induced impairment in memory acquisition in mice: Involvement of nitric oxide. Brain Research, 2011, 1386, 89-99.	1.1	25
762	Abundant Pleiotropy in Human Complex Diseases and Traits. American Journal of Human Genetics, 2011, 89, 607-618.	2.6	478
763	Failure to recapture cardioprotection with high-dose atorvastatin in coronary artery bypass surgery: a randomised controlled trial. Basic Research in Cardiology, 2011, 106, 1387-1395.	2.5	21
764	Why does atorvastatin inhibit renal crystal retention?. Urological Research, 2011, 39, 379-383.	1.5	26
765	Les statinesÂ: un rÃ1e possible dans le traitement de lâ€™arthroseÂ?. Revue Du Rhumatisme (Edition) Tj ETQq1 1 0.784314 rgBT /Ov	0.0	1
766	PDGF-induced proliferation of smooth muscular cells is related to the regulation of CREB phosphorylation and Nur77 expression. Journal of Huazhong University of Science and Technology [Medical Sciences], 2011, 31, 169-173.	1.0	7
767	Statins increase the risk of prostate cancer: A populationâ€based caseâ€“control study. Prostate, 2011, 71, 1818-1824.	1.2	47
768	Olfactory impairment in older adults: Fiveâ€year incidence and risk factors. Laryngoscope, 2011, 121, 873-878.	1.1	93
769	Inhibition of endothelial adhesion molecule expression by Monascus purpureus-fermented rice metabolites, monacolin K, ankaflavin, and monascin. Journal of the Science of Food and Agriculture, 2011, 91, 1751-1758.	1.7	59
770	Vascular recovery promoted by atorvastatin and simvastatin after experimental intracerebral hemorrhage: magnetic resonance imaging and histological study. Journal of Neurosurgery, 2011, 114, 1135-1142.	0.9	39
771	Statins Promote the Growth of Experimentally Induced Cerebral Aneurysms in Estrogen-Deficient Rats. Stroke, 2011, 42, 2286-2293.	1.0	43

#	Article	IF	Citations
772	Statin treatment reduces oxidative stress-associated apoptosis of sciatic nerve in diabetes mellitus. Biotechnic and Histochemistry, 2011, 86, 373-378.	0.7	13
773	Simvastatin Improves Retinal Ganglion Cell Survival and Spatial Vision after Acute Retinal Ischemia/Reperfusion in Mice. , 2011, 52, 2606.		26
774	Global effects of fluvastatin on the prothrombotic status of patients with antiphospholipid syndrome. Annals of the Rheumatic Diseases, 2011, 70, 675-682.	0.5	82
775	Nanoparticle-Mediated Delivery of Pitavastatin Into Lungs Ameliorates the Development and Induces Regression of Monocrotaline-Induced Pulmonary Artery Hypertension. Hypertension, 2011, 57, 343-350.	1.3	84
776	Effects of Rosuvastatin versus Atorvastatin on Rho-Associated Coiled-Coil Containing Protein Kinase Activity and Endothelial Function in Patients with Atherosclerosis. Journal of International Medical Research, 2011, 39, 2314-2322.	0.4	9
777	Inflammatory Animal Model for Parkinson's Disease: The Intranigral Injection of LPS Induced the Inflammatory Process along with the Selective Degeneration of Nigrostriatal Dopaminergic Neurons. ISRN Neurology, 2011, 2011, 1-16.	1.5	36
778	Statin Reverses Smoke-induced Pulmonary Hypertension and Prevents Emphysema but Not Airway Remodeling. American Journal of Respiratory and Critical Care Medicine, 2011, 183, 50-58.	2.5	86
779	Apposite Insulin-like Growth Factor (IGF) Receptor Glycosylation Is Critical to the Maintenance of Vascular Smooth Muscle Phenotype in the Presence of Factors Promoting Osteogenic Differentiation and Mineralization. Journal of Biological Chemistry, 2011, 286, 16623-16630.	1.6	22
780	Statin Use and the Risk of Liver Cancer: A Population-Based Caseâ€“Control Study. American Journal of Gastroenterology, 2011, 106, 894-898.	0.2	106
781	Vascular Stiffness and Increased Pulse Pressure in the Aging Cardiovascular System. Cardiology Research and Practice, 2011, 2011, 1-8.	0.5	162
782	Rho-kinase: important new therapeutic target in cardiovascular diseases. American Journal of Physiology - Heart and Circulatory Physiology, 2011, 301, H287-H296.	1.5	249
783	Statin Use Following Intracerebral Hemorrhage. Archives of Neurology, 2011, 68, 573-9.	4.9	110
784	Reactive Oxygen Species, SUMOylation, and Endothelial Inflammation. International Journal of Inflammation, 2012, 2012, 1-13.	0.9	21
785	Statins and the Risk of Hepatocellular Carcinoma in Patients With Hepatitis B Virus Infection. Journal of Clinical Oncology, 2012, 30, 623-630.	0.8	255
786	The Effects of Statins on Prevention of Stroke and Dementia. Journal of Cardiopulmonary Rehabilitation and Prevention, 2012, 32, 240-249.	1.2	10
787	Statin use and the risk of kidney cancer: a population-based caseâ€“control study. Expert Opinion on Drug Safety, 2012, 11, 543-549.	1.0	13
788	LDL lowering in peripheral arterial disease:are there benefits beyond reducing cardiovascular morbidity and mortality?. Clinical Lipidology, 2012, 7, 141-149.	0.4	9
789	Statins and Downstream Inhibitors of the Isoprenylation Pathway Increase Type 2 Iodothyronine Deiodinase Activity. Endocrinology, 2012, 153, 4039-4048.	1.4	3

#	Article	IF	Citations
790	Statin use and the risk of bladder cancer: a population-based caseâ€“control study. Expert Opinion on Drug Safety, 2012, 11, 733-738.	1.0	9
791	An Assessment of the Chondroprotective Effects of Intra-Articular Application of Statin and Tetracycline on Early-Stage Experimental Osteoarthritis. ISRN Orthopedics, 2012, 2012, 1-9.	0.7	9
792	Recent Advances in Pharmacotherapy Development for Abdominal Aortic Aneurysm. International Journal of Vascular Medicine, 2012, 2012, 1-9.	0.4	19
793	The Metabolic Syndrome and Risk of Chronic Kidney Disease: Pathophysiology and Intervention Strategies. Journal of Nutrition and Metabolism, 2012, 2012, 1-9.	0.7	16
794	From fungus to pharmaceuticals â€“ the chemistry of statins. Mini-Reviews in Medicinal Chemistry, 2012, 12, 1250-1260.	1.1	9
795	Effect of Rosuvastatin on ROCK Activity, Endothelial Function, and Inflammation in Asian Patients with Atherosclerosis. Internal Medicine, 2012, 51, 1177-1182.	0.3	13
796	Effects of Pitavastatin on Pressure Overload-Induced Heart Failure in Mice. Circulation Journal, 2012, 76, 1159-1168.	0.7	20
797	Thiazolidinedioneâ€independent activation of peroxisome proliferatorâ€activated receptor Î³ is a potential target for diabetic macrovascular complications. Journal of Diabetes Investigation, 2012, 3, 11-23.	1.1	2
798	Remodelling and adverse remodelling in CAD. Herz, 2012, 37, 590-597.	0.4	3
799	The effect of acute administration of statins on coronary microcirculation during the pre-revascularization period in patients with myocardial infraction. Atherosclerosis, 2012, 223, 184-189.	0.4	15
801	The Effects of Vitamin E-Coated Membrane Dialyzer Compared to Simvastatin in Patients on Chronic Hemodialysis. Renal Failure, 2012, 34, 1135-1139.	0.8	2
802	Statin inhibits hypoxia-induced endothelin-1 via accelerated degradation of HIF-1Î± in vascular smooth muscle cells. Cardiovascular Research, 2012, 95, 251-259.	1.8	39
803	Rosuvastatin improves pulse wave reflection by restoring endothelial function. Microvascular Research, 2012, 84, 60-64.	1.1	14
804	Anti-inflammatory effect of simvastatin in an experimental model of spinal cord trauma: involvement of PPAR-Î±. Journal of Neuroinflammation, 2012, 9, 81.	3.1	52
805	Pravastatinâ€induced proangiogenic effects depend upon extracellular FGFâ€2. Journal of Cellular and Molecular Medicine, 2012, 16, 2001-2009.	1.6	13
806	Statins and Pregnancy. Drugs, 2012, 72, 773-788.	4.9	56
807	TNF-Î± modulates statin effects on secretion and expression of MCP-1, PAI-1 and adiponectin in 3T3-L1 differentiated adipocytes. Cytokine, 2012, 60, 150-156.	1.4	30
808	The neurovascular unit and combination treatment strategies for stroke. Trends in Pharmacological Sciences, 2012, 33, 415-422.	4.0	125

#	Article	IF	Citations
809	Statin use and the risk of female lung cancer: A population-based case-control study. Lung Cancer, 2012, 75, 275-279.	0.9	24
810	Effect of simvastatin or its combination with ezetimibe on Toll-like receptor expression and lipopolysaccharide â€“ Induced cytokine production in monocytes of hypercholesterolemic patients. Atherosclerosis, 2012, 225, 381-387.	0.4	49
812	Statins in Unconventional Secretion of Insulin-Degrading Enzyme and Degradation of the Amyloid-Î² Peptide. Neurodegenerative Diseases, 2012, 10, 309-312.	0.8	22
813	Short-term statin administration in hypercholesterolaemic rabbits resistant to postconditioning: effects on infarct size, endothelial nitric oxide synthase, and nitro-oxidative stress. Cardiovascular Research, 2012, 94, 501-509.	1.8	55
814	Statins in the critically ill. Annals of Intensive Care, 2012, 2, 19.	2.2	33
815	Atorvastatin inhibits osteoclastogenesis by decreasing the expression of RANKL in the synoviocytes of rheumatoid arthritis. Arthritis Research and Therapy, 2012, 14, R187.	1.6	25
816	Fractional Flow Reserve Is Not Associated with Inflammatory Markers in Patients with Stable Coronary Artery Disease. PLoS ONE, 2012, 7, e46356.	1.1	5
817	The role of PPAR in myocardial response to ischemia in normal andâ€¯diseased heart. General Physiology and Biophysics, 2012, 30, 329-341.	0.4	30
818	Oxidative Stress and Heart Failure in Altered Thyroid States. Scientific World Journal, The, 2012, 2012, 1-17.	0.8	36
819	Statins enhance expression of growth factors and activate the PI3K/Akt-mediated signaling pathway after experimental intracerebral hemorrhage. World Journal of Neuroscience, 2012, 02, 74-80.	0.1	46
820	Mechanisms of Ischemic Induced Neuronal Death and Ischemic Tolerance. , 0, , .		0
821	Pharmacological Actions of Statins: A Critical Appraisal in the Management of Cancer. Pharmacological Reviews, 2012, 64, 102-146.	7.1	370
822	Targeting NADPH oxidases in vascular pharmacology. Vascular Pharmacology, 2012, 56, 216-231.	1.0	204
823	Reduction of serum lipids by the intake of the extract of garlic fermented with Monascus pilosus: A randomized, double-blind, placebo-controlled clinical trial. Clinical Nutrition, 2012, 31, 261-266.	2.3	19
824	Pravastatin normalizes endotheliumâ€derived contracting factorâ€mediated response via suppression of <scp>R</scp>hoâ€kinase signalling in mesenteric artery from aged type 2 diabetic rat. Acta Physiologica, 2012, 205, 255-265.	1.8	18
825	Cardioprotective effects of low-dose combination therapy with a statin and an angiotensin receptor blocker in a rat myocardial infarction model. Journal of Cardiology, 2012, 59, 91-96.	0.8	7
826	Relaxation of rat thoracic aorta by fibrate drugs correlates with their potency to disturb intracellular calcium of VSMCs. Vascular Pharmacology, 2012, 56, 168-175.	1.0	8
827	Pleiotropic effects of pitavastatin. British Journal of Clinical Pharmacology, 2012, 73, 518-535.	1.1	77

#	Article	IF	Citations
828	Therapeutic strategies to deplete macrophages in atherosclerotic plaques. British Journal of Clinical Pharmacology, 2012, 74, 246-263.	1.1	23
829	Randomized comparison of pitavastatin and pravastatin treatment on the reduction of urinary albumin in patients with type 2 diabetic nephropathy. Diabetes, Obesity and Metabolism, 2012, 14, 666-669.	2.2	34
830	Atorvastatin suppresses inflammatory response induced by oxLDL through inhibition of ERK phosphorylation, IÎºBÎ± degradation, and COXâ€2 expression in murine macrophages. Journal of Cellular Biochemistry, 2012, 113, 611-618.	1.2	30
831	Effect of atorvastatin on atherosclerotic plaque formation and platelet activation in hypercholesterolemic rats. Canadian Journal of Physiology and Pharmacology, 2013, 91, 680-685.	0.7	7
832	Cardioprotection by Farnesol: Role of the Mevalonate Pathway. Cardiovascular Drugs and Therapy, 2013, 27, 269-277.	1.3	21
833	Biomechanical factors as triggers of vascular growth. Cardiovascular Research, 2013, 99, 276-283.	1.8	96
834	Evolution and involution of atherosclerosis and its relationship with vascular reactivity in hypercholesterolemic rabbits. Experimental and Toxicologic Pathology, 2013, 65, 297-304.	2.1	12
835	High-Dose Atorvastatin Reduces Periodontal Inflammation. Journal of the American College of Cardiology, 2013, 62, 2382-2391.	1.2	103
836	Suppression of interactions between prostate tumor cellâ€surface integrin and endothelial ICAMâ€1 by simvastatin inhibits micrometastasis. Journal of Cellular Physiology, 2013, 228, 2139-2148.	2.0	27
837	Thrombomodulin and the vascular endothelium: insights into functional, regulatory, and therapeutic aspects. American Journal of Physiology - Heart and Circulatory Physiology, 2013, 304, H1585-H1597.	1.5	159
838	Statins and percutaneous coronary intervention: A complementary synergy. ClÃnica E InvestigaciÃ³n En Arteriosclerosis, 2013, 25, 112-122.	0.4	2
839	Clopidogrel effective for frequent transient monocular blindness caused by vulnerable plaque. Journal of Clinical Neuroscience, 2013, 20, 1455-1457.	0.8	0
840	Association between statins and infections after coronary artery bypass grafting. International Journal of Cardiology, 2013, 168, 117-120.	0.8	17
841	Dipyridamole. , 2013, , 1155-1170.		3
842	Reduction of platelet cytosolic phospholipase A2 activity by atorvastatin and simvastatin: Biochemical regulatory mechanisms. Thrombosis Research, 2013, 131, e154-e159.	0.8	30
843	Randomized controlled trial assessing the effect of simvastatin in primary biliary cirrhosis. Liver International, 2013, 33, 1166-1174.	1.9	42
844	Pleiotropic antioxidant potential of rosuvastatin in preventing cardiovascular disorders. European Journal of Pharmacology, 2013, 711, 57-62.	1.7	31
845	Efficacy of Subgingivally Delivered Simvastatin in the Treatment of Patients With Type 2 Diabetes and Chronic Periodontitis: A Randomized Doubleâ€Masked Controlled Clinical Trial. Journal of Periodontology, 2013, 84, 24-31.	1.7	89

#	Article	IF	Citations
846	Factors underlying regression of coronary atheroma with potent statin therapy. European Heart Journal, 2013, 34, 1818-1825.	1.0	61
847	Comparative study between atorvastatin and losartan on high fat dietâ€induced type 2 diabetes mellitus in rats. Fundamental and Clinical Pharmacology, 2013, 27, 489-497.	1.0	11
848	Can Statins Improve Outcomes After Isolated Cardiac Valve Surgery? A Systematic Literature Review. Clinical Cardiology, 2013, 36, 448-455.	0.7	3
849	The Impact of Statin and Macrolide Use on Early Survival in Patients With Pneumococcal Pneumonia. American Journal of the Medical Sciences, 2013, 345, 173-177.	0.4	22
850	Multiple Statistical Methods for Assessing Differential Gene Expression in Microarray Data of Diabetic Model Rats to Predict the Molecular Mechanism of Atorvastatin on Anti-Atherogenesis. Experimental and Clinical Endocrinology and Diabetes, 2013, 121, 272-279.	0.6	6
851	Targeting GGTase-I Activates RHOA, Increases Macrophage Reverse Cholesterol Transport, and Reduces Atherosclerosis in Mice. Circulation, 2013, 127, 782-790.	1.6	47
852	Simvastatin and GGTI-2133, a geranylgeranyl transferase inhibitor, increase erythrocyte deformability but reduce low O₂tension-induced ATP release. American Journal of Physiology - Heart and Circulatory Physiology, 2013, 304, H660-H666.	1.5	10
853	Pharmacological Modulation of Small GTPases in Cardiovascular Diseases. Journal of Cardiovascular Pharmacology, 2013, 62, 329-330.	0.8	1
854	Statins and lipid metabolism. Current Opinion in Lipidology, 2013, 24, 221-226.	1.2	29
855	Statins Exert the Pleiotropic Effects Through Small GTP-Binding Protein Dissociation Stimulator Upregulation With a Resultant Rac1 Degradation. Arteriosclerosis, Thrombosis, and Vascular Biology, 2013, 33, 1591-1600.	1.1	73
856	Cerebral cavernous malformation is a vascular disease associated with activated RhoA signaling. Biological Chemistry, 2013, 394, 35-42.	1.2	43
857	Statin use and the risk of esophageal cancer: a population-based case-control study. Expert Opinion on Drug Safety, 2013, 12, 293-298.	1.0	6
858	Could statins be a new therapeutic option for antiphospholipid syndrome patients?. Expert Review of Hematology, 2013, 6, 115-117.	1.0	6
859	The protective effect of clopidogrel and atorvastatin in patients undergoing carotid stenting. Interventional Cardiology, 2013, 5, 371-373.	0.0	0
860	Effects of Rosuvastatin vs. Simvastatin/ezetimibe on Arterial Wall Stiffness in Patients with Coronary Artery Disease. Internal Medicine, 2013, 52, 2715-2719.	0.3	9
861	Effects of Medical Treatment on the Prognosis and Risk of Embolic Events in Patients with Severe Aortic Plaque. Journal of Atherosclerosis and Thrombosis, 2013, 20, 821-829.	0.9	3
862	Very rapid effect of pitavastatin on microvascular function in comparison to rosuvastatin: reactive hyperemia peripheral arterial tonometric study. Drug Design, Development and Therapy, 2013, 7, 369.	2.0	2
863	Pitavastatin-Incorporated Nanoparticle-Eluting Stents Attenuate In-Stent Stenosis without Delayed Endothelial Healing Effects in a Porcine Coronary Artery Model. Journal of Atherosclerosis and Thrombosis, 2013, 20, 32-45.	0.9	58

#	Article	IF	Citations
864	Editorial: Can Statins Mitigate the Adverse Cardiovascular Effects of Smoking?. Current Vascular Pharmacology, 2013, 11, 777-778.	0.8	1
865	Effect of statins on platelet function in patients with hyperlipidemia. Archives of Medical Science, 2013, 4, 622-628.	0.4	25
866	Paraoxonases and Chemokine (Câ€“C Motif) Ligand-2 in Noncommunicable Diseases. Advances in Clinical Chemistry, 2014, 63, 247-308.	1.8	32
867	Effect of High Dose Rosuvastatin Loading before Percutaneous Coronary Intervention on Contrast-Induced Nephropathy. Korean Circulation Journal, 2014, 44, 301.	0.7	18
868	Effects of Simvastatin on Retinal Structure and Function of a High-Fat Atherogenic Mouse Model of Thickened Bruch's Membrane. , 2014, 55, 460.		18
869	Effect of Simvastatin on Inflammatory Cytokines Balance in Air Pouch Granuloma Model. Inflammation and Allergy: Drug Targets, 2014, 13, 74-79.	1.8	4
870	Changes in Lipoprotein Kinetics Associated With Type 2 Diabetes Affect the Distribution of Lipopolysaccharides Among Lipoproteins. Journal of Clinical Endocrinology and Metabolism, 2014, 99, E1245-E1253.	1.8	38
871	High-dose atorvastatin ameliorates the uterine microenvironment in streptozotocin-induced diabetic rats. Gynecological Endocrinology, 2014, 30, 789-793.	0.7	3
872	The Impact of Statins on FGFâ€“2â€”Stimulated Human Umbilical Vein Endothelial Cells. Postgraduate Medicine, 2014, 126, 118-128.	0.9	1
873	Involvement of the Heme Oxygenase System in the Development of Preeclampsia and as a Possible Therapeutic Target. Women's Health, 2014, 10, 623-643.	0.7	17
874	Anticoagulant effects of statins and their clinical implications. Thrombosis and Haemostasis, 2014, 112, 392-400.	1.8	95
875	Pharmacological potential of tocotrienols: a review. Nutrition and Metabolism, 2014, 11, 52.	1.3	220
876	Low intravitreal angiopoietinâ€2 and <scp>VEGF</scp> levels in vitrectomized diabetic patients with simvastatin treatment. Acta Ophthalmologica, 2014, 92, 675-681.	0.6	32
877	The pharmacology of statins. Pharmacological Research, 2014, 88, 3-11.	3.1	458
878	Monomethylarsonous acid inhibited endogenous cholesterol biosynthesis in human skin fibroblasts. Toxicology and Applied Pharmacology, 2014, 277, 21-29.	1.3	7
879	Nanoparticle-Mediated Delivery of Pitavastatin Inhibits Atherosclerotic Plaque Destabilization/Rupture in Mice by Regulating the Recruitment of Inflammatory Monocytes. Circulation, 2014, 129, 896-906.	1.6	137
880	Effects of peroxisome proliferator-activated receptor Î³ in simvastatin antiplatelet activity: Influences on cAMP and mitogen-activated protein kinases. Thrombosis Research, 2014, 134, 111-120.	0.8	23
881	Long-term effects of maximally intensive statin therapy on changes in coronary atheroma composition: insights from SATURN. European Heart Journal Cardiovascular Imaging, 2014, 15, 380-388.	0.5	139

#	Article	IF	Citations
882	Community-Acquired Pneumonia. New England Journal of Medicine, 2014, 371, 1619-1628.	13.9	486
883	The Gut Microbiome, Kidney Disease, and Targeted Interventions. Journal of the American Society of Nephrology: JASN, 2014, 25, 657-670.	3.0	553
884	Do Statins Have a Role in the Promotion of Postoperative Wound Healing in Cardiac Surgical Patients?. Annals of Thoracic Surgery, 2014, 98, 756-764.	0.7	11
885	Endothelial progenitor cells in diabetic patients with myocardial infarction â€“ Can statins improve their function?. European Journal of Pharmacology, 2014, 741, 25-36.	1.7	10
886	Effects of Rosuvastatin on Serum Lipids and Arteriosclerosis in Dyslipidemic Patients with Cerebral Infarction. Journal of Stroke and Cerebrovascular Diseases, 2014, 23, 2007-2011.	0.7	7
887	Statin use and the risk of breast cancer: a population-based caseâ€“control study. Expert Opinion on Drug Safety, 2014, 13, 287-293.	1.0	6
888	The Target for Statins, HMG-CoA Reductase, Is Expressed in Ductal Carcinoma-In Situ and May Predict Patient Response to Radiotherapy. Annals of Surgical Oncology, 2014, 21, 2911-2919.	0.7	12
889	Functional thyrotropin receptor expression in the ventricle and the effects on ventricular BNP secretion. Endocrine, 2014, 46, 328-339.	1.1	19
890	Statin (Mevalotin) preconditioning decreases infarct size in senile rat myocardial infarction model. Journal of Acute Medicine, 2014, 4, 127-132.	0.2	0
891	Rosuvastatin Ameliorates Early Brain Injury after Subarachnoid Hemorrhage via Suppression of Superoxide Formation and Nuclear Factor-Kappa B Activation in Rats. Journal of Stroke and Cerebrovascular Diseases, 2014, 23, 1429-1439.	0.7	45
892	Statins decrease thrombin generation in patients with hypercholesterolemia. European Journal of Internal Medicine, 2014, 25, 449-451.	1.0	14
893	Statins in neurological disorders: An overview and update. Pharmacological Research, 2014, 88, 74-83.	3.1	65
894	Pravastatin improves the impaired nitric oxide-mediated neurogenic and endothelium-dependent relaxation of corpus cavernosum in aged rats. Aging Male, 2014, 17, 259-266.	0.9	17
895	Unconventional approaches to the prevention of cancer associated thrombosis. Thrombosis Research, 2014, 133, S44-S48.	0.8	5
896	Statins in Low Doses Reduce VEGF and bFGF Serum Levels in Patients with Type 2 Diabetes Mellitus. Pharmacology, 2014, 93, 32-38.	0.9	21
897	Combination Therapy With Fasudil and Sildenafil Ameliorates Monocrotaline-Induced Pulmonary Hypertension and Survival in Rats. Circulation Journal, 2014, 78, 967-976.	0.7	42
898	Associations between apolipoprotein CIII concentrations and microalbuminuria in type 2 diabetes. Experimental and Therapeutic Medicine, 2014, 8, 951-956.	0.8	6
899	Hydroxymethylglutaryl-CoA reductase inhibitors (statins) for the treatment of sepsis. The Cochrane Library, 0, , .	1.5	1

#	Article	IF	Citations
900	Reply to: â€œCoagulation and fibrosis: A potential non-negligible target of statins in chronic hepatitisâ€• Journal of Hepatology, 2015, 63, 279.	1.8	1
901	Theme 3: Non-invasive management of (recurrent) venous thromboembolism (VTE) and post thrombotic syndrome (PTS). Thrombosis Research, 2015, 136, S13-S18.	0.8	4
902	Lipid Interventions in Aortic Valvular Disease. American Journal of the Medical Sciences, 2015, 350, 313-319.	0.4	4
903	Pravastatin inhibits fibrinogen- and FDP-induced inflammatory response via reducing the production of IL-6, TNF-Î± and iNOS in vascular smooth muscle cells. Molecular Medicine Reports, 2015, 12, 6145-6151.	1.1	11
904	Treatment of Blood Cholesterol to Reduce Risk for Atherosclerotic Cardiovascular Disease. Annals of Internal Medicine, 2015, 163, 280-290.	2.0	4
905	Nanoparticle-Mediated Drug Delivery System for Coronary Artery Disease. Drug Delivery System, 2015, 30, 299-308.	0.0	0
906	Effect of Simvastatin on Physiological and Biological Outcomes in Patients Undergoing Esophagectomy. Annals of Surgery, 2015, 262, e119.	2.1	0
907	The Role of Statin Therapy in Hemorrhagic Stroke. Pharmacotherapy, 2015, 35, 1152-1163.	1.2	10
908	Light and Dark of Reactive Oxygen Species for Vascular Function. Journal of Cardiovascular Pharmacology, 2015, 65, 412-418.	0.8	25
909	Statin-Based Palliative Therapy for Hepatocellular Carcinoma. Medicine (United States), 2015, 94, e1801.	0.4	24
910	High levels of LDL-C combined with low levels of HDL-C further increase platelet activation in hypercholesterolemic patients. Brazilian Journal of Medical and Biological Research, 2015, 48, 167-173.	0.7	9
911	Exploiting the Pleiotropic Antioxidant Effects of Established Drugs in Cardiovascular Disease. International Journal of Molecular Sciences, 2015, 16, 18185-18223.	1.8	58
912	Fluvastatin Upregulates the Expression of Tissue Factor Pathway Inhibitor in Human Umbilical Vein Endothelial Cells. Journal of Atherosclerosis and Thrombosis, 2015, 22, 660-668.	0.9	4
913	Pleiotropic Effects of Statins. , 2015, , .		2
915	Ultrasound Assessment of Carotid Plaque Echogenicity Response to Statin Therapy: A Systematic Review and Meta-Analysis. International Journal of Molecular Sciences, 2015, 16, 10734-10747.	1.8	41
916	2015 ATVB Plenary Lecture. Arteriosclerosis, Thrombosis, and Vascular Biology, 2015, 35, 1756-1769.	1.1	51
917	Statins meditate anti-atherosclerotic action in smooth muscle cells by peroxisome proliferator-activated receptor-Î³ activation. Biochemical and Biophysical Research Communications, 2015, 457, 23-30.	1.0	24
918	Inhibition of prenyltransferase activity by statins in both liver and muscle cell lines is not causative of cytotoxicity. Toxicology, 2015, 329, 40-48.	2.0	15

#	Article	IF	Citations
919	Preoperative Statin Therapy Decreases Early Mortality in Patients Undergoing Isolated Valve Surgery: Result From a Meta-Analysis. Journal of Cardiothoracic and Vascular Anesthesia, 2015, 29, 107-114.	0.6	8
920	Chronic Statin Administration May Attenuate Early Anthracycline-Associated Declines in Left Ventricular Ejection Function. Canadian Journal of Cardiology, 2015, 31, 302-307.	0.8	89
921	No effects of atorvastatin (10mg/d or 80mg/d) on nitric oxide, prostacyclin, thromboxane and oxidative stress in type 2 diabetes mellitus patients of the DALI study. Pharmacological Research, 2015, 94, 1-8.	3.1	11
922	A novel therapeutic effect of statins on nephrogenic diabetes insipidus. Journal of Cellular and Molecular Medicine, 2015, 19, 265-282.	1.6	29
923	Statins in rhegmatogenous retinal detachment are associated with low intravitreal angiopoietin-2, VEGF and MMP-2 levels, and improved visual acuity gain in vitrectomized patients. Graefe's Archive for Clinical and Experimental Ophthalmology, 2015, 253, 1685-1693.	1.0	13
924	Inhibitory Effect of Statins on Inflammation-Related Pathways in Human Abdominal Aortic Aneurysm Tissue. International Journal of Molecular Sciences, 2015, 16, 11213-11228.	1.8	48
925	Genetic basis for developmental toxicity due to statin intake using embryonic stem cell differentiation model. Human and Experimental Toxicology, 2015, 34, 965-984.	1.1	9
926	The effects of atorvastatin treatment on the mean platelet volume and red cell distribution width in patients with dyslipoproteinemia and comparison with plasma atherogenicity indicatorsâ€"A pilot study. Clinical Biochemistry, 2015, 48, 557-561.	0.8	30
927	Elevated Serum Angiopoietin-like Protein 2 in Patients with Acute Coronary Syndrome. Archives of Medical Research, 2015, 46, 257-264.	1.5	14
928	Neuroanesthesiology Update. Journal of Neurosurgical Anesthesiology, 2015, 27, 87-122.	0.6	11
929	Cancer Risk in HBV Patients With Statin and Metformin Use. Medicine (United States), 2015, 94, e462.	0.4	68
930	Cholesterol overload impairing cerebellar function: The promise of natural products. Nutrition, 2015, 31, 621-630.	1.1	20
931	Globally profiling sialylation status of macrophages upon statin treatment. Glycobiology, 2015, 25, 1007-1015.	1.3	7
932	Anti-platelet factor 4/heparin antibody is associated with progression of peripheral arterial disease in hemodialysis patients. International Urology and Nephrology, 2015, 47, 1565-1570.	0.6	4
933	Statin therapy and plasma vitamin E concentrations: A systematic review and meta-analysis of randomized placebo-controlled trials. Atherosclerosis, 2015, 243, 579-588.	0.4	5
934	Meta-analysis of the effects of statins on perioperative outcomes in vascular and endovascular surgery. Journal of Vascular Surgery, 2015, 61, 519-532.e1.	0.6	70
936	Perioperative Statin Treatment: Can it Decrease Postsurgical Cardiac Event Risk in Noncardiac Surgery?. American Surgeon, 2016, 82, 718-729.	0.4	0
937	Statins dose-dependently exert a chemopreventive effect against lung cancer in COPD patients: a population-based cohort study. Oncotarget, 2016, 7, 59618-59629.	0.8	24

#	Article	IF	Citations
938	Does Pre-Treatment with High Dose Atorvastatin Prevent Microvascular Dysfunction after Percutaneous Coronary Intervention in Patients with Acute Coronary Syndrome?. Korean Circulation Journal, 2016, 46, 472.	0.7	16
939	Effects of long-term exercise training on adipose tissue expression of fractalkine and MCP-1 in patients with type 2 diabetes and stable coronary artery disease: a substudy of a randomized controlled trial. Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy, 2016, 9, 55.	1.1	8
940	Stabilization of high-risk plaques. Cardiovascular Diagnosis and Therapy, 2016, 6, 304-321.	0.7	19
941	Simvastatin Ameliorates Matrix Stiffness-Mediated Endothelial Monolayer Disruption. PLoS ONE, 2016, 11, e0147033.	1.1	39
942	Heme Oxygenase-1 Expression Affects Murine Abdominal Aortic Aneurysm Progression. PLoS ONE, 2016, 11, e0149288.	1.1	24
943	Statin pretreatment inhibits the lipopolysaccharideâ€induced epithelialâ€mesenchymal transition via the downregulation of tollâ€like receptor 4 and nuclear factorâ€ÎºB in human biliary epithelial cells. Journal of Gastroenterology and Hepatology (Australia), 2016, 31, 1220-1228.	1.4	17
944	High-dose statin therapy and risk of intracerebral hemorrhage: a meta-analysis. Acta Neurologica Scandinavica, 2016, 134, 22-28.	1.0	53
945	Statin treatment is associated with a decreased risk of active tuberculosis: an analysis of a nationally representative cohort. Thorax, 2016, 71, 646-651.	2.7	56
946	HDL-c levels predict the presence of pleural effusion and the clinical outcome of community-acquired pneumonia. SpringerPlus, 2016, 5, 1491.	1.2	9
947	Statins improve outcomes of nonsurgical curative treatments in hepatocellular carcinoma patients. Medicine (United States), 2016, 95, e4639.	0.4	22
948	In vitro and in vivo downregulation of the ATP binding cassette transporter B1 by the HMG-CoA reductase inhibitor simvastatin. Naunyn-Schmiedeberg's Archives of Pharmacology, 2016, 389, 17-32.	1.4	19
949	Impact of Statin Therapy on Clinical Outcome in Patients With Coronary Spasm. Journal of the American Heart Association, 2016, 5, .	1.6	51
950	Statin Use and Hospital Length of Stay Among Adults Hospitalized With Community-acquired Pneumonia. Clinical Infectious Diseases, 2016, 62, 1471-1478.	2.9	25
951	Involvement of inhibition of RhoA/Rho kinase signaling in simvastatin-induced amelioration of neuropathic pain. Neuroscience, 2016, 333, 204-213.	1.1	22
952	Statin use after intracerebral hemorrhage: a 10â€year nationwide cohort study. Brain and Behavior, 2016, 6, e00487.	1.0	24
953	Modulation of paraoxonase 1 (PON1) activity and protein N-homocysteinylation by bisphosphonates in rats. Chemico-Biological Interactions, 2016, 259, 401-406.	1.7	3
954	Patients with calcific aortic stenosis exhibit systemic molecular evidence of ischemia, enhanced coagulation, oxidative stress and impaired cholesterol transport. International Journal of Cardiology, 2016, 225, 99-106.	0.8	34
955	Rosuvastatin Decreases Mean Platelet Volume in Patients With Diabetes Mellitus. Angiology, 2016, 67, 116-120.	0.8	21

#	Article	IF	Citations
956	Mevalonate Biosynthesis Intermediates Are Key Regulators of Innate Immunity in Bovine Endometritis. Journal of Immunology, 2016, 196, 823-831.	0.4	29
957	RhoA/Rho-Kinase in the Cardiovascular System. Circulation Research, 2016, 118, 352-366.	2.0	316
958	Lipoproteins as modulators of atherothrombosis: From endothelial function to primary and secondary coagulation. Vascular Pharmacology, 2016, 82, 1-10.	1.0	38
959	Statins up-regulate SmgGDS through Î²1-integrin/Akt1 pathway in endothelial cells. Cardiovascular Research, 2016, 109, 151-161.	1.8	15
960	Subgingivally delivered 1.2% atorvastatin in the treatment of chronic periodontitis among smokers: a randomized, controlled clinical trial. Journal of Investigative and Clinical Dentistry, 2017, 8, e12213.	1.8	16
961	Effects of simvastatin on CAT-1-mediated arginine transport and NO level under high glucose conditions in conditionally immortalized rat inner blood-retinal barrier cell lines (TR-iBRB). Microvascular Research, 2017, 111, 60-66.	1.1	6
962	Inflammation and Peritoneal Dialysis. Seminars in Nephrology, 2017, 37, 54-65.	0.6	58
963	NaoXinTong Enhances Atorvastatin-induced Plaque Stability While Ameliorating Atorvastatin-induced Hepatic Inflammation. Journal of Cardiovascular Pharmacology, 2017, 69, 55-64.	0.8	15
964	Ezetimibe in Combination With Statins Ameliorates Endothelial Dysfunction in Coronary Arteries After Stenting. Arteriosclerosis, Thrombosis, and Vascular Biology, 2017, 37, 350-358.	1.1	36
965	Cytokines and MicroRNA in Coronary Artery Disease. Advances in Clinical Chemistry, 2017, 82, 47-70.	1.8	84
966	Nanoparticle-Mediated Endothelial Cell-Selective Drug Delivery System. , 2017, , 247-266.		1
968	Response by Takase and Matoba to Letter Regarding Article, â€œEzetimibe in Combination With Statins Ameliorates Endothelial Dysfunction in Coronary Arteries After Stenting: The CuVIC Trial (Effect of) Tj ETQq1 1 0.784314 rgBT /Overlock Multicenter Randomized Controlled Trialâ€• Arteriosclerosis, Thrombosis, and Vascular Biology, 2017, 37, e54.	1.1	2
969	Ezetimibe reduces cholesterol content and NF-kappaB activation in liver but not in intestinal tissue in guinea pigs. Journal of Inflammation, 2017, 14, 3.	1.5	5
970	Targeting Mitochondrial Calcium Handling and Reactive Oxygen Species in Heart Failure. Current Heart Failure Reports, 2017, 14, 338-349.	1.3	67
971	Progression of Peripheral Artery Disease to Critical Limb Ischemia. , 2017, , 121-129.		0
972	Simvastatin alleviates airway inflammation and remodelling through upâ€regulation of autophagy in mouse models of asthma. Respirology, 2017, 22, 533-541.	1.3	57
973	Effect of statins on coronary blood flow after percutaneous coronary intervention in patients with stable coronary artery disease. Netherlands Heart Journal, 2017, 25, 258-263.	0.3	6
974	Platelets, Haemostasis and Inflammation. Cardiac and Vascular Biology, 2017, , .	0.2	5

#	Article	IF	Citations
975	Mechanisms of Platelet Activation in Diabetes Mellitus. Cardiac and Vascular Biology, 2017, , 137-152.	0.2	2
976	Effects of Statins and Xuezhikang on the Expression of Secretory Phospholipase A2, Group IIA in Rat Vascular Smooth Muscle Cells. International Heart Journal, 2017, 58, 115-124.	0.5	7
977	Anti-inflammatory Nanomedicine for Cardiovascular Disease. Frontiers in Cardiovascular Medicine, 2017, 4, 87.	1.1	70
978	A Double-Blinded Randomized Study Investigating a Possible Anti-Inflammatory Effect of Saxagliptin versus Placebo as Add-On Therapy in Patients with Both Type 2 Diabetes And Stable Coronary Artery Disease. Mediators of Inflammation, 2017, 2017, 1-9.	1.4	2
979	Statin consumption as a risk factor for developing colorectal cancer: a retrospective case study. World Journal of Surgical Oncology, 2017, 15, 222.	0.8	7
980	Chemoprevention of Gastric Cancer: Statins. The Korean Journal of Helicobacter and Upper Gastrointestinal Research, 2017, 17, 175.	0.1	0
981	Statin Therapy Does Not Significantly Alter Microvascular Function in Uncomplicated Hypertension. Journal for Vascular Ultrasound, 2017, 41, 66-70.	0.2	0
982	Statins may be beneficial for patients with pulmonary hypertension secondary to lung diseases. Journal of Thoracic Disease, 2017, 9, 2437-2446.	0.6	12
983	Is there evidence for statins in the treatment of aortic valve stenosis?. World Journal of Cardiology, 2017, 9, 667.	0.5	11
984	Novel bifurcation stents coated with bioabsorbable nanofibers with extended and controlled release of rosuvastatin and paclitaxel. Materials Science and Engineering C, 2018, 88, 61-69.	3.8	12
985	Disruptions in gut microbial-host co-metabolism and the development of metabolic disorders. Clinical Science, 2018, 132, 791-811.	1.8	32
986	Hypercoagulable state in sickle cell disease. Clinical Hemorheology and Microcirculation, 2018, 68, 301-318.	0.9	26
987	Do Statins Affect Thyroid Volume and Nodule Size in Patients with Hyperlipidemia in a Region with Mild-to-Moderate Iodine Deficiency? A Prospective Study. Medical Principles and Practice, 2018, 27, 1-7.	1.1	12
988	Statin use and vitreoretinal surgery: Findings from a Finnish populationâ€based cohort study. Acta Ophthalmologica, 2018, 96, 442-451.	0.6	15
989	Protection against the Neurotoxic Effects of Î²-Amyloid Peptide on Cultured Neuronal Cells by Lovastatin Involves Elevated Expression of Î±7 Nicotinic Acetylcholine Receptors and Activating Phosphorylation of Protein Kinases. American Journal of Pathology, 2018, 188, 1081-1093.	1.9	7
990	The attenuation of neurological injury from the use of simvastatin after spinal cord ischemia-reperfusion injury in rats. BMC Anesthesiology, 2018, 18, 31.	0.7	6
991	Synergistic effects of HMG â€CoA reductase inhibitor and angiotensin II receptor blocker on loadâ€induced heart failure. FEBS Open Bio, 2018, 8, 799-816.	1.0	6
992	Bioactive compounds as an alternative for drug co-therapy: Overcoming challenges in cardiovascular disease prevention. Critical Reviews in Food Science and Nutrition, 2018, 58, 958-971.	5.4	27

#	Article	IF	Citations
993	Curcumin as a potential candidate for treating hyperlipidemia: A review of cellular and metabolic mechanisms. Journal of Cellular Physiology, 2018, 233, 141-152.	2.0	192
994	Evaluation of protein C and protein S levels in patients with diabetes mellitus receiving therapy with statins and ACE inhibitors or angiotensin II receptor blockers. Diabetes Research and Clinical Practice, 2018, 135, 88-92.	1.1	4
995	Bioconversion of mevastatin to pravastatin by various microorganisms and its applications â€“ A review. Biocatalysis and Agricultural Biotechnology, 2018, 13, 62-74.	1.5	9
996	Statins protect diabetic myocardial microvascular endothelial cells from injury. International Journal of Diabetes in Developing Countries, 2018, 38, 424-436.	0.3	0
997	A Comparative Study of Muscle Symptoms of Atorvastatin with Rosuvastatin in Patients of Atherosclerotic Cardiovascular Disease. University Heart Journal, 2018, 14, 9-20.	0.0	0
998	Safety, Tolerability, and Pharmacokinetics of NK-104-NP. International Heart Journal, 2018, 59, 1015-1025.	0.5	18
999	Statins Reduce Thoracic Aortic Aneurysm Growth in Marfan Syndrome Mice via Inhibition of the Rasâ€Induced ERK (Extracellular Signalâ€Regulated Kinase) Signaling Pathway. Journal of the American Heart Association, 2018, 7, e008543.	1.6	28
1000	Nanoparticle-Mediated Targeting of Pitavastatin to Small Pulmonary Arteries and Leukocytes by Intravenous Administration Attenuates the Progression of Monocrotaline-Induced Established Pulmonary Arterial Hypertension in Rats. International Heart Journal, 2018, 59, 1432-1444.	0.5	17
1001	Atorvastatin modulates drug transporters and ameliorates nicotine-induced testicular toxicity. Andrologia, 2018, 50, e13029.	1.0	3
1002	Outcome of Carotid Artery Endarterectomy in Statin Users versus Statin-NaÃ¯ve Patients: A Systematic Review and Meta-Analysis. World Neurosurgery, 2018, 116, 444-450.e1.	0.7	13
1003	Neuroprotective effect of lovastatin through down-regulation of pro-apoptotic Mst1 gene expression in rat model pilocarpine epilepsy. Neurological Research, 2018, 40, 874-882.	0.6	5
1004	Acquired Disorders of Platelet Function. , 2018, , 1932-1943.e6.		1
1005	Anti-hypertrophy effect of atorvastatin on myocardium depends on AMPK activation-induced miR-143-3p suppression via Foxo1. Biomedicine and Pharmacotherapy, 2018, 106, 1390-1395.	2.5	15
1006	Rho Kinase Inhibitors as a Novel Treatment for Glaucoma and Ocular Hypertension. Ophthalmology, 2018, 125, 1741-1756.	2.5	179
1007	Preoperative Use of Statins in Carotid Artery Stenting: A Systematic Review and Meta-analysis. Journal of Endovascular Therapy, 2018, 25, 624-631.	0.8	9
1008	Childhood Pulmonary Arterial Hypertension. , 2019, , 556-579.e4.		0
1009	Pharmacogenetic Implications of eNOS Polymorphisms (Glu298Asp, T786C, 4b/4a) in Cardiovascular Drug Therapy. In Vivo, 2019, 33, 1051-1058.	0.6	7
1010	Urinary nucleic acid oxidation product levels show differential associations with pharmacological treatment in patients with type 2 diabetes. Free Radical Research, 2019, 53, 694-703.	1.5	5

#	Article	IF	Citations
1011	Identification of AnnexinA1 as an Endogenous Regulator of RhoA, and Its Role in the Pathophysiology and Experimental Therapy of Type-2 Diabetes. Frontiers in Immunology, 2019, 10, 571.	2.2	43
1012	Treat stroke to target trial design: First trial comparing two LDL targets in patients with atherothrombotic strokes. European Stroke Journal, 2019, 4, 271-280.	2.7	16
1013	Plasma LDL-Cholesterol Level at Admission is Independently Associated with Infarct Size in Patients with ST-Segment Elevation Myocardial Infarction Treated with Primary Percutaneous Coronary Intervention. Cardiology and Therapy, 2019, 8, 55-67.	1.1	5
1014	Outcomes of patients with and without baseline lipid-lowering therapy undergoing revascularization for left main coronary artery disease. Coronary Artery Disease, 2019, 30, 143-149.	0.3	1
1015	Cardioprotection Against Acute Myocardial Infarction. , 2019, , .		2
1016	RhoA and Rho-kinase inhibitors modulate cervical resistance: The possible role of RhoA/Rho-kinase signalling pathway in cervical ripening and contractility. European Journal of Pharmacology, 2019, 843, 27-33.	1.7	3
1017	Determinants of Vascular Age: An Epidemiological Perspective. Clinical Chemistry, 2019, 65, 108-118.	1.5	63
1018	Hydroxymethylglutaryl-CoA reductase inhibitors (statins) for the treatment of sepsis in adults â€“ A systematic review and meta-analysis. Clinical Microbiology and Infection, 2019, 25, 280-289.	2.8	40
1019	Influenza Vaccine Effectiveness and Statin Use Among Adults in the United States, 2011â€“2017. Clinical Infectious Diseases, 2019, 68, 1616-1622.	2.9	9
1020	Binding mechanism of caffeic acid and simvastatin to the integrin linked kinase for therapeutic implications: a comparative docking and MD simulation studies. Journal of Biomolecular Structure and Dynamics, 2019, 37, 4327-4337.	2.0	52
1021	Geranylgeranyl diphosphate synthase 1 knockout ameliorates ventilator-induced lung injury via regulation of TLR2/4-AP-1 signaling. Free Radical Biology and Medicine, 2020, 147, 159-166.	1.3	16
1022	Inhibition of Protein Prenylation of GTPases Alters Endothelial Barrier Function. International Journal of Molecular Sciences, 2020, 21, 2.	1.8	31
1023	Simvastatin Treatment Does Not Ameliorate Muscle Pathophysiology in a Mouse Model for Duchenne Muscular Dystrophy. Journal of Neuromuscular Diseases, 2020, 8, 1-19.	1.1	9
1024	Prestroke statin use enhances collateralization in acute ischemic stroke patients. Restorative Neurology and Neuroscience, 2020, 38, 311-321.	0.4	2
1025	Protective effects of pravastatin on the embryonic cardiovascular system during hypoxic development. FASEB Journal, 2020, 34, 16504-16515.	0.2	6
1026	Exposure of Aspergillus fumigatus to Atorvastatin Leads to Altered Membrane Permeability and Induction of an Oxidative Stress Response. Journal of Fungi (Basel, Switzerland), 2020, 6, 42.	1.5	6
1027	Diabetes mellitus: an important risk factor for peripheral vascular disease. Expert Review of Cardiovascular Therapy, 2020, 18, 131-137.	0.6	13
1028	Effect of Simvastatin Use in Free Tissue Transfer: An Experimental Study in a Rat Epigastric Free Flap Model. Journal of Reconstructive Microsurgery, 2020, 36, 281-288.	1.0	5

#	Article	IF	Citations
1029	Reactive oxygen species in cardiovascular health and disease: special references to nitric oxide, hydrogen peroxide, and Rho-kinase. Journal of Clinical Biochemistry and Nutrition, 2020, 66, 83-91.	0.6	33
1030	Cholesterol Serum Levels and Use of Statins in Graves' Orbitopathy: A New Starting Point for the Therapy. Frontiers in Endocrinology, 2019, 10, 933.	1.5	27
1031	Effects of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors on ageing: Molecular mechanisms. Ageing Research Reviews, 2020, 58, 101024.	5.0	38
1032	Synergistic effects of pomegranate juice and atorvastatin for improving cerebellar structure and function of breast-feeding rats maternally fed on a high cholesterol diet. Journal of Chemical Neuroanatomy, 2020, 107, 101798.	1.0	2
1033	Blood biomarkers in patients with bicuspid aortic valve disease. Journal of Cardiology, 2020, 76, 287-294.	0.8	3
1034	Therapeutic Arteriogenesis/Angiogenesis for Peripheral Arterial Disease by Nanoparticle-Mediated Delivery of Pitavastatin into Vascular Endothelial Cells. Annals of Vascular Diseases, 2020, 13, 4-12.	0.2	14
1035	Investigating asthma heterogeneity through shared and distinct genetics: Insights from genome-wide cross-trait analysis. Journal of Allergy and Clinical Immunology, 2021, 147, 796-807.	1.5	53
1036	Coronary Vasomotion Abnormalities. , 2021, , .		7
1037	Nanoparticle-Mediated Delivery of Pitavastatin to Monocytes/Macrophages Inhibits Angiotensin II-Induced Abdominal Aortic Aneurysm Formation in <i>Apoe</i>^{â^'/â^'} Mice. Journal of Atherosclerosis and Thrombosis, 2022, 29, 111-125.	0.9	11
1038	Pitavastatin-Incorporated Nanoparticles for Chronic Limb Threatening Ischemia: A Phase I/IIa Clinical Trial. Journal of Atherosclerosis and Thrombosis, 2022, 29, 731-746.	0.9	10
1039	Rosuvastatin Reduces L-Type Ca2+ Current and Alters Contractile Function in Cardiac Myocytes via Modulation of Î²-Adrenergic Receptor Signaling. Cardiovascular Toxicology, 2021, 21, 422-431.	1.1	3
1040	Update on Nanoparticle-Based Drug Delivery System for Anti-inflammatory Treatment. Frontiers in Bioengineering and Biotechnology, 2021, 9, 630352.	2.0	42
1041	The advantages of drug treatment with statins in patients with SARS-CoV-2 infection. Wiener Klinische Wochenschrift, 2021, 133, 958-965.	1.0	7
1042	Clinical considerations after endovascular therapy of peripheral artery disease. Expert Review of Cardiovascular Therapy, 2021, 19, 369-378.	0.6	1
1043	Effect of L-carnitine and atorvastatin on a rat model of ischemia-reperfusion injury of spinal cord. Journal of Immunoassay and Immunochemistry, 2021, 42, 1-24.	0.5	5
1044	Rho GTPases in kidney physiology and diseases. Small GTPases, 2022, 13, 141-161.	0.7	8
1045	Differential effect of statin use on coagulation markers: an active comparative analysis in the NEO study. Thrombosis Journal, 2021, 19, 45.	0.9	8
1046	Plausible Positive Effects of Statins in COVID-19 Patient. Cardiovascular Toxicology, 2021, 21, 781-789.	1.1	6

#	Article	IF	Citations
1047	MicroRNAs hsa-miR-618 and hsa-miR-297 Might Modulate the Pleiotropic Effects Exerted by Statins in Endothelial Cells Through the Inhibition of ROCK2 Kinase: in-silico Approach. Frontiers in Cardiovascular Medicine, 2021, 8, 704175.	1.1	3
1048	Forty-Year Anniversary of Arteriosclerosis, Thrombosis, and Vascular Biology. Arteriosclerosis, Thrombosis, and Vascular Biology, 2021, 41, 2353-2356.	1.1	3
1049	Effect of oral statin use on mitomycin-C augmented trabeculectomy outcomes. PLoS ONE, 2021, 16, e0245429.	1.1	1
1050	Dyslipidemia and Endothelial Dysfunction: Pathophysiology and Therapy. , 0, , 245-257.		3
1051	Mechanisms of Plaque Progression and Complications. , 0, , 36-54.		1
1052	Nutritional Significance of Milk Lipids. , 2006, , 601-639.		20
1053	Modulation of Macrophage Function and Metabolism. Handbook of Experimental Pharmacology, 2005, , 665-695.	0.9	5
1054	Statins and Age-Related Maculopathy. , 2007, , 185-196.		1
1055	Statin decreases IL-1 and LPS-induced inflammatory cytokines production in oral epithelial cells. , 2008, , 125-131.		2
1056	Cyclophilin A: Novel Biomarker for Oxidative Stress and Cardiovascular Diseases. Biomarkers in Disease, 2015, , 405-438.	0.0	1
1057	Vascular Biology and Atherosclerosis of Cerebral Arteries. , 2004, , 763-774.		1
1058	Dipyridamole. , 2007, , 1165-1179.		6
1059	Thromboangiitis Obliterans. , 2010, , 1169-1186.		3
1060	Neutrophil activation by the tissue factor/Factor VIIa/PAR2 axis mediates fetal death in a mouse model of antiphospholipid syndrome. Journal of Clinical Investigation, 2008, 118, 3453-61.	3.9	170
1062	Chronic Pravastatin but Not Atorvastatin Treatment Impairs Cognitive Function in Two Rodent Models of Learning and Memory. PLoS ONE, 2013, 8, e75467.	1.1	45
1063	Fluvastatin inhibits AGE-induced cell proliferation and migration via an ERK5-dependent Nrf2 pathway in vascular smooth muscle cells. PLoS ONE, 2017, 12, e0178278.	1.1	26
1064	Downregulation of monocytic differentiation via modulation of CD147 by 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors. PLoS ONE, 2017, 12, e0189701.	1.1	26
1065	Aldose reductase regulates hyperglycemia-induced HUVEC death via SIRT1/AMPK-Î±1/mTOR pathway. Journal of Molecular Endocrinology, 2019, 63, 11-25.	1.1	60

#	Article	IF	Citations
1066	Statins dose-dependently exert a significant chemopreventive effect on colon cancer in patients with chronic obstructive pulmonary disease: A population-based cohort study. Oncotarget, 2016, 7, 65270-65283.	0.8	18
1067	Lovastatin lactone elicits human lung cancer cell apoptosis via a COX-2/PPARÎ³-dependent pathway. Oncotarget, 2016, 7, 10345-10362.	0.8	44
1068	Treatment of severe sepsis: where next? Current and future treatment approaches after the introduction of drotrecogin alfa. Vascular Health and Risk Management, 2006, 2, 3-18.	1.0	15
1069	Perioperative use of statins in noncardiac surgery. Vascular Health and Risk Management, 2008, 4, 75-81.	1.0	11
1070	Pharmacological Prevention of Peri-, and Post-Procedural Myocardial Injury in Percutaneous Coronary Intervention. Current Cardiology Reviews, 2008, 4, 223-230.	0.6	6
1071	Anti-Inflammatory Effects of Different Drugs/Agents with Antioxidant Property on Endothelial Expression of Adhesion Molecules. Cardiovascular & Hematological Disorders Drug Targets, 2006, 6, 279-304.	0.2	86
1072	Simvastatin alleviates myocardial contractile dysfunction and lethal ischemic injury in rat heart independent of cholesterol-lowering effects. Physiological Research, 2009, 58, 449-454.	0.4	27
1073	Distinct Effects of Acute Pretreatment With Lipophilic and Hydrophilic Statins on Myocardial Stunning, Arrhythmias and Lethal Injury in the Rat Heart Subjected to Ischemia/Reperfusion. Physiological Research, 2011, 60, 825-830.	0.4	18
1074	Effects of Atorvastatin and Insulin in Vascular Dysfunction Associated With Type 2 Diabetes. Physiological Research, 2014, 63, 189-197.	0.4	10
1075	Atorvastatin and rosuvastatin do not prevent thioacetamide induced liver cirrhosis in rats. World Journal of Gastroenterology, 2013, 19, 241.	1.4	25
1076	Investigation of the Effects of Statin Therapy on Serum Vitamin E Status in Patients with Dyslipidemia. Pakistan Journal of Nutrition, 2008, 7, 561-565.	0.2	1
1077	Atorvastatin for Diabetic Macular Edema in Patients With Diabetes Mellitus and Elevated Serum Cholesterol. Ophthalmic Surgery Lasers and Imaging Retina, 2010, 41, 316-322.	0.4	28
1078	JUPITER to Earth: A statin helps people with normal LDL-C and high hs-CRP, but what does it mean?. Cleveland Clinic Journal of Medicine, 2009, 76, 37-44.	0.6	17
1079	Statin Pleiotropy: Fact or Fiction?. American Journal of Critical Care, 2004, 13, 244-249.	0.8	24
1080	Fast-tracking regenerative medicine for traumatic brain injury. Neural Regeneration Research, 2020, 15, 1179.	1.6	12
1081	Statins Therapy: Effects on Plasma Fibrinogen Levels and Fibrinolysis. , 2013, 03, .		5
1082	Statins Protect the Blood Brain Barrier Acutely after Experimental Intracerebral Hemorrhage. Journal of Behavioral and Brain Science, 2013, 03, 100-106.	0.2	42
1083	Effects of statins in an indomethacin-induced gastric injury model in rats. Turkish Journal of Gastroenterology, 2012, 23, 456-462.	0.4	9

#	Article	IF	Citations
1084	Contribution of oxidative stress to pulmonary arterial hypertension. World Journal of Cardiology, 2010, 2, 316.	0.5	87
1085	Simvastatin Induces Apoptosis and Suppresses Insulin-Like Growth Factor 1 Receptor in Bile Duct Cancer Cells. Gut and Liver, 2016, 10, 310.	1.4	20
1086	Lipid Lowering and Antioxidant Effects of Newly Synthesized 4-[(Butylsulfinyl)methyl]-1,2-benzenediol (SMBD) in Diet-induced Hypercholesterolemic Rabbits. Bulletin of the Korean Chemical Society, 2010, 31, 3327-3332.	1.0	4
1087	Relationship between Insulin Resistance and Effect of Atorvastatin in Non-diabetic Subjects. Journal of Atherosclerosis and Thrombosis, 2005, 12, 9-13.	0.9	8
1088	Effect of Low-and High-Dose Atorvastatin on Carotid Artery Distensibility Using Carotid Magnetic Resonance Imaging ^|^mdash;A Post-Hoc Sub Group Analysis of ATHEROMA (Atorvastatin Therapy:) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 5 20, 46-56.	0.9	14
1089	Statins decrease mean platelet volume irrespective of cholesterol lowering effect. Kardiologia Polska, 2013, 71, 1042-1047.	0.3	38
1090	Disturbed Lipid Metabolism in Diabetic Patients with Manifest Coronary Artery Disease Is Associated with Enhanced Inflammation. International Journal of Environmental Research and Public Health, 2021, 18, 10892.	1.2	2
1091	å‹•è„ˆç¡¬åŒ–ç”˜ç©¶ã®é€²æ©(<ã‚·ãƒªãƒ¼ã‚º>å¾ªç’°å™¨å¦2002å¹´ã®é€²æ©). Journal of JCS Cardiologists, 2003, 1, 117-120.	0.1	0
1092	Effect of Hydroxymethyl Glutaryl Coenzyme A Reductase Inhibitor on High Sensitivity C-Reactive Protein Levels in percholesterolemic Patients without Atherosclerotic Diseases. Sunhwan'gi, 2004, 34, 381.	0.3	3
1093	Possibilities of manipulating nitric oxide biosynthesis in the treatment of portal hypertension: statins. , 2004, , 111-120.		1
1094	Bedside Platelet Monitoring. , 2004, , 495-520.		0
1095	Childhood Pulmonary Arterial Hypertension. , 2006, , 910-926.		0
1096	Preoperative Cardiac Risk Assessment and Management of Elderly Men with an Abdominal Aortic Aneurysm. , 2006, , 3-12.		0
1097	The immune system in atherosclerosis and in acute myocardial infarction. Heart International, 2006, 2, 129.	0.4	0
1098	Pharmacological Therapy for Cardiovascular Disease. , 2007, , 121-148.		1
1099	Case report: Reduction of carotid plaque after fluvastatin using three ^|^ndash; dimensional (3D) ultrasonography. Neurosonology, 2008, 21, 123-126.	0.0	3
1100	PULMONARY ARTERIAL HYPERTENSION. , 2009, , 401-415.		0
1101	Achieving lipid targets with combination therapy. Independent Nurse, 2009, 2009, .	0.0	0

#	Article	IF	Citations
1102	Preoperative Cardiac Risk Assessment and Management of Elderly Men with an Abdominal Aortic Aneurysm. , 2010, , 3-13.		0
1103	Early Initiation of Statin Treatment Immediately after Acute Myocardial Infarction Improves Clinical Outcomes. Chonnam Medical Journal, 2010, 46, 25.	0.1	0
1104	Drug Therapy and Follow-Up. , 2011, , 563-631.		0
1105	Simvastatin improves survival and reduces leukocyte recruitment and hepatocyte apoptosis in endotoxin-induced liver injury. Scripta Medica, 2011, 42, 7-13.	0.0	0
1106	Rosuvastatin was Effective in Acute Heart Failure and Slow Coronary Flow: A Hypothesis-generating Case Report. Open Cardiovascular Medicine Journal, 2013, 7, 12-15.	0.6	0
1107	Cyclophilin A: Novel Biomarker for Oxidative Stress and Cardiovascular Diseases. , 2014, , 1-27.		0
1108	Differential and Combined Effects of Simvastatin and Vildagliptin on Angiogenic Markers and Oxidative Stress in Hind Limb Model of Ischemia in Diabetic Rats. British Journal of Medicine and Medical Research, 2014, 4, 5587-5603.	0.2	0
1109	Uso de Rosuvastatina em Esclerose MÃºltipla. Revista Neurociencias, 2007, 15, .	0.0	0
1110	Rosuvastatin pretreatment does not attenuate microalbuminuria after coronary artery bypass grafting. Turkish Journal of Thoracic and Cardiovascular Surgery, 2014, 22, 496-501.	0.2	0
1111	Evaluation of Short Term Effect of Atorvastatin on Myocardial Performance and Its Pleiotropic Effects on Ischemic Heart Failure. British Journal of Pharmaceutical Research, 2015, 6, 343-357.	0.4	1
1112	Reactive Oxygen Species in the Cardiovascular System. , 2016, , 287-303.		0
1113	Mechanism of thrombosis in arteriosclerotic diseases and Antithrombotic effects of statins.. Journal of the Japanese Coronary Association, 2018, 24, 137-142.	0.0	1
1114	Relationship between endothelial dysfunction and development of complications of metabolic syndrome. Kazan Medical Journal, 2018, 99, 784-791.	0.1	2
1115	Pharmacological Preconditioning. , 2019, , 9-27.		0
1116	Peripheral Arterial Disease and Diabetes Mellitus. , 2019, , 747-763.		1
1117	Extracranial Carotid Atherosclerosis and Acute Ischemic Stroke in a Tertiary Hospital in Burkina Faso. World Journal of Neuroscience, 2019, 09, 39-51.	0.1	1
1118	Do Statins Help Prevent VTE After Hemorrhagic Stroke During the Acute Period?. Journal of Neurointensive Care, 2019, 2, 25-30.	0.1	0
1120	Atorvastatin Inhibited ROS Generation and Increased IL-1Î² And IL-6 Release by Mononuclear Cells from Diabetic Patients. Endocrine, Metabolic and Immune Disorders - Drug Targets, 2019, 19, 1207-1215.	0.6	3

#	Article	IF	Citations
1121	Effects of a Secondary Prevention Combination Therapy with beta-Blocker and Statin on Major Adverse Cardiovascular Events in Acute Coronary Syndrome Patients. Medical Science Monitor, 2020, 26, e925114.	0.5	2
1122	Pathophysiology and Molecular Mechanisms of Coronary Artery Spasm. , 2021, , 21-37.		0
1123	Lipide. , 2005, , 362-377.		0
1125	New Directions in Pulmonary Hypertension Therapy. , 2008, , 405-430.		0
1126	Management strategies of dyslipidemia in the elderly: 2005. MedGenMed: Medscape General Medicine, 2005, 7, 8.	0.2	0
1127	Role of leptin in atherogenesis. Experimental and Clinical Cardiology, 2006, 11, 269-75.	1.3	40
1128	The role of HMG-CoA reductase inhibition in endothelial dysfunction and inflammation. Vascular Health and Risk Management, 2007, 3, 567-77.	1.0	50
1129	Targeting C-reactive protein levels using high-dose atorvastatin before coronary artery bypass graft surgery. Experimental and Clinical Cardiology, 2008, 13, 171-4.	1.3	10
1130	Comparing the effects of lovastatin and cornus MAS fruit on fibrinogen level in hypercholesterolemic rabbits. ARYA Atherosclerosis, 2010, 6, 1-5.	0.4	23
1132	Lovastatin Inhibits Low Molecular Weight Hyaluronan Induced Chemokine Expression via LFA-1 and Decreases Bleomycin-Induced Pulmonary Fibrosis. International Journal of Biomedical Science, 2014, 10, 146-57.	0.5	5
1133	Effects of statins on the risk of hepatocellular carcinoma. Gastroenterology and Hepatology, 2014, 10, 417-26.	0.2	16
1134	Impact of 3'UTR genetic variants in PCSK9 and LDLR genes on plasma lipid traits and response to atorvastatin in Brazilian subjects: a pilot study. International Journal of Clinical and Experimental Medicine, 2015, 8, 5978-88.	1.3	9
1136	The Reciprocal Relationship between LDL Metabolism and Type 2 Diabetes Mellitus. Metabolites, 2021, 11, 807.	1.3	17
1137	An update on emerging drugs for the treatment of hypercholesterolemia. Expert Opinion on Emerging Drugs, 2021, 26, 363-369.	1.0	4
1138	Synergistic actions between angiotensin-converting enzyme inhibitors and statins in atherosclerosis. Nutrition, Metabolism and Cardiovascular Diseases, 2022, 32, 815-826.	1.1	4
1139	Idiopathic chronic pancreatitis: Beyond antioxidants. World Journal of Gastroenterology, 2021, 27, 7423-7432.	1.4	4
1140	Effectiveness of rosuvastatin plus colchicine, emtricitabine/tenofovir and combinations thereof in hospitalized patients with COVID-19: a pragmatic, open-label randomized trial. EClinicalMedicine, 2022, 43, 101242.	3.2	22
1142	Inflammation and Matrix Metalloproteinases. , 0, , 140-161.		0

#	Article	IF	Citations
1143	Atorvastatin suppresses lipopolysaccharide-induced inflammation in human coronary artery endothelial cells. Brazilian Journal of Pharmaceutical Sciences, 0, 58, .	1.2	0
1146	Implication of Lipids in Calcified Aortic Valve Pathogenesis: Why Did Statins Fail?. Journal of Clinical Medicine, 2022, 11, 3331.	1.0	2
1147	Statins and statin intensity in peripheral artery disease. Vasa - European Journal of Vascular Medicine, 2022, 51, 198-211.	0.6	21
1148	Role of endothelial cells in vascular calcification. Frontiers in Cardiovascular Medicine, 0, 9, .	1.1	6
1149	Decoding microRNA drivers in atherosclerosis. Bioscience Reports, 2022, 42, .	1.1	11
1150	The effect of statin therapy in combination with ezetimibe on circulating C-reactive protein levels: a systematic review and meta-analysis of randomized controlled trials. Inflammopharmacology, 2022, 30, 1597-1615.	1.9	5
1152	Erythrocyte oxidative stress and thrombosis. Expert Reviews in Molecular Medicine, 2022, 24, .	1.6	20
1153	Hexokinase 2 Is a Pivot for Lovastatin-induced Glycolysis-to-Autophagy Reprogramming in Triple-Negative Breast Cancer Cells. Journal of Cancer, 2022, 13, 3368-3377.	1.2	3
1154	Comparison of the Treatment Efficacy of Rosuvastatin versus Atorvastatin Loading Prior to Percutaneous Coronary Intervention in ST-Segment Elevation Myocardial Infarction. Journal of Clinical Medicine, 2022, 11, 5142.	1.0	1
1156	Caffeic Acid-Grafted PLGA as a Novel Material for the Design of Fluvastatin-Eluting Nanoparticles for the Prevention of Neointimal Hyperplasia. Molecular Pharmaceutics, 0, , .	2.3	1
1157	KLF2 alleviates endothelial cell injury and inhibits the formation of THPâ€1 macrophageâ€derived foam cells by activating Nrf2 and enhancing autophagy. Experimental and Therapeutic Medicine, 2022, 24, .	0.8	1
1158	Selective delivery of pitavastatin-loaded nanoparticles induces arteriogenesis upon chronic myocardial ischemia. Materials Express, 2022, 12, 1027-1032.	0.2	1
1159	Comparative Muscle Tolerability of Different Types and Intensities of Statins: A Network Meta-Analysis of Double-Blind Randomized Controlled Trials. Cardiovascular Drugs and Therapy, 0, , .	1.3	1
1160	Statins change the cytokine profile in Trypanosoma cruzi-infected U937 macrophages and murine cardiac tissue through Rho-associated kinases inhibition. Frontiers in Immunology, 0, 13, .	2.2	1
1161	Rho-Kinase Inhibition Ameliorates Non-Alcoholic Fatty Liver Disease in Type 2 Diabetic Rats. Physiological Research, 0, , 615-630.	0.4	3
1162	Role of nanocarriers for inflammation treatment. , 2023, , 111-129.		0
1163	Influence of rosuvastatin on apolipoproteins and coagulation factor levels: Results from the STAtin Reduce Thrombophilia trial. Research and Practice in Thrombosis and Haemostasis, 2023, 7, 100063.	1.0	3
1164	Atorvastatin downregulates plasma procarboxypeptidase U concentrations and improves fibrinolytic potential dose-dependently in hyperlipidemic individuals. Journal of Thrombosis and Haemostasis, 2023, 21, 1266-1273.	1.9	0

#	Article	IF	Citations
1165	Effect of high-dose statin therapy on coagulation factors: Lowering of factor XI as a modifier of fibrin clot properties in coronary artery disease. Vascular Pharmacology, 2023, 149, 107153.	1.0	11
1166	Colorectal Cancer Chemoprevention: A Dream Coming True?. International Journal of Molecular Sciences, 2023, 24, 7597.	1.8	4
1168	Peripheral Arterial Disease and Diabetes Mellitus. , 2023, , 857-875.		0